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Jade Lyons Rimmer 
Title: The potential of CRL4-DCAF1 and KSR1 as potential therapeutic targets for low-
grade Merlin-deficient tumours 
Merlin is a tumour suppressor protein that is frequently mutated or downregulated in 
cancer. Biallelic Merlin inactivation is causative of tumour formation, including 
schwannoma, meningioma and ependymoma. These tumours can occur sporadically or 
as part of the genetic condition Neurofibromatosis type 2 (NF2) and cause significant 
morbidity. The current treatment options are restricted to surgery and radiotherapy, 
which are invasive and may cause further tumour development.  
The activity of both the E3 ubiquitin ligase complex Cullin 4 really interesting new gene 
(RING) E3 ubiquitin ligase- DNA damage binding protein (DDB1) and Cullin 4 associated 
factor 1 (CRL4-DCAF1) and Kinase suppressor of RAS 1 (KSR1) have been shown to be 
upregulated in schwannoma to drive tumour growth. KSR1 has also been shown to 
interact with components of the CRL4-DCAF1 complex. We investigated the 
expression, interaction and therapeutic potential of targeting these proteins in Merlin-
deficient schwannoma and meningioma using a primary human cell model and 
relevant cell lines. 
We found that DCAF1 and KSR1 protein were overexpressed in schwannoma and 
meningioma and confirmed that targeting both DCAF1 and KSR1 in meningioma had 
additive effects on proliferation. We also identified that CRL4-DCAF1 facilitates KSR1-
dependent RAF/Mitogen-activated protein kinase (MAPK)/ Extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK pathway activity. We showed MLN3651, a 
neddylation inhibitor that targets ubiquitin ligase activity, reduced proliferation and 
activated apoptosis in Merlin-deficient tumours. We also showed that Merlin-positive 
tumours were less sensitive to MLN3651 than Merlin-deficient tumours; therefore, 
MLN3651 sensitivity may be CRL4-DCAF1-dependent. Finally, combination of MLN3651 
and the MEK1/2 inhibitor AZD6244 had additive effects, particularly in meningioma. 
Combinatorial therapy activated the Hippo pathway, inhibited RAF/MEK/ERK pathway 
activity and proliferation demonstrating that targeting the activity and downstream 
pathways of both DCAF1 and KSR1 represents an attractive novel therapeutic strategy 
in Merlin-deficient tumours.  
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Merlin is a tumour suppressor protein that functions at the cell membrane, cytoplasm 
and nucleus to prevent tumour growth (Ammoun et al., 2012; Li et al., 2010; Morrison 
et al., 2007; Zhang et al., 2010). Merlin-deficient tumours arise when the 
Neurofibromin 2 (NF2) gene is mutated in both alleles; this mutation can occur as a 
result of the genetic condition Neurofibromatosis type 2 (NF2), or sporadically (Bianchi 
et al., 1994; Evans, 2009). NF2 is a genetic condition characterized by the growth of 
multiple low-grade tumours, namely schwannomas, meningiomas and ependymomas 
(Evans et al., 1992; Hanemann, 2008). The current standard treatment for 
schwannomas, meningiomas and ependymomas is surgery and rarely radiotherapy. 
Surgery is invasive and possibly linked to further morbidities (Evans, 2009). 
Unfortunately, there are no approved therapeutics that are able to shrink or prevent 
the growth of these tumours. As such, a successful therapeutic option is urgently 
required.  
Both Cullin 4 really interesting new gene (RING) E3 ubiquitin ligase- DNA damage binding 
protein (DDB1) and Cullin 4 associated factor 1 (CRL4-DCAF1) and Kinase suppressor of 
RAS 1 (KSR1) have been shown to be hyper-active in schwannoma (Li et al., 2014; Li et 
al., 2010; Zhou et al., 2016a). This hyper-activity contributes to tumourigenesis and is 
dependent on the loss of Merlin. The overall aim of this project was to explore the 
potential of CRL4-DCAF1 and KSR1 as novel therapeutic targets in low grade Merlin-





1.2 The Nf2 gene and Merlin signalling 
The Nf2 gene is located on chromosome 22q12 and encodes the tumour suppressor 
protein, Merlin (Trofatter et al., 1993). Merlin shares sequence homology with other 
ezrin/radixin/moesin (ERM) proteins and includes an N-terminal 4.1 protein ERM 
(FERM) domain followed by an alpha-helical domain and a C-terminal domain (Petrilli 
& Fernández-Valle, 2016). Merlin is different from other ERM proteins in that it lacks 
the actin-binding site in the C-terminal domain, which instead is found in the N-
terminal FERM domain (Xu & Gutmann, 1998). The functions of Merlin are varied 
dependent on post-translational modifications, spatial conformation, location and cell 
density. 
There are two isoforms of Merlin; Merlin-1 and Merlin-2 which are formed as a result 
of alternative splicing (Golovnina et al., 2005). Merlin-1 is the longest isoform and lacks 
exon 16 whereas Merlin-2 is slightly shorter, contains exon 16 and lacks the carboxy-
terminal residues required for intra-molecular binding (Bianchi et al., 1994; Sher et al., 
2012).  
1.2.1 Merlin regulation 
Merlin is regulated by post-translational modifications, predominantly by 
phosphorylation. Phosphorylation of S518 regulates the conformation of Merlin and 
therefore its activity (Bretscher, Edwards & Fehon, 2002; Shaw et al., 2001). It has 
been proposed that phosphorylation leads to an open conformation that activates the 
scaffold function of Merlin and inactivates its tumour suppressor roles, whereas 
dephosphorylation leads to a closed conformation and activation of tumour 
suppressor roles (Bretscher, Edwards & Fehon, 2002; Shaw et al., 2001). Conversely, 
Sher et al. demonstrated that wild type Merlin is neither fully open nor closed and 
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phosphorylation leads to a less-active more closed state of Merlin (Sher et al., 2012). In 
addition, lipid binding has been shown to regulate the open conformation of Merlin 
leading to membrane localization critical for Merlin’s tumour suppressive functions 
(Chinthalapudi et al., 2018). This demonstrates that the regulation of Merlin 
conformation is more complex and may be dependent on many factors other than 
phosphorylation. 
Both open and closed conformations can interact with binding partners and Merlin’s 
scaffolding role remains active regardless of its conformation (Petrilli & Fernández-
Valle, 2016). Expression of activated RAS related C3 botulinum toxin substrate 1 (RAC1) 
or Cell division cycle protein 42 homolog (CDC42) leads to Merlin phosphorylation at 
S518 (Shaw et al., 2001; Xiao et al., 2002). This phosphorylation is directly mediated by 
p21-activated kinases (PAK), a common downstream target of both RAC1 and CDC42 
and decreases Merlin’s association with the cytoskeleton (Rong et al., 2004a; Shaw et 
al., 2001; Xiao et al., 2002). Protein kinase A (PKA) can also phosphorylate S518 and 
S10 whereby regulating Merlin’s interaction with the actin cytoskeleton and leading to 
modification of cell morphology (Alfthan et al., 2004; Laulajainen et al., 2008). 
Morrison et al. reported that at high cell density Cluster of Differentiation 44 (CD44) is 
activated by its ligand, hyaluronate, leading to Merlin dephosphorylation and 
activation of tumour suppressor activities (Morrison et al., 2001). In addition, 
Hepatocyte growth factor-regulate tyrosine kinase substrate (HRS) is also required for 
Merlin-mediated growth suppression (Sun et al., 2002). 
v-akt murine thymoma viral oncogene homolog (AKT) phosphorylates Merlin at S10, 
T230 and S315 resulting in decreased interdomain binding and ubiquitination (Tang et 
al., 2007). This poly-ubiquitination leads to proteasome-mediated Merlin degradation 
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with a protein half-life of more than 24 hours (Cooper & Giancotti, 2014; Li et al., 
2010). The Merlin protein half-life is relatively long; therefore, it is unlikely to be as 
important as phosphorylation in the regulation of Merlin function. 
1.2.2 Downstream Merlin signalling 
Merlin is a tumour suppressor protein that acts as a contact-dependent inhibitor of 
growth by suppressing or activating cell signalling pathways and preventing normal 
cytoskeletal reorganization (Morrison et al., 2007). Merlin inhibits growth by regulating 
the number of receptor tyrosine kinases on the cell membrane, particularly, Platelet-
derived growth factor receptor (PDGFR), Erythroblastic oncogene B homolog 2 (ERBB2) 
and Erythroblastic oncogene B homolog 3 (ERBB3) (Ammoun et al., 2012). Merlin 
promotes PDGFR degradation when overexpressed in the human schwannoma cell line 
HEI 193 (Fraenzer et al., 2003). In addition, Merlin overexpression inhibits the delivery 
of receptors, such as ERBB2, ERBB3, Insulin-like growth factor 1 receptor (IGF1R)β and 
PDGFRβ, to the cell membrane via secretory vesicles, leading to their degradation 
(Lallemand et al., 2009). Accordingly, Merlin knockdown led to increased PDGFRβ, 
IGF1Rβ, Epidermal growth factor receptor (EGFR), ERBB2 and ERBB3 protein 
expression in human Schwann cells (Ahmad et al., 2010; Lallemand et al., 2009). In an 
analysis of ten Merlin-deficient schwannoma samples, EGFR was strongly activated as 
well as ERBB2, ERBB3 and ERBB4 receptors (Ammoun et al., 2010a). In addition, in 
some samples, PDGFRβ, AXL, SKY, Membrane estrogen receptor (MER) and Recepteur 
d'origine nantais (RON) phosphorylation was detected indicating receptor activation 
(Ammoun et al., 2010a). These data show that a wide range of receptors are 
upregulated and hyperactivated in the absence of Merlin, leading to subsequent 
downstream mitogenic pathway activation.  
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Merlin also directly interacts with many pathway components to regulate signalling 
and cell growth. Merlin inhibits the RAC1/PAK pathway via multiple mechanisms, 
leading to inhibition of downstream c-Jun N-terminal kinase (JNK) signalling. Merlin 
can regulate the subcellular localization of RAC1, and directly binds to PAK to inhibit its 
binding to RAC1 whereby restricting PAK recruitment to focal adhesions (Kaempchen 
et al., 2003; Kissil et al., 2003; Okada, Lopez-Lago & Giancotti, 2005; Shaw et al., 2001). 
Merlin can also inhibit RAC1/PAK signalling further upstream by forming a complex 
with Angiomotin, Pals1-associated tight junction protein (PATJ) and Protein-associated 
with Lin7 (PALS1) leading to the release of RICH1 which then inactivates Rac1 (Yi et al., 
2011). Finally, non-phosphorylated Merlin binds to and inhibits CD44 to mediate 
contact inhibition of growth at high cell density and thus prevents RAS and RAC 
activation via CD44 (Morrison et al., 2001). 
Merlin also inhibits RAS activation, independent of RAC1 inhibition, by displacing ERM 
proteins and RAS from the Growth factor receptor bound protein 2 (GRB2)- Son of 
Sevenless (SOS) complex therefore preventing RAS activation and downstream Rapidly 
accelerated fibrosarcoma (RAF)/Mitogen-activated protein kinase (MAPK)/ 
Extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signalling (Morrison et al., 
2007). Indeed, Merlin-deficient primary schwannoma cells displayed enhanced 
RAF/MEK/ERK activation that was further enhanced by PDGFRβ, supporting a role for 
Merlin in suppressing RAF/MEK/ERK activity (Ammoun et al., 2008). Merlin re-
expression in Merlin-deficient malignant mesothelioma cells led to a reduction in Focal 
adhesion kinase (FAK) phosphorylation at tyrosine 297 which then disrupted FAK 
interaction with SRC and p85 (Poulikakos et al., 2006). Ammoun et al. identified 
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increased FAK activation in Merlin-deficient schwannoma and showed that this 
activation led to a further increase in RAF/MEK/ERK activation (Ammoun et al., 2008).  
Merlin suppresses the Phosphoinositide 3-kinase (PI3K)/AKT/Mammalian target of 
rapamycin (MTOR) pathway by binding to and inhibiting the interaction between 
Phosphatidylinositol 3-kinase enhancer-L (PIKE-L) and PI3K (Rong et al., 2004b). 
Indeed, in the absence of Merlin there was an increase in AKT protein expression and 
phosphorylation in both schwannoma and meningioma (Hilton, Ristic & Hanemann, 
2009; Jacob et al., 2008; Johnson et al., 2002). 
In Merlin-deficient mouse embryonic fibroblasts, Mammalian target of rapamycin 
complex 1 (MTORC1) was elevated and the overexpression of wild-type Merlin but not 
a Merlin mutant was able to suppress MTORC1 signalling (James et al., 2009). mTORC1 
inhibition was independent of PI3K/AKT and RAF/MEK/ERK signalling as wortmannin 
and UO126, inhibitors of PI3K and MEK1/2 respectively, were unable to inhibit S6 
activation in Merlin-deficient cells (downstream of MTORC1) (James et al., 2009). 
MTOR signalling is an important factor in Merlin-deficient tumourigenesis as treatment 
of mouse and human schwannoma cells with rapamycin, an MTOR inhibitor, led to a 
significant decrease in proliferation at < 0.1 nM (Giovannini et al., 2014).  
Merlin interacts with Low-density lipoprotein receptor-related protein 6 (LRP6) to 
inhibit proliferation and prevents Wingless integration-1 (WNT) signalling activation, 
which in turn inhibits β-catenin-dependent transcription of genes such as c-Myc and 
Cyclin D1 (Kim & Jho, 2016). Increased nuclear β-Catenin, C-MYC and CYCLIN D1 has 
been observed in confluent primary human schwannoma cells, indicating elevated 
WNT signalling (Zhou et al., 2011). Using this model, WNT signalling was shown to be 
dependent upon PAK2 and PDGFR activation (Zhou et al., 2011). 
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Merlin activates the Hippo pathway and therefore inhibits the transcription of key 
growth regulatory genes at the cell cortex and nucleus (Zhang et al., 2010). Zhang et al. 
showed that Merlin, Kidney and brain expressed protein (KIBRA) and Salvador (SAV) 
proteins interact to stimulate Large tumor suppressor kinase 2 (LATS2) 
phosphorylation in HEK293T and ACHN cells (Zhang et al., 2010). In addition, Yin et al. 
showed that Merlin directly binds to and directs Large tumor suppressor kinase 1/2 
(LATS1/2) to the plasma membrane where it is phosphorylated by Mammalian Ste20-
like kinases 1/2 (MST1/2) facilitated by SAV (Yin et al., 2013). In vivo loss of NF2, 
specifically in hepatocytes and biliary mouse cells, reduced LATS1/2 and Yes-associated 
protein (YAP) phosphorylation, leading to hepatocellular carcinoma and bile duct 
hamartoma formation (Zhang et al., 2010). Tumour formation was largely ameliorated 
by further deletion of YAP, suggesting that Merlin functions as a tumour suppressor in 
a YAP-dependent manner (Zhang et al., 2010). In addition, using a conditional null 
mouse model, Merlin loss in Schwann cells inhibited nerve repair following nerve 
injury demonstrating that Merlin is essential for Schwann cell plasticity and nerve 
repair (Mindos et al., 2017). Failure to initiate nerve repair in Merlin-deficient Schwann 
cells was associated with increased YAP expression and indeed loss of YAP in Merlin-
null Schwann cells restored axonal regrowth and nerve repair following injury in this 
model (Mindos et al., 2017). 
Li et al. showed that Merlin suppressed CRL4-DCAF1 activity in the nucleus to regulate 
many signalling pathways such as the Hippo pathway (Li et al., 2010; Mori et al., 2014). 
Merlin shuttles to the nucleus at the early G1 cell cycle phase and binds to the 
carboxy-terminal tail of DDB1 and Cullin 4 associated factor 1 (DCAF1) directly 
competing with CRL4 binding to DCAF1 and preventing ubiquitin substrate recruitment 
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(Li et al., 2010; Muranen et al., 2005). Indeed, Merlin depletion in Cos7 cells led to a 
significant increase in CRL4-DCAF1 activity (Li et al., 2010). Furthermore, DCAF1 
knockdown in schwannoma cells was able to significantly inhibit growth demonstrating 
the importance of Merlin regulation of CRL4-DCAF1 (Li et al., 2010). Li et al. also 
demonstrated that Merlin activates the Hippo pathway through inhibition of CRL4-
DCAF1-dependent ubiquitination of LATS1/2 (Li et al., 2014). Reduced LATS1/2 
ubiquitination activates the Hippo kinase cascade and leads to phosphorylation of YAP; 
therefore, inactivation of YAP transcriptional activities (Li et al., 2014). 
Merlin loss leads to hyperactivation of mitogenic signalling and therefore drives 




Figure 1.1 - Merlin-deficient signalling. A summary of hyperactivated signalling pathways in Merlin-
deficient cells. Blue arrows represent activation of a protein and red arrows represent an inhibitory 
interaction whereas the green arrows represent the signalling outcome. When Merlin is lost, there is an 
increased accumulation of growth factor receptors (GFR) at the cell membrane leading to activation of 
downstream signalling (Lallemand et al., 2009). These GFRs include PDGFR, IGF1R, EGFR, ERBB2, ERBB3, 
ERBB4 and Tyro3, Axl, and Mer (TAM) family receptors (Ahmad et al., 2010; Ammoun et al., 2010a; 
Lallemand et al., 2009). Activation of the RAF/MEK/ERK, PI3K/AKT pathways by GFRs leads to increased 
gene transcription of genes involved in proliferation and downregulation of pro-apoptotic proteins. FAK 
is also hyper-activated in Merlin-deficient cells and activates the WNT/β-CATENIN pathway that 
modulates gene transcription as well as paxillin that forms focal adhesions to regulate cell adhesion and 
cell shape (Ammoun et al., 2008; Zhou et al., 2011). RAS, CDC42 and RAC1 activate PAK signalling and 
PAK activates NF-KB that regulates gene transcription (Balasenthil et al., 2004) and MTORC1 that 
initiates RNA translation (Flaiz et al., 2009; James et al., 2009; Kaempchen et al., 2003; Kissil et al., 2003; 
López-Lago et al., 2009; Morrison et al., 2007; Okada, Lopez-Lago & Giancotti, 2005; Shaw et al., 2001). 
In addition, RAC1 activates the JNK/c-JUN pathway that also initiates RNA translation (Cargnello et al., 
2012; Kaempchen et al., 2003; Patel et al., 2012). CRL4-DCAF1 is hyper-activated when Merlin is lost and 
inhibits LATS1/2, in the nucleus, therefore releasing the LATS1/2-dependent inhibition of YAP function 
allowing YAP to regulate gene transcription (Mori et al., 2014). CRL4-DCAF1 also has other unidentified 
substrates that regulate the growth of Merlin-deficient tumours (Li et al., 2010). Components of the 
pathways shown are also directly inhibited by Merlin and are more active in Merlin’s absence such as 
RAS, RAC, CDC42, FAK, PI3K, PAK, and CRL4-DCAF1 (Flaiz et al., 2009; Kissil et al., 2003; Li et al., 2010; 
Morrison et al., 2007; Poulikakos et al., 2006; Rong et al., 2004b).   
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1.3 Merlin-deficient tumours 
Inactivating Nf2 mutations and a significant reduction in Merlin protein expression has 
been observed with high frequency in cancers including mesothelioma, glioma, and 
hepatocellular carcinoma demonstrating its relevance in tumourigenesis (Bott et al., 
2011; Lau et al., 2008; Zhang et al., 2017). Furthermore, Nf2 mutations and/or 
inactivation has been identified at a much lower rate in; breast cancer, colorectal 
cancer, prostate cancer and melanoma (Petrilli & Fernández-Valle, 2016). Bi-allelic Nf2 
mutations are causative of tumour formation, especially in the case of NF2-related and 
sporadic schwannomas, meningiomas and ependymomas (Hanemann, 2008). 
1.3.1 Merlin loss in cancer 
Inactivating Nf2 mutations have been identified in 21% (11/53) of primary 
mesothelioma tumour DNA samples (Bott et al., 2011). Furthermore, 50% of 
mesothelioma cell lines have somatic Nf2 gene mutations (Bianchi et al., 1995; Sekido 
et al., 1995). In addition, Thurneysen et al. found that Merlin protein expression was 
significantly reduced in 43% of primary mesothelioma tissue samples and inactive in 
the remaining samples (Thurneysen et al., 2009). Low Merlin expression has been 
associated with reduced survival in mesothelioma patients highlighting the importance 
of Merlin as a tumour suppressor in these tumours (Meerang et al., 2016).   
Lau et al. identified reduced Merlin protein expression in 20/23 glioblastoma samples 
and decreased Merlin RNA expression in 21 out of 23 samples with significant 
concordance (Lau et al., 2008). Moreover, overexpression of Merlin in the glioma cell 
lines U87MG and U251 led to inhibition of anchorage-independent growth and 
reduced invasiveness in vitro which was specific to wild-type Merlin and the 
constitutively active non-phosphorylated form of Merlin (S518A) (Lau et al., 2008). In 
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addition, mice injected intracranially with U87MG cells overexpressing wild-type or 
S518A Merlin survived significantly longer than those injected with U87MG cells or 
U87MG cells overexpressing the phosphorylated form of Merlin (S518D) (Lau et al., 
2008). Collectively, these studies demonstrate the high rate of Merlin inactivation in 
glioblastoma and its critical role in tumour development. 
Spontaneous development of hepatocellular carcinoma occurs in around 10% of mice 
with a heterozygous Nf2 mutation suggesting that normal Merlin function is important 
in preventing tumour formation (Kalamarides et al., 2002; McClatchey et al., 1998). 
Zhang et al. showed that Merlin loss in hepatocytes and biliary cells at the perinatal 
stage led to the development of hepatocellular carcinomas in 100% of mutant mice 
demonstrating the critical role of Merlin in supressing tumour growth (Benhamouche 
et al., 2010). Interestingly, liver overgrowth and hepatocellular carcinoma 
development were dependent on functional Hippo signalling (Benhamouche et al., 
2010; Zhang et al., 2017). 
1.3.2 Schwannoma 
Benign schwannomas are often associated with NF2 but can occur sporadically and 
often harbour an Nf2 gene mutation (Bianchi et al., 1994; Evans, 2009). Schwannomas 
arise from Schwann cells that produce myelin and envelop nerves of the peripheral 
nervous system. Schwannomas can cause varying symptoms dependent on location 
including hearing loss, tinnitus, balance problems, headache and numbness (Petrilli & 
Fernández-Valle, 2016). Vestibular schwannomas are the most common and develop 
on the eighth cranial nerve, i.e., the vestibulocochlear nerve (Twist et al., 1994). 
Vestibular schwannomas are diagnosed by magnetic resonance imaging (MRI) in the 
general population at an incidence of around 2 per 100000 people per year (Lin et al., 
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2005; Stangerup & Caye-Thomasen, 2012). Interestingly, the prevalence is thought to 
be much higher as 3–4% of patients are found to have a head or neck schwannoma at 
post-mortem, suggesting that a proportion of schwannomas are asymptomatic 
(Hanemann & Evans, 2006). 
Observation, surgical resection and stereotactic radiotherapy are the main treatment 
options for vestibular schwannoma (Apicella et al., 2016). Most tumours can be 
successfully resected but preserving normal nerve function and hearing remains a 
challenge (Battaglia, Mastrodimos & Cueva, 2006). Stereotactic radiotherapy leads to 
similar tumour control rates and improved hearing preservation compared with 
surgery for small vestibular tumours (Maniakas & Saliba, 2012; Yamakami et al., 2003). 
However, stereotactic radiation can still lead to complications such as hearing loss, 
facial nerve palsy and trigeminal dysfunction (Hansasuta et al., 2011). One study found 
that radiation dose was a significant factor in hearing preservation with doses < 13 Gy 
leading to a higher hearing preservation rate compared with doses > 13 Gy (Yang et al., 
2010). Interestingly, a study reported that patients managed by observation compared 
with patients treated with stereotactic radiotherapy had a comparable profile of 
symptoms and quality of life (Breivik et al., 2013). In addition, hearing was lost in 76% 
of those under observation compared with 64% in stereotactic radiotherapy patients, 
which was not significant (Breivik et al., 2013). However, the study did report that 
there was a significant reduction in tumour volume and a reduction in the need for 
additional treatment in patients treated with radiotherapy (Breivik et al., 2013). 
Therefore, Muzevic et al. recommended that the treatment method should be chosen 
on an individual basis in the absence of substantial evidence to show that stereotactic 
radiotherapy is superior to observation or surgery (Muzevic et al., 2014).  
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Hadfield et al. detected one Nf2 gene mutation in 89% of NF2-associated 
schwannomas and two Nf2 gene mutations in 79% of NF2-associated schwannomas 
(Hadfield et al., 2010). However, it is well documented that all NF2-associated 
schwannomas have one germline Nf2 mutation and therefore the methods used were 
not sensitive enough to detect all mutations. Therefore, the majority (possibly all) NF2-
associated schwannoma have biallelic inactivation of the Nf2 gene. In addition, most 
sporadic schwannomas harbour mutations in the Nf2 gene. Indeed, Hadfield et al. 
detected at least one Nf2 mutation in 66% of sporadic schwannomas tested (Hadfield 
et al., 2010). Similarly, Havik et al. detected Nf2 mutations in 35/46 (76%) of sporadic 
schwannomas and reported that 16/46 (35%) had two Nf2 mutations (Håvik et al., 
2018). Lassaletta et al. also reported at least one mutation in 72% sporadic vestibular 
schwannoma with two mutations detected in 45% of tumours (Lassaletta et al., 2013). 
Tumours with only one Nf2 mutation retained Merlin protein expression and the 
presence of two Nf2 mutations correlated well with Merlin protein loss (Chen et al., 
2017). However, some tumours with a mutation in both Nf2 alleles had a proportion of 
cells that expressed Merlin suggesting that sporadic schwannomas can contain both 
one-hit and two-hit schwannoma cells (Chen et al., 2017). In addition, Havik et al. 
identified mutations in Cell division cycle protein 27 homolog (Cdc27) (11%) and 
Ubiquitin Specific Peptidase 8 (Usp8) (7%) genes in sporadic schwannoma samples 
which were exclusive of Nf2 mutations (Håvik et al., 2018).  
Merlin loss leads to schwannoma development caused by changes in Schwann cells 
such as increased proliferation, increased resistance to apoptosis, increased adhesion 
to the extracellular matrix and a change to a multipolar shape (Hilton, Ristic & 




Meningiomas are the most common intracranial tumours and arise from the 
meningeal cells of the arachnoidal layer of the leptomeninges surrounding the brain 
and spinal cord (Ostrom et al., 2015; Wiemels, Wrensch & Claus, 2010). Meningiomas 
most commonly occur in the elderly (> 65 years) and more frequently in females 
(Klaeboe et al., 2005; Ostrom et al., 2013). The majority of meningiomas are benign 
and classified as World Health Organisation (WHO) I and consist of meningothelial, 
fibrous, and transitional subtypes (Mawrin, Chung & Preusser, 2015). Atypical, clear 
cell, and chordoid meningiomas, classified as WHO II, account for up to 34% of all 
meningiomas whilst anaplastic meningiomas, classified as WHO III, account for 1–2% 
(Durand et al., 2009; Pearson et al., 2008).  
Meningiomas often present as headaches and/or cranial nerve deficits (Wu et al., 
2018). Other symptoms are dependent on tumour location. The primary treatment for 
meningiomas is surgery, although complete resection is not always possible meaning a 
greater likelihood of recurrence (Gousias, Schramm & Simon, 2016). Radiotherapy is 
considered after resection of a recurrent tumour or WHO III meningioma but may also 
be useful where surgery is not possible due to tumour location (Dziuk et al., 1998; 
Walcott et al., 2013). Interestingly, the primary environmental risk factor for 
meningiomas is ionising radiation exposure and therefore radiotherapy may increase 
the risk of meningioma recurrence (Wiemels, Wrensch & Claus, 2010). 
Around 60% of sporadic meningioma and 100% of meningiomas associated with NF2 
have a Nf2 gene mutation (Lomas et al., 2005; Ruttledge et al., 1994; Wellenreuther et 
al., 1995). Paediatric meningiomas are rare and strongly associated with NF2 rather 
than occurring sporadically (Preusser, Brastianos & Mawrin, 2018). Clark et al. 
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detected Switch/Sucrose Non-fermentable-related matrix-associated actin-dependent 
regulator of chromatin subfamily B member 1 (Smarcb1) mutations in 6.4% of Nf2-
mutant meningioma highlighting that Nf2 mutations are not necessarily exclusive of 
other alterations (Clark et al., 2016). 
Several more mutations have been identified in meningioma in the TNF receptor-
associated factor 7 (Traf7), Krupple-like factor 4 (Klf4), v-akt murine thymoma viral 
oncogene homolog 1 (Akt1) and smoothened, frizzled family receptor (Smo) genes 
(Clark et al., 2013). Additional somatic mutations identified in meningioma include 
polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa (Polr2a), PI3K catalytic 
subunit, alpha (Pik3ca), v-akt murine thymoma viral oncogene homolog 3 (Akt3), PI3K 
regulatory subunit, alpha (Pik3r1), protein kinase, Cyclic Adenosine Monophosphate 
(cAMP)-dependent, regulatory, type I, alpha (Prkar1a) and suppressor of fused 
homolog (Drosophila) (Sufu) (Clark et al., 2016). Akt1, Pik3ca and Smo mutations, as 
well as Smarcb1, can co-occur with Nf2 mutations in a small proportion of meningioma 
(Clark et al., 2016). Differentially expressed in adenocarcinoma of the lung 1 (DAL-1) 
protein is normally expressed in the brain and testes (Perry et al., 2000). The Dal-1 
gene is downregulated in around 75% of meningiomas leading to loss of the DAL-1 
protein (Perry et al., 2000). Nf2 mutations and Dal-1 mutations or protein 
downregulation can co-occur, most commonly in WHO II and III meningiomas, 
suggesting DAL-1 loss causes additional meningioma growth and/or invasion rather 
than driving meningioma development (Nunes et al., 2005; Perry et al., 2000; Perry et 
al., 2001).  
Nevoid basal cell carcinoma syndrome (gorlin syndrome) is a genetic disease which 
leads to the development of tumours including basal cell carcinomas, 
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medulloblastoma, meningiomas, and ovarian tumours (Santos et al., 2011; Wicking et 
al., 1997). Mutations in the Protein patched homolog 1 (Ptch1) gene encoding the 
PTCH1 protein are the most common cause of nevoid basal cell carcinoma (Boutet et 
al., 2003; Rimkus et al., 2016). Interestingly, both PTCH1 and SMO are components of 
the Hedgehog signalling pathway highlighting this pathway as dysregulated in a subset 
of meningiomas. 
1.3.4 Ependymoma 
Ependymomas arise from ependymal cells of the spinal cord and cranial ventricles, 
which are responsible for the production of cerebrospinal fluid (Gilbert, Ruda & 
Soffietti, 2010). Whilst two thirds of ependymomas in adults arise in the spinal cord, 
90% of paediatric ependymomas occur in the cranial ventricles (Hamilton & Pollack, 
1997). The main treatment for ependymomas is surgery followed by radiotherapy; 
however, tumour recurrence may occur even when the tumour is completely resected 
(Hamilton & Pollack, 1997; Kawabata et al., 2005; Merchant & Fouladi, 2005).  
Chromosomal abnormalities are frequently identified in ependymomas, particularly 
chromosome 22 and c11orf95-v-rel avian reticuloendotheliosis viral oncogene 
homolog A (Rela) gene fusions (Hamilton & Pollack, 1997; Pajtler et al., 2015; von 
Haken et al., 1996). Whilst NF2 patients frequently develop ependymomas, Nf2 
mutations in sporadic paediatric ependymomas are rare and Nf2 mutations are found 
most commonly in adult spinal ependymomas (Buccoliero et al., 2010; Ebert et al., 
1999; Lamszus et al., 2001; Rubio et al., 1994; von Haken et al., 1996). Methylation 
profiling identified nine distinct ependymoma groups (Pajtler et al., 2015). Some of 
these sub-groups had distinct genetic profiles; for example, 88% of ependymomas in 
the supratentorial ependymoma chromothripsis; rela-fusion (ST-EPN-RELA) sub-group 
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had one of the two major types of C11orf95-Rela gene fusions (Pajtler et al., 2015). 
Furthermore, loss of 22q (containing the Nf2 locus) was predominantly, but not 
exclusively, found in the spinal ependymoma (SP-EPN) sub-group of ependymomas as 
expected. Interestingly, a microarray study of 19 paediatric ependymomas identified 
the Schwannomin interacting protein 1 (Schip-1) gene, on chromosome 22, as 
commonly downregulated (Suarez-Merino et al., 2005). SCHIP-1 protein has been 
shown to regulate Merlin function demonstrating that Merlin protein dysregulation 
may have a prominent role in ependymoma pathogenesis (Goutebroze et al., 2000). 
Misdiagnosis can complicate genetic analysis and cell culture of ependymomas; 
therefore, this project focussed on schwannoma and meningioma. 
1.4 Neurofibromatoses 
Neurofibromatoses are a small group of genetic diseases which predispose patients to 
tumour formation as well as other conditions such as cataracts or scoliosis. These 
conditions are caused by a mutation in one allele of a tumour suppressor. A secondary 
somatic mutation leads to complete protein loss and therefore loss of tumour 
suppressor function leading to tumour formation. The neurofibromatoses include 
Neurofibromatosis type 1 (NF1), NF2 and schwannomatosis.   
1.4.1 Neurofibromatosis type 1 
NF1 is caused by a germline mutation in the Neurofibromin 1 (Nf1) gene and has an 
incidence of 1:2500 (Ferner & Gutmann, 2002). NF1 patients develop a somatic 
mutation in the remaining normal allele leading to loss of Neurofibromin 1 protein in 
cells and tumour development. These tumours include plexiform neurofibromas, 
cutaneous neurofibromas and malignant peripheral nerve sheath tumours (MPNST) 
(Ferner et al., 2007). There is no evidence of malignant change of cutaneous 
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neurofibromas, but they can be removed by surgery if they cause cosmetic problems 
or excessive itching (Ferner et al., 2007). However, plexiform neurofibromas cause 
significant morbidity as they can grow along nerves and infiltrate soft tissue and 
surround bone (Ferner et al., 2007). Furthermore, the growth rate of plexiform 
neurofibromas can be unpredictable and can lead to the development of MPNSTs 
(Ferner et al., 2007). NF1 patients also have characteristic café au lait macules and 
cutaneous neurofibromas which aid diagnosis (Ferner et al., 2007; Lu-Emerson & 
Plotkin, 2009). In addition, NF1 patients may have a lower than average IQ, scoliosis 
and/or congenital heart defects (Akbarnia et al., 1992; Ferner, Hughes & Weinman, 
1996; Friedman et al., 2002).  
NF1 patients have a lifetime risk of 8–13% of developing MPNSTs which represents the 
main cause of mortality in these patients (Evans et al., 2002). MPNSTs are aggressive 
malignancies associated with significant morbidity and a median survival time of just 
17 months (Zehou et al., 2013). Unfortunately, NF1 patients have a reduced life 
expectancy of around 15 years less than the general population, which is often due to 
MPNST formation and malignancy (Zöller et al., 1995). Therefore, NF1 patients must be 
monitored at least every 12 months for clinical features of MPNSTs such as persistent 
pain, neurological symptoms and changes in the size or texture of an existing 
neurofibroma (Ferner et al., 2007). 
Neurofibromin 1, the protein product of the Nf1 gene, mediates RAS inactivation to 
suppress RAF/MEK/ERK signalling and therefore inhibits cell growth (Johansson et al., 
2008). Mutations in Nf1 lead to aberrant RAF/MEK/ERK activation that drives tumour 
formation (Jessen et al., 2013). Nf1 mutations are the only mutations identified in NF1-
associated plexiform neurofibromas and is suggested to drive tumour formation 
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(Pemov et al., 2017). Furthermore, Neurofibromin 1 protein is often lost in sporadic 
MPNSTs, glioblastoma, lung adenocarcinoma and ovarian cancer demonstrating its 
importance as a tumour suppressor (Jessen et al., 2013). 
1.4.2 Neurofibromatosis type 2  
NF2 has an incidence rate of 1:25000 and is an autosomal dominant genetic disease 
caused by a mutation in the Nf2 gene (Bianchi et al., 1994; Evans et al., 2005; 
Hanemann, 2008). NF2 is characterized by the development of multiple benign 
tumours including schwannomas, meningiomas and ependymomas throughout life 
(Hanemann, 2008). Bilateral vestibular and spinal schwannoma, intracranial and 
intraspinal meningioma and ependymomas are common in NF2 patients (Evans, 2009). 
Spinal tumours are identified in around 60% of NF2 patients including spinal 
schwannoma, meningiomas and ependymomas (Dow et al., 2005; Egelhoff et al., 1992; 
Mautner et al., 1995). These tumours represent a significant burden to NF2 patients 
with multiple symptoms and are currently managed with surgery or radiosurgery 
(Hanemann, 2008; Petrilli & Fernández-Valle, 2016). In addition, NF2 patients may 
have ocular abnormalities such as early onset cataracts and skin abnormalities 
including subcutaneous nodular schwannomas (Mautner et al., 1997; Ragge et al., 
1997). 
NF2 leads to a shortened life expectancy and has a significant effect on quality of life 
(Baser et al., 2002a). In 1992, Evans et al. reported a mean survival of 62 years in NF2 
patients compared with 76.4 years in the general UK population in the same year 
(Evans et al., 1992; Office-for-National-Statistics, 2016). Considerable morbidity is 
often due to pre and post-operative complications such as seizures, paralysis and 
wasting (Evans, Sainio & Baser, 2000). Interestingly, NF2 patient mortality has 
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significantly improved since 1980 and this may be attributable to the improved care 
received at specialist centres (Hexter et al., 2015). Indeed, in 2014, 97% of NF2 
patients living in the UK were managed by one of four speciality centres (Hexter et al., 
2015). 
The presence of bilateral vestibular schwannoma is the most characteristic feature of 
NF2 and is primarily used for diagnosis. The original criteria for NF2 diagnosis was the 
National Institutes of Health (NIH) criteria [1987] which diagnosed patients with either 
bilateral vestibular schwannoma or a family member with NF2 as well as a unilateral 
vestibular schwannoma or two other NF2-associated tumours (Conference-statement, 
1988). However, improved sensitivity in detecting vestibular schwannoma means that 
a greater proportion of patients are diagnosed with bilateral vestibular schwannoma at 
an older age, despite the absence of NF2 (Evans et al., 2015). Conversely, bilateral 
vestibular schwannoma in NF2 patients may not occur until adolescence preventing 
early NF2 diagnosis and management (Baser et al., 2002b). The Manchester criteria 
was created to address and improve the sensitivity and specificity of diagnosis, table 
1.1 (Evans, 2009). In addition, identification of a pathogenic Nf2 mutation also leads to 
a NF2 diagnosis. Alternatively, the Baser criteria for diagnosis of NF2 [2011] (table 1.2) 
permits earlier diagnosis in a greater proportion of patients compared with other 





Bilateral vestibular schwannoma or 
Family history of NF2 plus 
Unilateral vestibular schwannoma or 
Any two of: meningioma, glioma, neurofibroma, schwannoma, posterior subcapsular 
lenticular opacities 
Additional criteria 
Unilateral vestibular schwannoma plus 
Any two of: meningioma, glioma, neurofibroma, schwannoma, posterior subcapsular 
opacities, alternatively 
Multiple meningiomas (two or more) plus 
Unilateral vestibular schwannoma or any two of: glioma, neurofibroma, 
schwannoma, and cataract 




A NF2 diagnosis is given if there is a score of six or more according to the below 
criteria: 
Feature Score if present 
< 30 years 
Score if present 
> 30 years 
First-degree relative with NF2 2 2 
Unilateral vestibular schwannoma 2 1a 
Second vestibular schwannoma 4 3a 
One meningioma 2 1 
Second meningioma 2 1 
Cutaneous schwannoma 2 1 
Cranial nerve tumour (excluding vestibular) 2 1 
Mononeuropathy 2 1 
Cataract 2 0 
a – No points if age of vestibular schwannoma diagnosis > 70 years 
• A definite NF2 diagnosis can also be given if a constitutional pathogenic Nf2 
mutation is identified 
• Mosaic NF2 is diagnosed if no constitutional pathogenic Nf2 mutation is 
identified but a pathogenic mutation is found in the blood OR if no pathogenic 
Nf2 mutation is found in the blood but the same pathogenic NF2 mutation is 
identified in two separate tumours 
• Possible NF2 is diagnosed if there is no constitutional pathogenic Nf2 mutation 
identified, pending further clarification 
Table 1.2 - Baser criteria [2011] used for diagnosis of NF2. Adapted from (Baser et al., 2011) 
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Management of patients after diagnosis involves evaluation every 12 months in 
patients without acute problems (Ruggieri et al., 2016). MRI scans of the brain, spinal 
cord and of symptomatic lesions outside the brain are used to monitor tumour growth 
as well as audiology examinations and brainstem auditory evoked responses (BAER) to 
assess eighth cranial nerve dysfunction associated with vestibular schwannomas 
(Ruggieri et al., 2016). Whilst surgery and stereotactic radiotherapy are options for 
individual tumours, the presence of multiple tumours in NF2 patients means that each 
tumour must be assessed individually (Ruggieri et al., 2016). Treatment decisions are 
based on preserving function and minimizing the effects on quality of life (Ruggieri et 
al., 2016).  
There are several additional considerations to consider when choosing a treatment for 
schwannoma, meningioma and ependymoma in NF2 patients compared with sporadic 
patients. Firstly, stereotactic radiotherapy treatment outcomes are worse for 
vestibular schwannomas in NF2 patients compared with sporadic vestibular 
schwannomas (Ruggieri et al., 2016). Secondly, stereotactic radiotherapy may increase 
the risk of secondary malignancies more so in NF2 patients than sporadic patients 
(Ruggieri et al., 2016). Thirdly, NF2-associated schwannomas and ependymomas are 
often multi-lobulated due to several distinct tumours, with different Merlin mutations, 
merging to form a larger tumour (Dewan et al., 2015). This multi-lobulated appearance 
complicates surgical removal of NF2-associated tumours compared with sporadic 
tumours. Finally, NF2-associated ependymomas are commonly asymptomatic and 
surgery is often avoided in favour of monitoring growth and appearance of symptoms 
(Nowak et al., 2016). For example, Nowak et al. reported that 2 out of 34 NF2 patients 
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underwent surgery for ependymoma excision between 1998 and 2014 (Nowak et al., 
2016).  
The treatment and management of NF2 patients can also be influenced by the type of 
germline Nf2 mutation. Frameshift and nonsense mutations that result in production 
of a truncated form of Merlin are associated with a more severe disease phenotype 
and reduced life expectancy compared with missense mutations, large deletions and 
in-frame mutations that result in complete loss of Merlin protein (Selvanathan et al., 
2010). Truncating Nf2 gene mutations are also associated with an earlier age of onset 
of symptoms such as hearing loss, increased prevalence of meningiomas and spinal 
tumours and an earlier age of diagnosis of vestibular schwannoma (Selvanathan et al., 
2010). Evans et al. show that patients with truncating mutations have an average age 
at onset of symptoms of 19 years compared with 27.8 years for patients with splice-
site mutations, missense mutations or large deletions (Evans et al., 1998). Therefore, 
truncating Nf2 gene patients should be evaluated more often than other Nf2 gene 
mutation patients. Furthermore, Nf2 mosaicism exists in up to 33% of NF2 patients 
(Bernards & Gusella, 1994; Evans et al., 2007). Mosaicism is a mutation which occurs in 
the post-zygotic stage after fertilization and during development. Mosaicism leads to 
segmental and milder disease even in the presence of truncating mutations (Evans et 
al., 1998; Kluwe & Mautner, 1998). Unfortunately, mosaic NF2 is often undetectable in 
the blood of patients, which confounds diagnosis (Ruggieri et al., 2016). However, as 
mosaic NF2 is a milder disease, management and treatment can be more conservative 






Schwannomatosis is caused by a mutation in the Smarcb1 or Leucine zipper-like 
transcription regulator 1 (Lztr1) gene and leads to the formation of multiple cranial, 
spinal and peripheral schwannomas and, less commonly, vestibular schwannoma 
(Ruggieri et al., 2016). Schwannoma formation in schwannomatosis is thought to 
follow the four-hit, three-step model of tumourigenesis (Ruggieri et al., 2016). This 
model involves the inactivation of the Nf2 gene as well as the Smarcb1/Lztr1 genes and 
therefore re-iterates the importance of Merlin in tumour formation. The main 
symptom of schwannomatosis is pain and the annual incidence is 0.58 cases per 
million people, so the condition is extremely rare, even in comparison with the other 
neurofibromatoses (Merker et al., 2012). NF2 diagnosis can be complicated by 
schwannomatosis individuals as these patients can have a unilateral vestibular 
schwannoma and two non-intradermal schwannomas (Smith et al., 2017). Smith et al. 
reported that 5/204 patients diagnosed with NF2 had a germline Lztr1 mutation; 
therefore, schwannomatosis should be considered in the absence of a germline Nf2 
mutation. 
1.5 Treatment and clinical trials for Merlin-deficient tumours 
Treatment options for all the forms of neurofibromatosis is still limited with no Food 
and Drug Administration (FDA)-approved drugs available. Most often, tumours are 
removed during surgery. However, there are some drugs that have been tested/are 
being tested in clinical trials, which are detailed below, and ongoing trials are outlined 
in table 1.3. 
As there is no effective therapeutic regimen currently available, further investigation 
of the pathways associated with Merlin loss will propel the understanding of NF2-
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associated tumourigenesis. This will allow the discovery of new targets for the 

























Early phase I Ongoing Unknown 













Early phase I Recruiting August 
2018 
NCT02934256 Icotinib NF2-related II Recruiting June 2018 














































II Recruiting Unknown 
NCT03095248 Selumetinib NF2-related II Recruiting May 2021 
NCT03079999 Aspirin Vestibular 
schwannoma 




Table 1.3 - Ongoing clinical trials for the treatment of NF2-related and sporadic tumours. Information 
was derived from publicly available information from (Clinicaltrialsregister.eu[Internet]) and 





Lapatinib is an EGFR/ERBB2 inhibitor which reduces tyrosine phosphorylation of both 
EGFR and ERBB2 and thus their activation (Xia et al., 2002). Lapatinib was able to 
supress ERK1/2 and AKT activation, downstream of EGFR and ERBB2 receptors, to 
inhibit proliferation in schwannoma (Ammoun et al., 2010a; Xia et al., 2002). A phase II 
clinical trial recruited 21 NF2 patients with progressive vestibular schwannoma 
(Karajannis et al., 2012). The primary endpoint was a reduction in vestibular 
schwannoma of more than 15% (which is slightly less than the 20% recommended by 
the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) 
consortium) and the secondary endpoint was a hearing improvement of 10 dB pure 
tone average or increase in word recognition scores (Karajannis et al., 2012). Only four 
patients reached the primary endpoint of more than a 15% volumetric reduction in 
vestibular schwannoma size and four met the secondary endpoint of improved hearing 
with acceptable toxicities (Karajannis et al., 2012). Unfortunately, in this study there 
was no meningioma response observed by imaging (Karajannis et al., 2012). In 
addition, a phase II clinical study of Lapatinib in paediatric patients with recurrent 
ependymoma showed that there was no measurable response reported in any of the 
14 ependymoma patients enrolled (Fouladi et al., 2013). Due to the modest responses 
observed in schwannoma, lack of response in meningioma or ependymoma, and side 
effects such as diarrhoea, rash and fatigue, Lapatinib is unlikely to be suitable as a 
monotherapy for NF2 patients. Paldor et al. implanted mouse schwannoma cells (SC4) 
in the mouse sciatic nerve and compared tumour growth after treatment with 
Lapatinib or treatment with Lapatinib and radiotherapy (Paldor et al., 2017). Lapatinib 
in combination with radiotherapy reduced tumour growth rates significantly compared 
50 
 
with Lapatinib alone and these tumours did not regrow after Lapatinib treatment 
ended (Paldor et al., 2017). This suggests that the combination of targeted therapy 
with conventional therapy, such as radiotherapy, may be efficacious.  
1.5.2 Everolimus 
Everolimus is an inhibitor of the MTORC1, which is activated in Merlin-deficient cells 
such as meningioma (James et al., 2009). A phase II study of Everolimus treatment in 
ten progressive vestibular schwannoma patients reported that no patients had more 
than a 20% reduction in tumour volume after 12 months of treatment (Goutagny et al., 
2015). However, five patients experienced a decrease in the median annual growth 
rate during Everolimus treatment of 66.5% compared with before treatment 
(Goutagny et al., 2015). In addition, the growth rate of six meningiomas in the same 
study was delayed during Everolimus treatment reflective of the cytostatic properties 
of the drug (Goutagny et al., 2015). Similarly, another phase II study of nine NF2 
patients with progressive vestibular schwannoma showed partial tumour shrinkage of 
< 15% in 3 out of 11 vestibular schwannomas analysed after Everolimus treatment and 
no hearing improvements (Karajannis et al., 2014). This evidence suggests that 
Everolimus may have a growth-delaying effect on vestibular schwannoma that cannot 
be confirmed without a larger sample size, and is relatively ineffective to reduce 
tumour size or preserve hearing in NF2 patients. 
1.5.3 PDGFR inhibitors 
Imatinib is a PDGFR/C-KIT inhibitor that decreases viability, proliferation and increases 
apoptosis of the schwannoma cell line, HEI-193 (Altuna et al., 2011; Mukherjee et al., 
2009). A case study of a single NF2 patient with progressive vestibular schwannoma 
who was treated with Imatinib experienced a decrease in schwannoma growth and 
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self-reported improvements in hearing (Lim & de Souza, 2013). However, Imatinib was 
discontinued after four months due to side effects including nausea, vomiting and 
abdominal pain accompanied by hearing loss (Lim & de Souza, 2013). A phase II study 
of Imatinib in patients with recurrent meningiomas showed no partial or full responses 
in any of the 22 patients treated (Wen et al., 2009). 
Nilotinib is an Adenosine triphosphate (ATP) competitive PDGFR inhibitor that also has 
activity against Breakpoint cluster region (BCR)- Abelson murine leukemia viral 
oncogene homolog 1 (ABL) fusion kinase protein and C-KIT receptor kinases (Deremer, 
Ustun & Natarajan, 2008). Nilotinib inhibits Platelet-derived growth factor (PDGF)-
mediated activation of PDGFRβ, ERK1/2 and AKT leading to reduced proliferation of 
human primary schwannoma cells at a concentration ten-fold lower than that of 
Imatinib (Ammoun et al., 2011). Nilotinib also decreased viability, proliferation and 
increased apoptosis in the schwannoma cell line, HEI-193 (Sabha et al., 2012). Nilotinib 
also significantly reduced the growth of tumours derived from the SC4 cell line and 
implanted in the flank of a mouse (Paldor et al., 2017). This suggests that Nilotinib may 
have more potential as a therapeutic for Merlin-deficient tumours than Imatinib due 
to increased potency. Indeed, investigation of intra-tumoural concentration and 
activity of Nilotinib in cutaneous schwannomas of NF2 patients is currently underway 
(EudraCT: 2010-023508-28). 
The PDGFR and C-RAF inhibitor Sorafenib is also a potential therapeutic for Merlin-
deficient tumours which has been shown to reduce ERK1/2 and AKT activity as well as 
proliferation of human primary schwannoma cells and was more effective than 
Nilotinib (Ammoun et al., 2008). Investigation of in vivo intra-tumoural concentration 
and activity of Sorafenib in cutaneous schwannomas of NF2 patients is currently 
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ongoing (EudraCT: 2011-001789-16). Unfortunately, the outcome of this trial was 
negative highlighting the need for further research into potential treatment options 
(unpublished data). 
1.5.4 Bevacizumab  
Vascular endothelial growth factor (VEGF) is overexpressed in both NF2-related and 
sporadic schwannomas, which correlates with tumour growth rate (Cayé-Thomasen et 
al., 2003; Cayé-Thomasen et al., 2005). Bevacizumab, a VEGF inhibitor, has been tested 
in vestibular schwannoma where tumour regression, reductions in tumour growth 
rates and improved hearing have been reported (Alanin et al., 2015; Hochart et al., 
2015; Mautner et al., 2010; Plotkin et al., 2012). One study showed a response of more 
than 20% tumour shrinkage in 50% of patients and 50% also reported subjective 
neurological improvements (Alanin et al., 2015). A retrospective study of 15 NF2 
patients treated with Bevacizumab for progressive vestibular schwannoma showed a 
response of more than 20% tumour volume shrinkage in 14/48 meningiomas (Nunes et 
al., 2013). Unfortunately, in nine cases, the response was not maintained following 
discontinuation of Bevacizumab treatment, and the tumours increased in volume at 
the same rate as the non-responding tumours (Nunes et al., 2013). In another study, 
there was a partial response in two atypical meningiomas treated with Bevacizumab 
for nine months and stable disease in an additional five meningiomas (Hawasli et al., 
2013). A retrospective study of Bevacizumab in eight patients with recurrent 
ependymoma (WHO II and III) reported a partial radiographic response in 75% of 
patients treated with Bevacizumab-containing regimens (Green et al., 2009). However, 
5/6 patients received Bevacizumab alongside chemotherapy such as temozolomide or 
carboplatin making it difficult to determine the therapeutic agent responsible for the 
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tumour response (Green et al., 2009). There are currently two ongoing phase II clinical 
trials: testing Bevacizumab in children in young adults with NF2 (NCT01767792); and 
assessing Bevacizumab potential in treating patients with recurrent or progressive 
meningioma (NCT01125046). 
1.5.5 Selumetinib (AZD6244) 
AZD6244 is a MEK1/2 inhibitor with demonstrated anti-tumourigenic activity in a 
primary human schwannoma model. AZD6244 was able to completely abrogate 
Platelet-derived growth factor (PDGF) induced ERK1/2 activation and proliferation but 
had no effect on cell viability at concentrations tested (Ammoun et al., 2010b). A phase 
I trial of Selumetinib in NF1 children with inoperable plexiform neurofibromas was 
carried out to determine the maximum tolerated dose (Dombi et al., 2016). The study 
reported that 60% of the recommended adult dose of Selumetinib could be 
administered long-term in children. In addition, 71% of children had a partial response 
in their plexiform neurofibromas (tumour volume decrease > 20%) (Dombi et al., 
2016). Selumetinib has been shown to be safe, efficacious and suitable for long-term 
treatment; therefore, it has the potential to be translated into the treatment of NF2 
patients. A phase II clinical trials of AZD6244 in NF2 patients with NF2-asscoiated 
tumours is currently recruiting patients (NCT03095248). 
1.5.6 Combination therapy 
Combinatorial regimens targeting different activated pathways in Merlin-deficient 
tumours may have a beneficial effect in reducing tumour size compared with one drug 
alone. A phase II clinical trial of Bevacizumab and Everolimus treatment for recurrent, 
progressive meningiomas showed that the majority of meningiomas treated had a 
stable disease pattern after treatment (15/17) (Shih et al., 2016). However, there was 
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no reduction in tumour volume in any of the meningiomas and four patients 
discontinued treatment due to toxicity demonstrating the unsuitability of this drug 
combination to treat NF2 patients long term (Shih et al., 2016). In addition, lower 
concentrations of Bevacizumab and Everolimus for the treatment of low grade Merlin-
deficient tumours should be tested. 
Unfortunately, a phase II study of Bevacizumab and Lapatinib in 24 patients with 
recurrent ependymoma showed no response (DeWire et al., 2015). This was 
particularly disappointing as an earlier retrospective study in recurrent ependymoma 
suggested Bevacizumab was efficacious and led to reductions in tumour size (Green et 
al., 2009). However, the combination of Bevacizumab and Lapatinib has not yet been 
tested in less aggressive, non-recurrent, Merlin-deficient tumours. 
Nilotinib and AZD6244 were tested in human primary schwannoma cells and were 
shown to be more effective at reducing proliferation when delivered together 
(Ammoun et al., 2011). However, consideration must be given to long-term toxicity of 
any potential therapeutic as NF2 patients would need long term treatment to be 
effective on multiple tumours that continue to grow throughout life. Combination of 
drugs leads to increased complexity when determining tolerated long-term toxicities.  
1.6 CRL4-DCAF1 
The CRL4-DCAF1 complex comprises Cullin 4A/B, the adaptor protein DDB1 and DCAF1 
as the substrate receptor protein (Angers et al., 2006; He et al., 2006; Jin et al., 2006). 
CRL4-DCAF1 is an E3 ubiquitin ligase complex that ubiquitinates lysine residues within 
substrates, often resulting in substrate degradation (Jin et al., 2006; Kaur et al., 2012; 
Li et al., 2014; Yu et al., 2015). There are around 600 E3 ubiquitin ligase complexes that 
are responsible for ubiquitin modification of over 20% of all intracellular proteins 
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(Jackson & Xiong, 2009; Soucy et al., 2009). The type of ubiquitin modification 
determines the function of the ubiquitination. Poly-ubiquitination often directs the 
substrate to the proteasome or lysosome where it is degraded, whereas mono-
ubiquitination can significantly alter protein function, summarized in figure 1.2 
(Hershko & Ciechanover, 1998; Sugiura et al., 2014). For example, mono-ubiquitination 





Figure 1.2 - Roles of ubiquitination. Ubiquitination regulates protein signalling predominantly through 
poly-ubiquitination of substrates leading to proteasome-mediated and lysosome-mediated degradation 
(Hershko & Ciechanover, 1998; Sugiura et al., 2014). (multi)Mono-ubiquitination regulates protein 
signalling by altering binding partners, localization, conformation and kinase activity (Komander & Rape, 
2012). Mono-ubiquitination can also be the precursor to poly-ubiquitination of substrates indicated by a 
blue arrow (Windheim, Peggie & Cohen, 2008). The green arrows show examples of (multi)mono-
ubiquitination regulating degradation-independent protein functions. Dissociation of the Small worm 
phenotype (SMA) Mothers Against Decapentaplegic (MAD) (SMAD4)/Receptor regulated Small worm 
phenotype (SMA) Mothers Against Decapentaplegic (MAD) (R-SMAD) complex is mediated by 
ECTO/Transcriptional intermediary factor 1 (TIF1-γ) induced mono-ubiquitination of SMAD4 (Dupont et 
al., 2005). Neural precursor cell expressed developmentally down-regulated protein 4 (NEDD4)-1 mono-
ubiquitinates Phosphatase and tensin homolog (PTEN) leading to nuclear import (Trotman et al., 2007). 
Conversely, NEDD4-1 mono-ubiquitination of DCNL1 mediates nuclear export (Wu et al., 2011). Mono-
ubiquitination of Zeta-chain-associated protein kinase 70 (ZAP-70) at K476 can stabilize an active ZAP-70 
conformation (Ball et al., 2016). Association of thyroid hormone-activating type 2 deiodinase with 
WSB01 leads to ubiquitination, a change in conformation and inhibition of catalytic activity (Sagar et al., 





1.6.1 CRL4-DCAF1 roles and regulation 
Cullin-RING ligase (CRL) ubiquitin complexes are activated by neddylation, which leads 
to a conformational change allowing the Cullin-substrate to bind and thus be 
ubiquitinated (Duda et al., 2008; Saha & Deshaies, 2008; Zheng et al., 2002; Zhou et al., 
2018). The Neural precursor cell expressed developmentally down-regulated protein 8 
(NEDD8) E3 ligase, Ring-Box 1 (RBX1), pairs with the E2, Ubiquitin conjugating enzyme 
E2 M (UBE2M) and the NEDD8-activating enzyme E1 (NAE) to catalyse the neddylation 
of Cullin 1, 2, 3, 4A, 4B and 5 proteins (Hochstrasser, 1998; Jones et al., 2008). 
DCAF1, also known as Viral protein R binding protein (VPRBP) was first discovered in 
1994 as a protein of unknown function that bound to the HIV1 Viral protein R (VPR) 
(Hochstrasser, 1998). VPR can activate CRL4-DCAF1’s ubiquitin ligase activity and has 
been shown to facilitate ubiquitination and subsequent degradation of Uracil-DNA 
glycosylase 2 (UNG2) (Ahn et al., 2010). Conversely, CRL4-DCAF1 activity is inhibited by 
the closed, active form of Merlin which binds to the C-terminal of DCAF1 in the nucleus 
and prevents substrate recruitment (Li et al., 2010).  
DCAF1 inhibition prevents ubiquitin modification of LATS1/2 and therefore enhances 
YAP phosphorylation and subsequent degradation to control growth (Li et al., 2014). 
When active, CRL4-DCAF1 targets LATS1/2 for ubiquitination in the nucleus which 
inhibits the Hippo pathway kinase cascade and downregulates the phosphorylation of 
YAP. This leads to nuclear retention of YAP and activation of Hippo-mediated gene 
transcription required for proliferation (Li et al., 2014). CRL4-DCAF1 also poly-
ubiquitinates the transcription factor Forkhead Box M1 (FOXM1) which leads to 
proteasomal-mediated degradation (Wang et al., 2017). Interestingly, DCAF1 has an 
additional role in FOXM1 regulation and activates FOXM1 in an E3 ubiquitin ligase 
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independent manner highlighting the complexity of CRL4-DCAF1 signalling (Wang et 
al., 2017). In addition, DCAF1 has an E3 ubiquitin ligase independent function as a 
kinase that phosphorylates histone 2A (H2A) in the nucleus (H2AT120p) (Kim et al., 
2013).  
There is evidence from our group that KSR1, a scaffold protein of the RAF/MEK/ERK 
pathway may also interact with CRL4-DCAF1 (Zhou et al., 2016a). Transfected KSR1 
was immunoprecipitated from HEK293T cells and the complex was then analysed by 
mass spectrometry (Zhou et al., 2016a). This analysis identified 225 binding partners, 
30% of which were nuclear proteins including several components of the CRL4-DCAF1 
ubiquitin ligase complex; Cullin 4B, DDB1 and DCAF1 (Zhou et al., 2016a). Additional 
characterization of the DCAF1/KSR1 interaction and downstream signalling is 
necessary. 
1.6.2 CRL4-DCAF1 in cancer 
CRL4-DCAF1’s most significant role in cancer is in Merlin-deficient tumourigenesis. 
Indeed, Li et al. demonstrated that DCAF1 is required for Merlin-deficient 
tumourigenesis and thus DCAF1 inhibition by Merlin is an essential tumour suppressor 
function (Li et al., 2010). Increased CRL4-DCAF1 function in other cancers has also been 
reported. Expression of Long noncoding uc. 134 (long non-coding RNA) was reduced in 
hepatocellular carcinoma tissues compared with adjacent normal tissue and was 
shown to inhibit Cullin 4A (CUL4A)-mediated LATS1 ubiquitination suggesting that 
CRL4-DCAF1 is important in hepatocellular carcinoma development (Ni et al., 2017). 
Furthermore, overexpression of p62 and DCAF1 in Non-small-cell lung carcinoma 
(NSCLC) patients was associated with poor prognosis (Wang et al., 2013). CRL4-DCAF1 
is also essential for cell cycle progression into S phase. However, it is still unclear 
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whether the role of DCAF1 in cell cycle progression is crucial for cancer growth (Hrecka 
et al., 2007).   
Interestingly, DCAF1’s contribution to the growth of some cancers may be CRL4-DCAF1 
independent. DCAF1 protein expression is upregulated in high-grade serous ovarian 
tumours, which correlates with an increase in FOXM1 activation (Wang et al., 2017). In 
addition, in bladder, breast and prostate cancer tissues there was a correlation 
between DCAF1 expression and H2AT120p, a substrate downstream of DCAF1 kinase 
activity (Kim et al., 2013). H2A phosphorylation inhibits gene transcription of tumour 
suppressor genes and DCAF1 depletion by Short hairpin RNA (shRNA) led to a decrease 
in H2AT120p as well as a decrease in proliferation and viability (Kim et al., 2013). 
Importantly, overexpression of kinase-dead DCAF1 (K194R) did not restore 
proliferation of colony formation suggesting DCAF1 kinase activity has a pertinent 
oncogenic role in some tumour types (Kim et al., 2013).  
1.6.3 Targeting CRL4-DCAF1 and DCAF1 kinase activity 
There are no specific CRL4-DCAF1 inhibitors. However, MLN4921 (and its successor 
MLN3651) are NAE inhibitors that bind to the NAE active site and prevent the 
neddylation and activation of Cullins (Brownell et al., 2010). Interestingly, neddylation 
also has roles in the activation and/or the inactivation of proteins such as p53 and 
Mouse double minute 2 homolog (MDM2), independent of Cullins (Dohmesen, 
Koeppel & Dobbelstein, 2008; Xirodimas et al., 2004). E3 ubiquitin ligase dependent 
ubiquitination of substrates is reduced following MLN4924 treatment (Zhou et al., 
2018). Accordingly, MLN4924 leads to the accumulation of Cullin substrates such as 
Chromatin Licensing And DNA Replication Factor 1 (CDT1), Hypoxia-inducible factor 1-
alpha (HIF1α) and CYCLIN E (Soucy et al., 2009). The accumulation of Cullin–RING ligase 
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(CRL) substrates following MLN4924 treatment in cancer cells leads to DNA re-
replication (Soucy et al., 2009), apoptosis (Lin et al., 2010; Swords et al., 2010), 
senescence (Jia, Li & Sun, 2011) and protective autophagy (Luo et al., 2012). MLN4924 
was also able to inhibit the growth of tumour xenografts derived from HCT-116 or 
H522 cells (Soucy et al., 2009).  
MLN4924 inhibited LATS1/2 ubiquitination suggesting that the drug effectively 
prevents CRL4-DCAF1 neddylation (Cooper et al., 2017). Furthermore, MLN4924 
treatment in the mouse schwannoma cell line, FC-1801 led to increased YAP 
phosphorylation at S127 (downstream of LATS1/2) and decreased neddylated Cullins 
(Cooper et al., 2017). Importantly, MLN4924 suppressed growth of Merlin-deficient FC-
1801 cells but not the Merlin expressing FH-912 Schwann cells at 0.28 µM showing 
that Merlin-deficient cells are particularly sensitive to neddylation inhibition which 
could be CRL4-DCAF1 dependent (Cooper et al., 2017). Whilst YAP phosphorylation 
was increased, downstream YAP target genes were unchanged in both cell lines (FC-
1801 and FH-912) therefore suggesting that MLN4924’s growth suppressive effects are 
not dependent on Hippo pathway activation (Cooper et al., 2017).  
Cooper et al. noticed that MLN4924 did not inhibit the MTOR pathway or S6 
phosphorylation and therefore suggested that combination of MLN4924 and GDC-
0980, a dual mTOR/PI3K inhibitor, may be beneficial in inhibiting Merlin-deficient cell 
growth (Cooper et al., 2017). Indeed, combination of MLN4924 and GDC-0980 
completely suppressed tumour growth of the malignant mesothelioma cell line, VAMT-
1 when injected into the flanks of mice (Cooper et al., 2017). Treatment of primary 
schwannoma cells with both MLN4924 and GDC-0980 led to a significant decrease in 
proliferation compared with MLN4924 treatment alone (Cooper et al., 2017). This 
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demonstrates that neddylation inhibition can be combined with inhibitors of other 
pertinent pathways in Merlin-deficient cells to enhance treatment efficacy. 
Using in vitro kinase assays, DCAF1 and H2A were incubated with various compounds 
to identify a DCAF1 kinase inhibitor (Kim et al., 2013). B32B3 was identified and shown 
to reduce H2AT120p after 24 hours with an IC50 of 0.5 μM in DU145 cells (Kim et al., 
2013). This reduction correlated with a reduction in the number of colonies after cells 
were plated on soft agar (Kim et al., 2013). Mice were then inoculated with DU145 
cells and treated with B32B3 for three weeks leading to reduced tumour growth and 
reduced H2AT120p in tumour xenografts demonstrating the potential of B32B3 as a 
therapeutic agent (Kim et al., 2013).  
1.7 KSR1 
The KSR proteins are encoded by Ksr1 and Kinase suppressor of RAS 2 (Ksr2) genes 
with significant homology and 43% sequence identity (Channavajhala et al., 2003; 
Therrien et al., 1995). KSR1 is highly expressed in the brain with expression also 
detected in bladder, ovary, testis and lung mouse tissue whereas KSR2 protein is only 
detected in the brain (Costanzo-Garvey et al., 2009; Giblett et al., 2002). A novel splice 
variant of KSR1, named Brain isoform-Kinase suppressor of RAS-1 (B-KSR1) has also 
been identified in mouse brain tissues (Müller et al., 2000). Both KSR1 and KSR2 
contain five conserved domains (CA1-CA5) and interact with the RAF/MEK/ERK 
pathway (Channavajhala et al., 2003; Therrien et al., 1995). KSR1 and KSR2 also have 
distinct roles. For example, KSR2 regulates proliferation through Adenosine 
monophosphate-activated protein kinase (AMPK) in a RAF/MEK/ERK-independent 
fashion (Fernandez, Henry & Lewis, 2012; Liu et al., 2009). We chose to investigate 
KSR1 as its roles in cancer are better defined than KSR2. In addition, KSR1 deficiency 
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prevented v-Ha-RAS-mediated skin tumour formation in mice whereas the role of KSR2 
in resistance to tumour formation has not yet been explored (Lozano et al., 2003). 
1.7.1 KSR1 roles and regulation 
KSR1 is a cytoplasmic scaffold protein of the RAF/MEK/ERK pathway, which brings the 
three components together to allow sequential activation of the pathway following 
growth factor stimulation at the cell membrane (Matallanas et al., 2011). Activated 
RAF induces a change in KSR1 that stimulates phosphorylation of the constitutively 
bound MEK1/2 to allow ERK1/2 activation (Brennan et al., 2011). MEK1/2 and RAF bind 
to the CA5 putative kinase domain within the C terminus of the protein whilst ERK1/2 
binds to the S/T-rich CA4 domain (Morrison, 2001). KSR1 is classified as a pseudokinase 
which lacks the lysine residue responsible for ATP orientation and hydrolysis within its 
CA5 kinase domain and is therefore thought not to have enzymatic activity (Clapéron & 
Therrien, 2007; Roy et al., 2002). However, recent evidence suggests that some 
pseudokinases can adopt a conformation which is permissive of autophosphorylation 
and phosphorylation of specific substrates meaning that the possibility of KSR1 kinase 
activity cannot be excluded (Zhang et al., 2012).   
Increasing levels of KSR1 promote RAF/MEK/ERK signalling and proliferation (Kortum & 
Lewis, 2004; Zhou et al., 2016a). However, at high concentrations KSR1 can inhibit 
signalling, a phenomenon common to many scaffold proteins (Kortum & Lewis, 2004). 
Therefore, KSR1 concentrations are tightly regulated within the cell by nuclear 
shuttling, phosphorylation and sub-cytoplasmic partitioning, which is regulated 
predominantly by the cysteine-rich CA3 domain, summarized in figure 1.3 (Brennan et 
al., 2002; Müller et al., 2001; Razidlo et al., 2004). For example, KSR1 shuttles out of 
the nucleus in a manner dependent on both T274 and S392 phosphorylation (around 
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the CA3 domain) and association with MEK1/2 (CA5 domain) (Brennan et al., 2002; 
Razidlo et al., 2004). In addition, phosphorylation of S392 by CDC25C-associated kinase 
1 (C-TAK1) regulates 14-3-3 protein binding to KSR1 leading to increased cytoplasmic 
accumulation (Müller et al., 2001). Conversely, Protein phosphatase 2A (PP2A) 
dephosphorylates KSR1 at S392 leading to KSR1 and 14-3-3 dissociation and 
subsequent KSR1 plasma membrane recruitment to activate signalling (Ory et al., 
2003). KSR1’s scaffolding function are also regulated by Casein kinase 2 (CK2) which 
modulates RAF/MEK/ERK activation. CK2 binds within the CA3 domain of KSR1 and 
facilitates Raf kinase activity (Ritt et al., 2007). Accordingly, loss of CK2 inhibits 
RAF/MEK/ERK activation without affecting KSR1 localization or RAF/MEK/ERK binding 
to KSR1 (Ritt et al., 2007). 
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Figure 1.3 - KSR1 regulation. A. Inactive KSR1 signalling. In the absence of growth factors (GF) and 
growth factor receptor (GFR) activation, KSR1 is maintained in an inactive state by 14-3-3 which retains 
KSR1 in the cytoplasm and prevents RAF/MEK/ERK activation (Jagemann et al., 2008). 14-3-3 binding to 
KSR1 is mediated by C-TAK1-dependent KSR1 phosphorylation (P) at S392 (Müller et al., 2001). B. Active 
KSR1 signalling. When a growth factor binds and activates a growth factor receptor, RAS is 
phosphorylated which mediates RAF/MEK/ERK pathway activation. KSR1 is dephosphorylated by PP2A 
which leads to the release of 14-3-3 and allows translocation to the cell membrane (Ory et al., 2003). 
RAF kinase activity is also regulated by CK2 binding to KSR1 (Ritt et al., 2007). KSR1 is a scaffold protein 




The known roles of KSR1 are predominantly related to regulation of RAF/MEK/ERK 
activity. However, there is some evidence that suggests there may be RAF/MEK/ERK 
independent roles of KSR1. Zhang et al. identified that KSR1 suppresses Deleted in 
bladder cancer protein 1 (DBC1) phosphorylation whilst Stebbing et al. showed that 
KSR1 increased Breast cancer 1 (BRCA1)-associated RING domain protein 1 (BARD1) 
protein levels in breast cancer cells line which may be independent of MEK1/2 
(Stebbing et al., 2015; Zhang et al., 2013). Furthermore, Zhou et al. described a 
MEK1/2 independent role of KSR1 in schwannoma adhesion (Zhou et al., 2016a).   
1.7.2 Roles in cancer 
Despite multifaceted regulation, KSR1 is frequently overexpressed in several cancers 
including colorectal cancer (Fisher et al., 2015), endometrial carcinoma (Llobet et al., 
2011), breast cancer (Stebbing et al., 2015) and schwannoma (Zhou et al., 2016a). 
Increased KSR1 expression in colorectal cancer is inversely correlated with expression 
of microRNA-497 (Wang et al., 2016). Wang et al. discovered that overexpression of 
microRNA-497 led to a significant reduction of KSR1 expression and mutation of KSR1 
at the proposed microRNA-497 binding site abrogated this change, suggesting that 
microRNA-497 directly regulates KSR1 expression (Wang et al., 2016). In addition, 
overexpression of KSR1 led to increases in cell proliferation, migration and invasion in 
the colorectal cell line model (Wang et al., 2016). Llobet et al. demonstrated that KSR1 
was overexpressed in endometrial carcinoma compared with normal endometrium. 
Furthermore, KSR1 knockdown in two endometrial cancer cell lines reduced 
proliferation which correlated with decreased pERK1/2 and CYCLIN D1 (Llobet et al., 
2011). Interestingly, KSR1 was not required for tumourigenesis in a K-RAS driven 
pancreatic cancer mouse model with heterozygous loss of p53 (Germino et al., 2018). 
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Finally, Yu et al. showed that mRNA and protein expression of Tissue factor protein is 
partly dependent on KSR1 (Yu et al., 2010). Tissue factor is a key component of the 
coagulation process and is also upregulated and involved in cancer metastasis 
suggesting a role for KSR1 in invasion (Ruf et al., 2011). KSR1 is also significantly 
upregulated in primary schwannoma cells at both the mRNA and protein level (Zhou et 
al., 2016a). Two KSR1 short hairpin RNA (shRNA) constructs significantly reduced 
proliferation, increased apoptosis, reduced focal adhesions, and altered cells from a 
multipolar to a bipolar shape demonstrating that KSR1 contributes to schwannoma 
pathology (Zhou et al., 2016a). 
Conversely, KSR1 was shown to act as a tumour suppressor in breast cancer (Stebbing 
et al., 2015). Stebbing et al. discovered a significant association between KSR1 
expression and disease-free survival (Stebbing et al., 2015). In addition, overexpression 
of KSR1 in breast cancer cell lines led to inhibition of tumour growth demonstrating 
that KSR1 protein function is dependent on cell type (Stebbing et al., 2015).  
The RAF/MEK/ERK pathway, which is often dependent on active KSR1 signalling, is 
commonly upregulated in cancer cells due to hyper-activation of receptor tyrosine 
kinases as well as mutated forms of RAS or RAF in some tumours leading to increased 
proliferation and decreased apoptosis (Niault & Baccarini, 2010; Tsuda, Kanje & Dahlin, 
2011). RAF/MEK/ERK signalling is also upregulated in Merlin-deficient tumours and 
drives cell proliferation as a result of PDGFR-β overexpression (Ammoun et al., 2008). 
This upregulation is also illustrated clearly by immunohistochemical staining of 
traumatic neuroma and human schwannoma tissue showing a large increase in both 
phosphorylated MEK1/2 and phosphorylated ERK1/2 expression, particularly within 
the nucleus (Hilton, Ristic & Hanemann, 2009).  
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1.7.3 Targeting KSR1 
Terbinafine is a potent inhibitor of squalene epoxidase, a component of the cholesterol 
biosynthetic pathway essential for the growth of pathogenic fungi (Nowosielski et al., 
2011). At higher concentrations Terbinafine also inhibits mammalian squalene 
epoxidase (Ryder & Dupont, 1985), as reviewed by Jain and Sehgal (Jain & Sehgal, 
2000). Terbinafine also has anti-proliferative effects in many cancers (Brown et al., 
2016; Lee et al., 2003; Li et al., 2013; Yang et al., 2006). It has been suggested by Li et 
al. that Terbinafine anti-tumour effects are dependent on KSR1 inhibition (Li et al., 
2013). Indeed, Terbinafine treatment in the oral squamous cell carcinoma cell line, KB, 
led to reduced KSR1 protein expression as well as significant decreases in pRaf, 
pMEK1/2 and pERK1/2 (Li et al., 2013). Unfortunately, a concentration of 291 µM (85 
µg/µl) was required to reduce the proliferative rate of KB cells by half demonstrating 
that terbinafine is not particularly potent (Li et al., 2013). In contrast, Terbinafine anti-
cancer activity in breast cancer cell lines was attributed to its mammalian squalene 
epoxidase activity known to be amplified in breast cancer (Brown et al., 2016). 
Terbinafine has modest anti-cancer activity and the mechanism of action is yet to be 
conclusively determined. Therefore, terbinafine was not used in this study. 
A phosphorothioate antisense oligonucleotide was designed to target KSR1 
nucleotides 214–231, which resulted in a 90% reduction of KSR1 expression in 
epidermoid carcinoma (A431) and pancreatic carcinoma (PANC-1) cell lines (Xing et al., 
2003). Continuous infusion of KSR1-specific antisense oligonucleotide 2 days before 
A431 or PANC1 implantation reduced tumour growth in a tumour model compared 
with no infusion (Xing et al., 2003). However, phosphorothioate oligonucleotides may 
interact with growth factor receptors such as EGFR and a non-specific 
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phosphorothioate oligonucleotide suppressed glioblastoma growth in a mouse model 
demonstrating potential non-target anti-tumourigenic effects (Rockwell et al., 1997).  
The KSR inhibitor, APS_2_79, was shown to block the dimerization of RAF with MEK1/2 
by maintaining KSR2 in an inactive state, whereby preventing MEK1/2 phosphorylation 
(Dhawan, Scopton & Dar, 2016). Importantly, KSR1-dependent phosphorylation of 
MEK1/2 and ERK1/2 was reduced with the addition of APS_2_79 for two hours in 
HEK293H cells overexpressing both KSR1 and MEK1/2 (Dhawan, Scopton & Dar, 2016). 
This suggests that APS_2_79 inhibits both KSR1 and KSR2 signalling. APS_2_79 activity 
was dependent on disruption of ATP binding as treatment of 293H HEK cells 
overexpressing the active site mutant, KSR1(A690F) had less of an effect on MEK1/2 
and ERK1/2 phosphorylation than wild-type KSR1 (Dhawan, Scopton & Dar, 2016). 
Unfortunately, this drug has limited efficacy alone in RAS-mutant cell lines (HCT-116 
and A549) and B-RAF-mutant cell lines (SK-MEL-239 and A375) (Dhawan, Scopton & 
Dar, 2016). However, APS_2_79 has synergistic activity with the MEK1/2 inhibitor, 
trametinib, specifically in K-RAS-mutant cell lines (Dhawan, Scopton & Dar, 2016). 
Dhawan et al. proposed that APS_2_79 potentiates the negative feedback loop 
induced by MEK1/2 inhibition in RAS mutant cancers (Dhawan, Scopton & Dar, 2016). 
The efficacy of APS_2_79 alone or in combination with a MEK1/2 inhibitor in other 
indications is not yet known (Dhawan, Scopton & Dar, 2016). 
1.8 Aims 
There is evidence that KSR1 is upregulated in schwannoma but DCAF1 expression has 
not been explored. In addition, DCAF1 and KSR1 expression in Merlin-deficient 
meningioma have not been reported. The first aim of this project was to analyse 
DCAF1 and KSR1 expression in schwannoma and meningioma. We also aimed to 
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determine the role of DCAF1 in Merlin-deficient cells. We hypothesised that DCAF1 
regulates KSR1 expression, localization or activity and thus contributes to Merlin-
deficient tumourigenesis.  
CRL4-DCAF1 and KSR1 interact and therefore our second aim was to characterise the 
DCAF1 and KSR1 interaction. Whilst DCAF1 and overexpressed KSR1 have been shown 
to interact in schwannoma, we wanted to show that the endogenous proteins interact. 
In addition, we used overexpressed proteins to determine the domains involved in the 
DCAF1/KSR1 interaction and the cellular location of the interaction, which may inform 
the relevance of the interaction. Finally, we assessed if DCAF1 knockdown changed the 
binding of KSR1 and RAF/MEK/ERK proteins to regulate the pathway. 
Our third and final aim was to assess the therapeutic potential of DCAF1 and KSR1 
inhibitors, particularly in combination. Combined shRNA knockdown of both KSR1 and 
DCAF1 had an additive effect on reducing proliferation of schwannoma cells implying 
that combination of DCAF1 and KSR1 inhibitors may be beneficial (Zhou et al., 2016a). 
We tested the potential of the neddylation inhibitor, MLN3651, the DCAF1 kinase 
inhibitor, B32B3, the KSR1 inhibitor, APS_2_79, as well as the RAF/MEK/ERK inhibitor, 












2.1 Buffers and reagents 
Transport medium (TM) - Dulbecco’s modified eagle medium (DMEM) (Gibco), 10% 
(v/v) foetal bovine serum (FBS) (Sigma), 500 U/ml penicillin/streptomycin (Gibco), 2.5 
µg/ml amphotericin B (Sigma) 
Schwannoma digestion medium - DMEM, 10% FBS, 500 U/ml penicillin/streptomycin, 
1.25 U/ml dispase grade I (Sigma), 160 U/ml collagenase type 1A (Sigma) 
Meningioma digestion medium - DMEM, 10% FBS, 100 U/ml penicillin/streptomycin, 
20 U/ml collagenase type III (Sigma) 
Nerve digestion medium - DMEM, 10% FBS, 500 U/ml penicillin/streptomycin, 0.8 U/ml 
dispase grade I, collagenase type 1A 160 U/ml 
Freezing medium - 45% FBS, 45% cell culture medium and 10% Dimethyl sulphoxide 
(DMSO) (Sigma) 
Low salt lysis buffer - 30 mM Trizma-base (Sigma) pH 8, 75 mM sodium chloride 
(Sigma), 10% v/v glycerol (for molecular biology) (Sigma), 1% v/v Triton X-100 (Sigma) 
4X sample reducing buffer - 1M Trizma-base pH 6.8, 200 mM Dithiothreitol (DTT) 
(Sigma), 8% Sodium dodecyl sulphate (SDS) (Fisher), 40% glycerol, 0.04% bromophenol 
blue 
Immunohistochemistry citrate buffer - 10 mM citric acid (Sigma), pH 6 
Immunohistochemistry Tris-Ethylenediaminetetraacetic acid (EDTA) buffer - 20 mM 
Trizma-base, 1 mM EDTA, pH 9 
Immunohistochemistry Tris-buffered saline-Tween 20 (TBST) buffer - 50 mM Trizma-
base, 140 mM sodium chloride, pH 7.6 with 0.045% v/v Tween 20 (Sigma 
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Copper sulphate 3’3 diaminobenzidine (DAB) enhancer - 50 mM copper sulphate 
(Sigma), 250 mM sodium chloride 
Lentiviral reagent mix - 3 µg of packaging plasmid (pCMV-dR8.91), 0.3 µg of envelope 
plasmid (VSV-G) and 3 µg of the hairpin-pLKO.1 vector dilute in Opti-mem® previously 
incubated with 18 µl of FuGENE® 6 transfection reagent (in Opti-mem® medium) 
Restriction enzyme plasmid digestion reaction - 0.5 µg Plasmid DNA, 0.2 µl acetylated 
Bovine serum albumin (BSA), 2 µl buffer, 0.5 µl restriction enzyme (NEB) and water to 
a total of 20 µl 
Radioimmunoprecipitation assay (RIPA) buffer - 50 mM Trizma-base pH 8, 150 mM 
sodium chloride, 1 mM EDTA pH 7.4, 1% nonidet p40 (NP-40), 0.5% sodium 
deoxycholate (Sigma), 0.1% SDS 
Western blot running buffer - 25 mM Trizma-base, 20 mM glycine, 3.5 mM SDS 
Western blot transfer buffer - 25 mM Trizma-base, 20 mM glycine and 15% v/v 
methanol 
Western blot TBST - 20 mM Trizma-base, 150 mM sodium chloride, 0.1% v/v Tween 20 
Western blot blocking buffer- 5% w/v milk (Sigma), 2% w/v BSA in TBST 
Western blot wash buffer - 100 mM glycine pH 2.4, 2 mM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) (Sigma) in deionised water 
Western blot stripping buffer - 1M Trizma-base pH 6.8, 10% w/v SDS, 0.7% v/v β-





2.2 Cell culture 
2.2.1 Sample collection 
All primary schwannoma, meningioma and normal tissues used throughout this project 
were obtained from consented individuals following the ethical guideline included in 
the ‘Investigation into the expression of signalling molecules in human brain tumour 
samples (Research Ethics Committee (REC) number 6/Q2103/123)’ and the ‘Identifying 
and validating molecular targets in low grade brain tumours (REC number 
14/SW/0119) study’. 
Peripheral nerves for Schwann cell culture were retrieved from donors post mortem 
after consent. The NHS Blood and Transplant (NHSBT) research study is entitled 
‘Collection of peripheral nerves for control cells for brain tumour treatment research’, 
NHSBT study reference: 61. Full research project title was ‘Identifying and validating 
molecular targets in low grade brain tumours; REC number: 14/SW/0119’. 
2.2.2 Tumour digestion 
Tumour specimens were collected and transported in Falcon tubes containing a 
transport medium (TM), in order to maintain live cells. In our laboratory, TM was 
removed and the tumour specimen washed with Dulbecco’s phosphate buffered saline 
(DPBS) (Gibco) and then transferred into a 10 cm petri dish with 20 ml of fresh TM. 
When possible tumours were processed obtaining primary cells, DNA, RNA, protein 
lysates and optimal cutting temperature (OCT) inclusions for immunofluorescence. 
Primary cells were obtained by incubating the tumour specimen in a digestion medium 
following two different protocols: one for schwannoma and another for meningioma. 
Schwannoma digestion medium or meningioma digestion medium were freshly made 
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and filtered with a 0.22 µM millex GP filter unit Millipore express Polyethersulfone 
(PES) membrane (Millipore) before applying the digestion procedure.  
In addition, tumour specimens were minced in smaller pieces using a sterile scalpel 
and tissues mechanically disrupted after 24 hours of incubation by pipetting using glass 
pipettes of decreasing diameter size. The digested sample was collected and 
centrifuged for seven minutes at 400 x g, the supernatant was removed and the pellet 
containing the cells was re-suspended in schwannoma or meningioma culture medium, 
according to the tissue type. After digestion, cells obtained from schwannoma tissues 
were plated on coated plates and incubated at 37 ᵒC/10% CO2 whilst cells obtained 
from meningioma cells were plated on uncoated plates and incubated at 37 ᵒC/5% CO2. 
All schwannoma plates were coated with 0.1 mg/ml poly-L-lysine (PLL) (Sigma) for 30 
minutes at room temperature and 4 µg/ml laminin (Fisher) overnight at 4 ᵒC. Tumour 
digestion was performed by the author and members of the research group but 
primarily by Dr Emanuela Ercolano. 
Phosphorylated Merlin and Merlin expression were checked by Western blot and only 








Figure 2.1 - Determining schwannoma and meningioma Merlin status. A: Representative Western blot 
showing pNF2 and Merlin (NF2) expression in human meningeal cells (HMC) and primary meningioma 
cells (MN), GAPDH- loading control. HMC were used as a positive control for the expression of pNF2 and 
NF2. Meningioma samples with no Merlin expression were used for experiments and assumed to have a 
Nf2 mutation in at least one allele. B: Representative Western blot showing pNF2 and Merlin (NF2) in 
primary Schwann cells (MOS), primary schwannoma cells (NF), meningioma cells (MN) and Benign 
Meningioma 1 (BenMen-1) cells. MOS were used as a positive control for pNF2 and NF2 whilst BenMen-












2.2.3 Normal nerve digestion 
Normal nerves were dissected at Derriford hospital and transported using TM as 
described above. TM was removed and the nerve was washed with DPBS before 
adding incubation media and transferring the sample to a 10 cm plate. Fascicles were 
pulled out of the nerve using sterile forceps under a microscope in a horizontal flow 
hood. The fascicles were incubated at 37 ᵒC/10% CO2 for 7-14 days. Nerve digestion 
was performed by adding nerve digestion medium and incubating overnight. The nerve 
was then cut into small pieces and mechanically digested using glass pipettes of 
decreasing diameter size. The digested sample was centrifuged at 400 x g for seven 
minutes and the pellet containing cells was resuspended before plating on a coated six 
well plate. Digestion of normal nerve was performed by Dr Emanuela Ercolano. 
2.2.4 Cell splitting and storage 
Cell medium was replaced every 3 days and cells were split when they reached 
confluency. Passaging the cells was performed by washing with DPBS and adding 
0.05% trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco). The cells were 
incubated for up to five minutes at 37 ᵒC before neutralizing trypsin with cell culture 
medium. Cells were then collected, centrifuged and re-suspended accordingly into 
fresh vessels. 
Primary cell and cell line storage was performed by re-suspending cell pellets in a 
freezing medium using cryogenic tubes. Freezing procedure was performed by 
maintaining cells in a freezing container overnight at -80 ᵒC and transferring to liquid 




2.2.5 Cells and medium 



















10% FBS (Sigma), 100 U/ml 
penicillin/streptomycin (Gibco), 
0.5 µM forskolin (Tocris), 2.5 
µg/ml amphotericin, 2.5 µg/ml 
insulin (Thermo Fisher 
Scientific), 10 nM β1-heregulin 
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2.3.1 Endogenous DCAF1 IP 
Confluent 10 cm plates of Benign meningioma cell line 1 (BenMen-1) cells were lysed 
and scraped in 250 µl low salt lysis buffer with Halt protease and phosphatase 
inhibitors (Thermo Fisher Scientific) (1:1000). Alternatively, schwannoma or 
meningioma tissue was homogenised in 1 ml low salt lysis buffer. BenMen-1 lysates 
were concentrated using Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-10 
membrane (Millipore) to maximise amount of protein used for immunoprecipitation. 
At least 3 mg of protein were used for BenMen-1 experiments. 
50µl of protein G sepharose 4 fast flow (GE healthcare) was added to fresh Eppendorf 
tubes using a 200µl pipette tip with the end cut off to prevent damage to the beads. 
The beads were washed three times with low salt lysis buffer followed by a 1 minute 
centrifuge at 7000 x g at 4 ᵒC. Ready-to-use beads were added to 3 mg of protein and 
rotated for 1 hour at room temperature to remove any proteins that bind to the beads 
(pre-clearing). The pre-cleared protein lysate was then collected after centrifuging the 
beads and DCAF1 antibody (Santa Cruz Biotechnology) or normal mouse IgG (Santa 
Cruz Biotechnology) was added at a concentration of 4 µg for each milligram of 
protein. The pre-cleared protein and antibody complex were further rotated overnight 
at 4 ᵒC. 
The beads used to pre-clear the protein were washed a further three times with low 
salt lysis buffer and 40 µl 2X sample reducing buffer was added. 2X sample reducing 
buffer was made by diluting 4X sample reducing buffer with low salt lysis buffer. The 
beads were heated at 95 ᵒC and stored at -80 ᵒC. 
79 
 
Fresh beads were washed three times with low salt lysis buffer and added to the pre-
cleared protein and antibody complex for one hour rotated at room temperature. 
Following the incubation, the beads were washed three times using a low salt lysis 
buffer and 40 µl 2X sample reducing buffer. The beads were heated at 95 ᵒC for five 
minutes and stored at -80 ᵒC. 
2.3.2 FLAG IP 
A 10 cm plate of HEK293T cells transfected with FLAG-tagged proteins were lysed in 1 
ml of low salt lysis buffer. 40 µl of anti-FLAG M2 affinity gel (Sigma) for each 
experimental condition was washed with low salt lysis buffer followed by 
centrifugation at 7000 x g for 1 minute at 4 ᵒC. Low salt lysis buffer was removed and 
0.1 M glycine (Santa Cruz Biotechnology) pH 3.5 was added to remove any unbound 
anti-FLAG antibody from the resin suspension. This was followed by three further 
washes with low salt lysis buffer and the addition of at least 1 mg of protein lysate 
(except the cytoplasmic and nuclear fractionation FLAG immunoprecipitation in which 
at least 100 µg of protein was added).  
The volume of each experimental condition was equalised using low salt lysis buffer 
and resin was rotated overnight at 4 ᵒC. The protein-resin complex was then washed 
three times with low salt lysis buffer and 40 µl 2X sample reducing buffer was added. 
The resin was heated at 95 ᵒC for five minutes and stored at -80 ᵒC. 
2.3.3 Myc IP 
A 10 cm plate of HEK293T cells transfected with myc-tagged proteins was lysed in 1ml 
low salt lysis buffer. Two protocols were used for myc IP.  
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Protocol one (#) - 50 µl protein G sepharose 4 fast flow was washed three times with 
low salt lysis buffer at 4 ᵒC and then 1 mg of protein was added and rotated for one 
hour at room temperature. The pre-cleared protein was removed from the beads and 
placed in a fresh Eppendorf. 1 µl of Myc-tag antibody (Cell Signalling Technology) was 
then added to the pre-cleared protein and rotated overnight at 4 ᵒC. The next day 50 µl 
protein G sepharose 4 fast flow were washed three time with low salt lysis buffer and 
added to the protein-antibody complex for 1 hour rotating at room temperature. The 
complex was then washed three times with low salt lysis buffer and 40 µl 2X sample 
reducing buffer was added. The beads were heated for five minutes at 95 ᵒC and stored 
at -80 ᵒC until needed. 
Protocol two (*) – 50 µl protein G sepharose 4 fast flow was washed three times with 
low salt lysis buffer at 4 ᵒC and then 1 mg of protein and 1 µl of Myc-tag antibody (Cell 
Signalling Technology) was added. The beads were rotated overnight at 4 ᵒC and then 
the protein-bead complex was washed three times with low salt lysis buffer. 40 µl 2X 
sample reducing buffer was added and the beads were heated for five minutes at 95 ᵒC 









Antibody Type Clone Company Catalog Dilution 
DCAF1 Mouse 
monoclonal 







  Santa Cruz 
Biotechnology 
Sc-2025 4 µg/mg 
Myc tag Mouse 
monoclonal 
9B11 CST 2276 1 µl/ml 




2.4 Cytoplasmic and nuclear fractionation 
Cells were fractionated using the nuclear and cytoplasmic extraction reagents (NE-PER) 
kit (Thermo Fisher Scientific) using the recommended protocol. Briefly, cells were 
collected using trypsin and re-suspended in ice-cold DPBS. Cells were then centrifuged 
at 500 x g for 2 minutes at 4 ᵒC to remove DPBS and re-suspended in the recommended 
amount of ice-cold Cytoplasmic Extraction Reagent I (CER I) (with protease and 
phosphatase inhibitors). The cell pellet was vortexed for 15 seconds and incubated on 
ice for 10 minutes followed by the addition of Cytoplasmic Extraction Reagent I (CER II) 
to rupture the cell membrane. The supernatant containing cytoplasmic extract was 
collected and ice-cold Nuclear extraction reagent (NER) (with protease and 
phosphatase inhibitors) was added to the nuclear pellet. The nuclear pellet was 
vortexed repeatedly and centrifuged to release the nuclear extract which was 
collected and stored at -80 ᵒC. Protein estimation was calculated for both the 
cytoplasmic and nuclear fraction and all experiments using these lysates were based 
on equal protein.  
2.5 Drug treatments 
2.5.1 Drugs used 
MLN3651, a neddylation inhibitor, was provided by Takeda pharmaceuticals at a 
concentration of 10 mM. MLN3651 was diluted in DMSO to make stocks of 0.1 mM, 
0.3 mM, 0.6 mM, 1 mM, 3 mM, 6 mM and 10 mM. These drug stocks were further 
diluted in phenol-free cell culture medium (DMEM; Gibco, 11880-028) at 1:1000 for 
drug treatments.   
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B32B3, a DCAF1 kinase inhibitor, was purchased from Sigma and re-suspended in 
DMSO to make stocks of 20 mM and 60 mM. Final dilutions were made in phenol-free 
cell culture medium at a concentration of 1:1000 from the DMSO stocks. 
Selumetinib (AZD6244), a MEK1/2 inhibitor, was purchased from Selleckchem and re-
suspended in DMSO to make stock of 50 mM and 100 mM. Final dilutions were made 
in phenol-free cell culture medium to achieve a final concentration of 0.1% DMSO. 
2.5.2 ATP viability assay 
Cells were plated in clear bottom, opaque walled 96 well plates (4000 cells per well for 
primary cells and 3000 cells per well for cell lines). After 24 hours, the medium was 
removed and replaced with varying concentrations of B32B3 or MLN3651 diluted in 
phenol-free cell culture medium. After the drug treatment (see figures for drug 
treatment times), the plate was placed at room temperature for 30 minutes following 
the Celltiter-Glo® luminescent cell viability assay (Promega) instructions. The reagents 
were equilibrated to room temperature and 100 µl of reconstituted reagent was added 
to each well using fresh filter tips to avoid ATP contamination. The plate was placed on 
an orbital shake for two minutes and incubated at room temperature for 10 minutes 
before reading the luminescent signal with the BMG Labtech Fluostar Omega plate 
reader. A Repeated Measures Analysis of Variance (ANOVA) with Tukey’s Multiple 
Comparison Post Test was used to test statistical significance between drug-treated 
cells and DMSO control (p< 0.05). IC50 was determined using Graphpad Prism 5 with 
automatic outlier elimination. Cell viability experiments for MLN3651-treated cells 





2.5.3 Caspase 3/7 assay 
As above, except 100 µl of reconstituted Caspase-Glo 3/7 assay (Promega) reagents 
are added to the cells. The plate was then placed on an orbital shaker for 30 seconds 
and incubated at room temperature for 1 hour before reading the luminescent signal 
with the BMG Labtech Fluostar Omega plate reader. A Repeated Measures ANOVA 
with Tukey’s Multiple Comparison Post Test was used to test statistical significance 
between drug-treated cells and DMSO control (p< 0.05). Caspase 3/7 experiments for 
MLN3651-treated cells were performed by Dr Emaneula Ercolano and the author as 
part of a Takeda-funded study. 
2.6 Immunocytochemistry 
2.6.1 Ki-67 
Immunocytochemistry on cells were performed using 8-well chamber slides (Nunc™ 
Lab-Tek™ Chamber Slide System, Thermo Fisher Scientific) Briefly, 10000 cells were 
plated in each well of the labtek and left to grow overnight before adding drug 
treatments. After the drug treatment, the medium was removed, cells washed with 
phosphate buffered saline (PBS) (Thermo Fisher Scientific) and fixed with 4% 
paraformaldehyde (PFA) diluted from 16% PFA weight/volume (w/v) (Thermo Fisher 
Scientific)/PBS. Cells were permeabilised and fixed with ice-cold methanol at -20 ᵒC for 
10 minutes; blocking was performed with 10% v/v goat serum (Abcam) in 1% w/v 
bovine serum albumin (BSA) (Thermo Fisher Scientific)/PBS for 1 hour. Cells were 
incubated overnight with Ki-67 (1:200) (DAKO) in 1% BSA/PBS and Goat anti-Mouse 
IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 594 (Thermo Fisher 
Scientific) (1:500) in 1% BSA/PBS for 1 hour at room temperature. Finally, 4',6-
diamidino-2-phenylindole (DAPI) nuclear stain was added 1:500 in DPBS for 15 minutes 
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and the chamber of the labtek was removed. A cover slip was added with vectashield 
mounting medium for fluorescence (Vector Laboratories) and sealed with nail polish 
before imaging with an inverted Leica DMi8 microscope. 
Ki-67 staining was quantified by taking in account at least three 20x images of each 
condition and manually counting the number of Ki-67 positive cells versus the total 
number of cells (positive for DAPI staining) using ImageJ software. Statistical analysis 
was performed, on raw data, using a Repeated Measures ANOVA (with Tukey’s 
Multiple Comparison Test) or Student’s Paired T-test, p< 0.05. 
2.6.2 FLAG 
Immunocytochemistry on cells was performed using 8-well chamber slides (Nunc™ 
Lab-Tek™ Chamber Slide System, Thermo Fisher Scientific). 10000 cells were plated in 
each well of the labtek and left to grow overnight before adding KSR1 constructs. 48 
hours after transfection, the medium was removed, cells washed with phosphate 
buffered saline (PBS) (Thermo Fisher Scientific) and fixed with 4% PFA diluted from 
16% PFA weight/volume (w/v) (Thermo Fisher Scientific)/PBS. Cells were 
permeabilised with 0.2 Triton X-100 for 5 minutes; blocking was performed with 10% 
v/v goat serum (Abcam) in 1% w/v bovine serum albumin (BSA) (Thermo Fisher 
Scientific)/PBS for 1 hour. Cells were incubated overnight with FLAG (1:500) (Sigma) in 
1% BSA/PBS and Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 488 (Thermo Fisher Scientific) (1:500) in 1% BSA/PBS for 1 hour at room 
temperature. Finally, DAPI nuclear stain was added 1:500 in DPBS for 15 minutes and 
the chamber of the labtek was removed. A cover slip was added with vectashield 
mounting medium for fluorescence (Vector Laboratories) and sealed with nail polish 




Schwann cell culture quality was assessed by S100 immunocytochemistry, as described 
above but with S100 (Dako, Z0311, rabbit polyclonal) antibody diluted (1:100) in 1% 
BSA in DPBS. Only Schwann cell cultures with more than 90% S100 positive cells were 


















Figure 2.2 - Proportion of S100-positive cells in Schwann cell cultures. A: Representative Schwann cell 
culture stained with a S100 antibody and counter-stained with the nuclear marker, DAPI. The image 
shows cells at 20x magnification and demonstrates that the majority of the culture is S100-positive and 
















2.7 Immunohistochemistry  
Formalin fixed paraffin embedded sections (4 µM) were provided by Derriford hospital, 
Plymouth, UK (Dr D. Hilton, Cellular and Anatomical Pathology). Briefly, slides were 
baked at 60 ᵒC for one hour and rehydrated using xylene followed by two ethanol 
washes. The slides were washed in running tap water for five minutes and then 
blocked in 3% H2O2/methanol for 30 minutes at room temperature. Slides were 
equilibrated with citrate (10 mM citric acid (Sigma), pH 6) or Tris-EDTA (20 mM Trizma-
base, 1 mM EDTA, pH 9) buffer dependent on the antibody being used. Slides for KSR1 
(H70) (Santa Cruz Biotechnology) were equilibrated in citrate buffer whilst slides for 
CUL4A (Proteintech) and VPRBP (DCAF1) (Proteintech) staining were equilibrated in 
Tris-EDTA buffer. Slides were then heated for 30 minutes in the microwave (700 W).  
The slides were washed in immunohistochemistry TBST buffer (50 mM Trizma-base, 
140 mM sodium chloride, pH 7.6 with 0.045% v/v Tween 20 (Sigma)) and blocking 
solution from the Vectastain universal elite ABC kit (Vector Laboratories) was made 
and added for 30 minutes. Primary antibody (CUL4A 1:100, VPRBP (DCAF1) 1:1000, 
KSR1 (H-70) 1:500) was diluted in TBST and added to the slides overnight at 4 ᵒC.  
A universal biotinylated secondary antibody (which contains a mixture of rabbit and 
mouse antibodies) and a streptavidin/biotin complex (provided with the Vectastain 
universal elite ABC kit) was then applied to the slides for 30 minutes each, at room 
temperature. Sigmafast 3’3 diaminobenzidine (DAB) tablets (Sigma) were used to 
make a DAB solution which is added to the slides for five minutes followed by copper 
sulphate DAB enhancer (50 mM copper sulphate (Sigma), 250 mM sodium chloride) for 
2–5 minutes. The slides are then washed with tap water and counterstained with 
Mayers haemotoxylin (Sigma) for two minutes. Finally, slides were dehydrated in 
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ethanol and then xylene and mounted onto cover slips using Distyrene, plasticizer, and 
xylene (DPX) mountant for histology (Fluka). 
Slides were kindly imaged and quantified by Dr David Hilton. DCAF1 antibody staining 
for schwannoma was conducted at the Cellular and Anatomical Pathology (Dr D. 
Hilton, Derriford hospital, Plymouth, UK) whereas all other staining was performed by 
the author. A score of 1-4 was given to each sample corresponding to 0–25%, 25–50%, 
50–75%, 75-100%, respectively. Percentage refers to the proportion of cells that are 
positive for the protein of interest. A Mann-Whitney test, Wilcoxon signed rank test or 
Kruskal-Wallis test with Dunn Multiple Comparison’s Post Tests was used to assess 






















Proteintech 10693-1-AP 1:100 
KSR1 H-70 Rabbit 
polyclonal 
H-70 Santa Cruz 
Biotechnology 






Proteintech 11612-1-AP 1:1000 




2.8 Lentivirus production and infection 
2.8.1 Lentivirus production 
HEK293FT cells (passage < 15) were plated in DMEM, 10% FBS into 10 cm culture 
plates and left growing overnight. A lentiviral reagent mix was added when cells 
reached 70% of confluence and maintained for 24 hours to facilitate cell infection. The 
lentiviral reagent mix consists of 3 µg of a packaging plasmid (pCMV-dR8.91), 0.3 µg of 
an envelope plasmid (VSV-G) and 3 µg of the hairpin-pLKO.1 vector in Opti-mem® 
previously incubated with 18 µl of FuGENE® 6 transfection reagent (in Opti-mem® 
medium) for 30 minutes at room temperature. 
After 24 hours, the medium containing the lentiviral reagent mix was removed and 
replaced with fresh medium (DMEM, 20% FBS, 100 U/ml penicillin/streptomycin). 
Supernatant, containing lentiviruses, was collected after 24 hours: medium was 
centrifuged at 400 x g for five minutes to remove cell debris. Lentiviral medium was 
aliquoted and stored at -80 ᵒC. 
2.8.2 Lentivirus infection 
HEK293T, schwannoma or meningioma cells were grown to at least 70% confluency 
before infection. Medium was replaced with medium supplemented with 16 µg/ml 
hexadimethrine bromide (Sigma) (cell lines) or protamine sulphate (Sigma) (primary 
cells). Homemade virus (DCAF1 shRNA, KSR1 overexpression) was then added at 1:1 
ratio with medium for 24 hours. Commercially available viruses (TRCN0000006230, 
KSR1 shRNA) were added at an Multiplicity of infection (MOI) of 20 to medium 
supplemented with 8 µg/ml polybrene or protamine sulphate. After 24 hours, fresh 
medium was added. After a further 24 hours, medium supplemented with 4 µg/ml 
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puromycin (Sigma) was added and replaced every 3–4 days for a total of seven days. 
Protein upregulation and downregulation was assessed by Western blot. 
2.8.3 Lentiviral information 
MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA was used as a 
Scramble control for all DCAF1 and KSR1 knockdown experiments and was purchased 
from Sigma. Scramble control lentiviral particles were produced in-house using 
methods mentioned above. 
The shDCAF1 lentivirus clone, TRCN0000129909, was purchased from Open Biosystem 
with a sequence of CCGGGCTGAGAATACTCTTCAAGAACTCGAGTT 
CTTGAAGAGTATTCTCAGCTTTTTTGGCTGAGAATACTCTTCAAGAA. Lentiviral particles 
were produced in-house using methods mentioned above. 
The shKSR1 lentivirus clones, TRCN0000006230, was purchased from Sigma with a 
sequence of CCGGGTGCCAGAAGAGCATGATATTCTCG 
AGAATATCATGCTCTTCTGGCACTTTTT. Lentiviral particles were purchased and 
manufactured by Sigma. 
A custom overexpression vector was used to produce a lentiviral plasmid that 
overexpressed human KSR1 (VectorBuilder; Cyagen). The human KSR1 sequence, NM 
_014238.1, with a C-terminal FLAG tag was cloned into the vector under the CMV 
promoter. A cleavage linker followed by Enhanced green fluorescent protein (EGFP) 
was used to allow co-expression of both human KSR1 and EGFP without compromising 
KSR1 structure and/or function. The plasmid contained ampicillin resistance for 
bacterial amplification and puromycin resistance for mammalian cell selection. A 
control plasmid was used that contained EGFP and puromycin resistance in a similar 
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vector. The control and KSR1 overexpression lentiviral particles were produced in-
house using methods mentioned above.  
Control plasmid, pLV[Exp]-EGFP:T2A:Puro-EF1A>mCherry, and human KSR1 
overexpression plasmid, pLV[Exp]-Puro-





Figure 2.3- Control and human KSR1 overexpression plasmid maps used for lentiviral production. 





2.9.1 Plasmid information  
pCMV5 WT KSR1 (K1) was a gift from Rob Lewis (Addgene plasmid # 25970) and 
contained the KSR1 sequence (NM_013571) with a C-terminal FLAG tag between the 5’ 
cloning site EcoR1 and the 3’ cloning site Kpn1 of pCMV5 (Yu et al., 1998). 
pCMV5 N539 (KN) was a gift from Rob Lewis (Addgene plasmid # 25972) and contained 
the KSR1 sequence (NM_013571) with deleted amino acids 540–873. A FLAG tag was 
added to the C-terminal and the sequence was between the 5’ cloning site EcoR1 and 
the 3’ cloning site Xba1 of pCMV5 (Yu et al., 1998). 
pCMV5 C540 (KC) was a gift from Rob Lewis (Addgene plasmid # 25971) and contained 
the KSR1 sequence (NM_013571) with deleted amino acids 1–539. A FLAG tag was 
added to the C-terminal and the sequence was between the 5’ cloning site EcoR1 and 
the 3’ cloning site Kpn1 of pCMV5 (Yu et al., 1998). 
pRK5-Myc-DCAF1 (D1), pRK5-Myc-DCAF1 (1–744)(D2) and pRK5-Myc-DCAF1 (D3) (745–
1507) plasmids were produced and kindly provided by Li et al. (Li et al., 2010).  
2.9.2 Plasmid amplification 
Plasmids were transformed into DH5α competent cells (Thermo Fisher Scientific) by 
adding 5 µl plasmid DNA into 50 µl competent cells in an Eppendorf tube. The 
plasmid/competent cell mix was incubated on ice for 30 minutes, heat shocked for 45 
seconds at 42 ᵒC and incubated on ice for 2 minutes. 250 µl sterile Luria Bertani (LB) 
broth (Sigma) was added and the plasmid/competent cell mix was then incubated in 
an orbital incubator shaker for 1 hour at 150 rpm, 37 ᵒC. Transformed competent cells 
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were plated onto sterile LB agar (Sigma) plates with ampicillin (100μg/ml) (Sigma) and 
incubated overnight at 37 ᵒC for selection. 
Plasmid amplification was performed from a single colony grown initially into 5 ml LB 
broth supplemented with (100 μg/ml) ampicillin overnight at 37 ᵒC in an orbital 
incubator shaker (150 rpm); 200 µl of this bacteria suspension was transferred into 100 
ml LB broth supplemented with (100 μg/ml) ampicillin and incubated overnight in an 
orbital incubator shaker at 150 rpm/37 ᵒC.  
Plasmid DNA was obtained from the bacteria culture using the Qiagen plasmid mini kit 
(Qiagen) following manufacturer’s protocol. We conducted a digestion of the plasmid 
DNA of interest using specific restriction enzymes to check whether the digested bands 
obtained are as expected for the individual plasmid. 
2.9.3 Restriction enzyme plasmid digestion 
A solution of 0.5 µg Plasmid DNA, 0.2 µl acetylated BSA, 2 µl buffer, 0.5 µl restriction 
enzyme (NEB) (specific enzymes listed in figures) and water to a total of 20 µl was 
incubated at 37 ᵒC for one hour. 6X DNA loading buffer was added and the samples 
were loaded onto a 1% agarose/Tris/Borate/EDTA (TBE) gel with gel red. The DNA was 
separated at 120 volts for 40 minutes and imaged. Restriction digests for DCAF1 and 







Figure 2.4 - DCAF1 plasmid digests. A: pRK5 wild type (WT) DCAF1 (D1), pRK5 (1–744 amino acids) 
DCAF1 (D2) and pRK5 (745–1507 amino acids) DCAF1 (D3) were digested with restriction enzymes as 
indicated on the plasmid maps. The agarose gel shows uncut plasmids and digested plasmid fragments 













Figure 2.5 - KSR1 plasmid digests. A: pCMV5 wild type (WT) KSR1 (K1), pCMV5 (C540) KSR1 (KC) and 
pCMV5 (N539) KSR1 (KN) were digested with restriction enzymes as indicated on the plasmid maps. The 











2.9.4 Plasmid transfection 
HEK293T cells were transfected at 60% confluency with FuGENE® 6 transfection 
reagent (Promega) at a ratio of 3:1 to the amount of plasmid added. For a 10 cm plate, 
6 µg K1, 4 µg KC, 2 µg KN, 4.5 µg D1, 3 µg D2 or 2.5 µg D3 was added to Opti-mem® 
(Gibco). The FuGENE® 6 transfection reagent/plasmid mix was then added to cells after 
45 minutes incubation at room temperature. Fresh medium was added to cells 24 
hours after transfection and cells were lysed 48 hours post-transfection. 
2.10 Western blotting 
2.10.1 Cell lysis/tissue homogenisation 
Cells were lysed by removing medium, washing with DPBS and adding RIPA buffer with 
Halt protease and phosphatase inhibitors (1:1000). Cells were removed using a plate 
scraper and stored at -80 ᵒC overnight before centrifuging at 13000 x g for 15 minutes 
at 4 ᵒC. The supernatant containing protein was then stored at -80 ᵒC before protein 
estimation and Western blot analysis. 
Tissue was washed in DPBS before adding low salt lysis buffer and digested using a 
glass homogeniser. The tissue was stored overnight at -80 ᵒC before centrifuging at 
13000 x g for 15 minutes.  
2.10.2 Protein estimation 
BSA protein standards were prepared in RIPA or low salt lysis buffer at varying 
concentrations between 0–2 mg/ml. Protein standards and samples were added to a 
96-well plate and 100 µl of PierceTM bicinchoninic acid (BCA) protein assay kit (Thermo 
Fisher Scientific) reagents (A:B at a ratio of 50:1) was added to each well. The 96 well 
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plate was incubated for 30 minutes at 37 ᵒC and protein concentration was established 
using a BMG Labtech Fluostar Omega plate reader. 





















The resolving gel was made using the following recipe and added to glass plates:-  
1 gel 6% 8% 10% 12% 15% 
30% acrylamide (Biorad) 2ml 2.67ml 3.33ml 4ml 5ml 
1.5 M Tris-Hydrochloric acid 
(HCL) pH 8.8 
2.5ml 2.5ml 2.5ml 2.5ml 2.5ml 
10% SDS 100μl 100μl 100μl 100μl 100μl 
Water 5.29ml 4.62ml 3.96ml 3.29ml 2.29ml 
10% Ammonium 
persulphate (APS) (Sigma) 




10μl 10μl 10μl 10μl 10μl 




Stacking gel was made and added using the following recipe:- 
4% Stacking gel 5ml (one gel) 10ml (two gel) 
30% acrylamide 650μl 1.3ml 
1 M Tris-HCL pH 6.8 625μl 1.25ml 
10% SDS 50μl 100μl 
Water 3.68ml 7.34ml 
10% APS 50μl 100μl 
TEMED 10μl 20μl 




2.10.4 Protein separation and transfer 
The gels were set up in the running apparatus in running buffer (25 mM Trizma-base, 
20 mM glycine, 3.5 mM SDS). Most commonly, 20 µg of protein with 4X sample 
reducing buffer was loaded into the gels and separated at a constant voltage of 120V 
for 70 minutes. Transfer onto polyvinylidene fluoride (PVDF) membrane (Biorad) (after 
pre-wetting with methanol) was set up in transfer buffer (25 mM Trizma-base, 20 mM 
glycine and 15% v/v methanol) and transferred at a constant current of 400mA for 80 
minutes. The ice pack was exchanged half way through the transfer and a magnetic 
stirrer maintained an even temperature throughout the tank. 
2.10.5 Membrane probing 
Following the transfer the membrane was washed in TBST (20 mM Trizma-base, 150 
mM sodium chloride, 0.1% v/v Tween 20) blocked using blocking buffer (5% w/v milk 
(Sigma), 2% w/v BSA in TBST) for one hour at room temperature on a rocker. The 
membrane was then washed three times with TBST and primary antibody was added 
overnight at 4 ᵒC. Primary antibody was diluted in 5% BSA/TBST (see antibody table for 
dilutions). After three TBST washes, secondary HRP-conjugated antibody (Biorad) was 
added for one hour at room temperature diluted at 1:5000 in 2.5% milk, 1% BSA in 
TBST. The membrane was washed with TBST and then twice with TBS before 
developing.   
Pierce Enhanced chemiluminescent substrate (ECL) Western blotting substrate or 
Pierce ECL plus Western blotting substrate (Thermo Fisher Scientific) was added to the 
membranes and incubated for two minutes. Then the membranes were either 
manually developed using Amersham hyperfilm ECL (GE healthcare) and a Xograph film 
104 
 


























CST 9422 1:1000 
CYCLIN D1 Rabbit 
polyclonal 
 










CST 9102 1:1000 
FLAG Mouse 
monoclonal 
M2 Sigma F1804 1:5000 
GAPDH Mouse 
monoclonal 
6C5 Millipore MAB374 1:20000 
HDAC1 Mouse 
monoclonal 




CST 4640S 1:500 
KSR1 H-70 Rabbit 
polyclonal 
H-70 Santa Cruz 
Biotechnology 




CST 9153 1:1000 
LATS2 Rabbit 
monoclonal 




CST 9122 1:1000 
Merlin Rabbit 
polyclonal 
D1D8 CST 6995 1:1000 
Myc tag Mouse 
monoclonal 















41G9 CST 9154 1:1000 
p-Merlin (S518) Rabbit 
polyclonal 
 
CST 9163 1:500 
p-YAP (S127) Rabbit 
polyclonal 
 




CST 3933 1:1000 










2.10.6 Stripping and storing membranes 
Stripping membranes was avoided when possible as protein may also be removed. 
Stripping was conducted by adding a wash buffer (100 mM glycine pH 2.4, 2 mM 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) (Sigma) in 
deionised water) followed by incubation with stripping buffer (1M tris-HCL pH 6.8, 10% 
w/v SDS, 0.7% v/v β-metacarpoethanol (Sigma) in deionised water) pre-heated to 56 ᵒC 
for 10 minutes. The membrane was then re-blocked with blocking milk and re-probed. 
Membranes were stored at -20 ᵒC when no longer needed.  
2.10.7 Western blot analysis 
Manually developed films were scanned in at 600dpi in greyscale. Image J was used for 
quantification of all Western blot bands, using Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as a loading control. Statistical analysis was performed on the 
raw densitometry values using Graphpad Prism 5, p< 0.05. Student’s Paired T test or 
Student’s Unpaired T test was used to assess statistical significance when there was 
two samples whereas a one-way ANOVA/Repeated Measures ANOVA was used if there 













Chapter 3 - DCAF1 and KSR1 expression and regulation 





The aim of this chapter was to examine DCAF1 expression in schwannoma, determine 
if DCAF1 and KSR1 expression was increased in Merlin-deficient models, focussing on 
meningioma in particular, and to determine if DCAF1 regulated KSR1 in these cells. In 
addition, we wanted to determine if targeting both DCAF1 and KSR1 expression in 
meningioma and BenMen-1 would have an additive effect on reducing RAF/MEK/ERK 
activity and proliferation compared with DCAF1 or KSR1 knockdown alone.   
3.2 DCAF1 is overexpressed in schwannoma 
DCAF1 and KSR1 are frequently overexpressed or dysregulated in cancer (Cooper et al., 
2017; Fisher et al., 2015; Kim et al., 2013; Llobet et al., 2011; Stebbing et al., 2015; 
Wang et al., 2017; Zhou et al., 2016a). Merlin is a suppressor of DCAF1 activity and 
therefore, DCAF1 is activated in Merlin-deficient tumours (Li et al., 2014; Li et al., 
2010). We have previously shown that KSR1 protein expression is increased in 
schwannoma tissue compared with normal nerve and traumatic neuroma, by 
immunohistochemistry (Zhou et al., 2016a). We wanted to determine if DCAF1 protein 
expression was also increased in Merlin-deficient schwannoma. We stained normal 
nerve, traumatic neuroma and schwannoma with DCAF1 antibody counterstained with 
haematoxylin to stain the nucleus and compared DCAF1 protein expression. Figure 
3.1A shows representative images at 400x magnification of five replicates showing that 
there is little DCAF1 staining in normal nerve and traumatic neuroma compared with 
schwannoma tissue, in which DCAF1 is highly expressed, particularly in the nucleus. 
The five replicates of each tissue type were given a score of 1, 2, 3 or 4 according to 
the percentage of cells expressing DCAF1. A score of 1 is given when less than 25% of 
cells expressed protein, a score of 2 for between 25% and 50% of cells expressing 
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protein, a score of 3 for between 51% and 75% of cells and a score of 4 for more than 
75% of cells expressing the protein. Figure 3.1B shows that four out of five 
schwannoma tissue samples were scored as 4 and one was scored as 3 whereas 
scoring for normal nerve and traumatic neuroma was much lower. A Kruskal-Wallis 
test was used to test statistical significance of differences in the medians of each group 
and Dunn’s multiple comparison post test showed that median DCAF1 protein 
expression was significantly higher in schwannoma tissue compared with normal nerve 
(p< 0.01). There was no significant difference in protein expression between normal 
nerve and traumatic neuroma or between traumatic neuroma and schwannoma (p> 
0.05).  
To confirm the results from immunohistochemistry, we used an alternative method to 
determine DCAF1 and KSR1 protein expression in normal nerve and schwannoma 
tissue (figure 3.1C). The Western blot shows there was increased DCAF1 protein 
expression in three schwannomas compared with one normal nerve. KSR1 expression 
was relatively absent in normal nerve and 1 schwannoma whereas there was clear 
KSR1 expression in two schwannoma (figure 3.1C). We did not quantify this Western 








Figure 3.1 - DCAF1 is overexpressed in schwannoma tissue. A: Representative immunohistochemical 
images of normal nerve (NF+/+), traumatic neuroma and merlin-deficient schwannoma (NF-/-) tissue 
stained with DCAF1 antibody and counterstained with haematoxylin are shown at 400x magnification. 
DCAF1 expression was increased in schwannoma compared to normal nerve and traumatic neuroma, 
particularly in the nucleus, scale bar- 50 µM. Immunohistochemical staining, imaging and scoring was 
carried out by Dr David Hilton. B: The graph shows the proportion of DCAF1 positive cells in five normal 
nerves, five traumatic neuromas and five schwannoma tissues where a score of 1 was less than 25% of 
cells expressing DCAF1, a score of 2 was between 25% and 50%, a score of 3 was between 51% and 75% 
and a score of 4 was more than 75%. Schwannoma tissue had significantly more cells expressing DCAF1 
than normal nerve, **- p< 0.01. C: Western blot showing DCAF1 and KSR1 expression in one normal 
nerve (Nerve-1–18 and three schwannoma tissue (NF) samples. DCAF1 was increased in schwannoma 
compared with normal nerve. KSR1 were increased in two schwannoma samples (NF1116_1 and 





Previously, we demonstrated that KSR1 protein was upregulated in schwannoma cells 
compared with Schwann cells, derived from schwannoma tissue and normal nerve 
respectively, via Western blot (Zhou et al., 2016a). We analysed DCAF1 protein 
expression in Schwann cells and Merlin-deficient schwannoma cells, shown in figure 
3.2A and B. We confirmed loss of Merlin protein expression by Western blot (figure 
2.1). DCAF1 expression was highly variable in Schwann cell and schwannoma samples. 
Figure 3.2C shows densitometry quantification of DCAF1 (normalized to 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) and whilst the mean expression 
in schwannoma samples was higher than the mean expression in Schwann cell 
samples, this was not statistically significant (Unpaired Student’s T test, p> 0.05). 
Overall, the results suggest that both DCAF1 and KSR1 proteins are overexpressed in 














Figure 3.2 - DCAF1 expression is highly variable in schwannoma cells. A, B: Western blots showing 
DCAF1 expression in Schwann (MOS) and schwannoma (NF) cells. DCAF1 expression is highly variable in 
Schwann and schwannoma cells. C: Mean DCAF1 expression and standard error of the mean (SEM) in 
Schwann cells and schwannoma from blots shown in A and B normalized to the loading control, GAPDH. 






















3.3 DCAF1 and KSR1 are overexpressed in meningioma  
DCAF1 and KSR1 expression in Merlin-deficient meningioma has never been explored 
and is important for this project where the aim was to test inhibitors of DCAF1 and 
KSR1 activity. Therefore, we analysed DCAF1 and KSR1 expression in human meninges 
and Merlin-deficient meningioma. Figure 3.3A shows representative images of normal 
brain with intact meninges (as shown by the insert) and Merlin-deficient meningioma 
tissue stained with DCAF1 and counterstained with the nuclear stain, haematoxylin. 
DCAF1 protein was mostly nuclear with some diffuse cytoplasmic expression. DCAF1 
was scored, by Dr David Hilton, according to the criteria described in figure 3.1B and 
shown in figure 3.3C. The proportion of cells expressing DCAF1 was significantly higher 
in meningioma (n=7) than in meninges (n=9) (p< 0.01, Mann-Whitney test). Figure 3.3B 
shows representative images of normal brain with intact meninges and Merlin-
deficient meningioma tissue stained with KSR1 and counterstained with the nuclear 
stain, haematoxylin. KSR1 was diffuse and granular in the cytoplasm with strong 
paranuclear nuclear expression in four out of seven meningioma samples. KSR1 was 
scored, by Dr David Hilton, according to the criteria described in figure 3.1B and the 
results are displayed in figure 3.3D. Interestingly, all seven meningioma samples had 
more than 75% of cells expressing KSR1 and thus were scored as 4. The proportion of 
cells expressing KSR1 was significantly higher in meningioma (n=7) compared with 
meninges (n=9) and this difference was statistically significant (p< 0.05, Wilcoxon 





Figure 3.3 - DCAF1 and KSR1 are overexpressed in meningioma tissue. A: Representative 
immunohistochemical images of normal meninges (200x with 400x insert) and meningioma (400x) tissue 
stained with DCAF1 antibody and counterstained with haematoxylin. DCAF1 expression was mostly 
nuclear with some diffuse cytoplasmic expression in meningioma. Immunohistochemical staining was 
carried out by the author whereas the images were taken and scored by Dr David Hilton. B: 
Representative Immunohistochemical images of normal meninges (200x with 400x insert) and 
meningioma (400x) tissue stained with KSR1 antibody and counterstained with haematoxylin. KSR1 
expression was diffuse and granular in the cytoplasm with some strong paranuclear nuclear expression 
in meningioma. Scale bar- 50 µM. C: Proportion of DCAF1 positive cells in nine normal meninges and 
seven meningioma tissues are plotted where a score of 1 was less than 25% of cells expressing DCAF1, a 
score of 2 was between 25% and 50%, a score of 3 was between 51% and 75% and a score of 4 was 
more than 75%. Meningioma tissue had significantly more cells expressing DCAF1 than normal 
meninges, **- p< 0.01. D: Proportion of KSR1 positive cells in nine normal meninges and seven 
meningioma tissues are plotted. Meningioma tissue had significantly more cells expressing KSR1 than 
normal meninges, *- p< 0.05. 
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To confirm overexpression of both DCAF1 and KSR1 in meningioma tissue compared 
with normal meningeal tissue, we analysed protein expression in three normal 
meninges samples and three Merlin-deficient meningioma samples via Western blot 
(figure 3.4A). Figure 3.4B shows the raw densitometry values obtained when 
quantifying figure 3.4A using Image J software confirming the overexpression of both 
DCAF1 and KSR1 in Merlin-deficient meningioma (Student’s Unpaired T-test, p< 0.05).  
Human meningeal cells (HMC) were purchased from Sciencell and meningioma cells 
were derived from Merlin-deficient meningioma tissue. We confirmed loss of Merlin 
protein expression by Western blot (figure 2.1). HMC and meningioma protein lysate 
were probed with DCAF1 and KSR1 antibodies via Western blot and are shown in figure 
3.4C. DCAF1 and KSR1 expression were highly variable across the meningioma 
samples, hence a large sample size was analysed. In figure 3.4D, densitometry analysis 
of DCAF1 and the two KSR1 bands in HMC and meningioma cells is reported. DCAF1 
and KSR1 expression were significantly increased in meningioma compared with HMC 
(Student’s unpaired T test; p< 0.05 and p< 0.01 respectively). Therefore, DCAF1 and 
KSR1 expression are consistently overexpressed in both meningioma cells and tissue 
compared to normal controls. 
We used the WHO I Benign meningioma cell line, BenMen-1 and WHO III meningioma 
cell line, KT21-MG1-Luc5D as models of Merlin-deficient meningioma for drug 
treatment experiments, in vitro. Therefore, we wanted to determine if DCAF1 and 
KSR1 protein were overexpressed in these models when compared with HMC cells. We 
analysed DCAF1 and KSR1 protein expression by Western blot (figure 3.4E). The bar 
chart in figure 3.4F shows the mean DCAF1 and KSR1 expression in each cell line and 
the SEM normalized to the loading control, GAPDH. A one-way ANOVA with Tukey’s 
116 
 
Multiple Comparison Test was performed using GraphPad Prism software and DCAF1 
expression was significantly higher in KT21-MG1-Luc5D than in HMC (p< 0.05). On the 
contrary, the mean DCAF1 expression in BenMen-1 was increased but not statistically 
significant when compared with HMC. There was no statistical significance for KSR1 











Figure 3.4 - DCAF1 and KSR1 are overexpressed in meningioma cells. A: Western blot showing DCAF1 
and KSR1 expression in normal meninges tissue (NMT) and primary meningioma tissue (MN), GAPDH-
loading control. B: Mean DCAF1 and KSR1 expression and SEM in NMT and MN normalized to the 
loading control. DCAF1 and KSR1 expression were significantly increased in MN compared with NMT, *- 
p< 0.05. C: Western blot showing DCAF1 and KSR1 expression in human meningeal cells (HMC) and 
meningioma cells (MN). DCAF1 and KSR1 expression are highly variable in primary meningioma cells. D: 
Mean DCAF1 and KSR1 expression and SEM in three HMC and 14 MN normalized to the loading control, 
GAPDH. DCAF1 and KSR1 expression were significantly increased in MN compared with HMC, *- p< 0.05, 
**- p< 0.01. E: Representative Western blot, of three replicates (n=3), to show DCAF1 and KSR1 
expression in HMC, Benign meningioma 1 (BenMen-1) and WHO III meningioma cell line (KT21-MG1-
Luc5D) (KT21). F: Mean DCAF1 and KSR1 expression and SEM in three HMC, BenMen-1 and KT21 
normalized to the loading control, GAPDH. DCAF1 was significantly increased in KT21 compared with 
HMC, *- p< 0.05. DCAF1 and KSR1 were unchanged in BenMen-1 compared to HMC and KSR1 was 






We also analysed DCAF1 and KSR1 expression in alternative models of Merlin-
deficiency including the mouse model, described in Mindos et al. (data not shown) 
(Mindos et al., 2017). In uninjured (Control) sciatic nerve, DCAF1 and KSR1 expression 
could not be detected or was very low in both wild type and Merlin conditional null 
nerve tissue and therefore could not be quantified accurately. 
Altogether, these data suggest that DCAF1 and KSR1 proteins are overexpressed in 
primary Merlin-deficient meningioma whereas expression was more variable in 
meningioma cell lines, BenMen-1 and KT21-MG1-Luc5D.  
3.4 The higher molecular weight KSR1 band 
Interestingly, there were two bands detected in figure 3.4C and 3.1C using the Cell 
Signalling Technology KSR1 antibody that binds to the region surrounding G910 of 
human KSR1. One of these bands at 100 kDa is the expected size and the additional 
band is around 10 kDa larger at 110 kDa. We showed that two bands were also present 
using an alternative KSR1 antibody (Abcam) that binds to human KSR1 around the 
region of S392 and were present in Schwann cell, schwannoma and BenMen-1 cell 
protein (data not shown).  
We suspected that the additional band was a post-translationally modified form of 
KSR1 yet there was no shift in molecular weight using lambda phosphatase or Peptide: 
N-glycosidase F (PNGase F) (data not shown). Therefore, the additional band is not due 
to phosphorylation or N-glycosylation. Furthermore, DCAF1 knockdown did not lead to 
a shift in the molecular weight of KSR1 further excluding DCAF1-dependent 
ubiquitination as the identity of the band (Zhou et al., 2016a and figure 3.5A). 
Ubiquitin is a small protein around 8.5 kDa in size and therefore the additional band 
could represent DCAF1-independent mono-ubiquitination of KSR1 (Terrell et al., 1998).  
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As we have shown that the additional KSR1 band is detected by two antibodies that 
target different KSR1-specific sequences, is not phosphorylated or glycosylated and is 
diminished with the use of a KSR1 targeting shRNA construct (Zhou et al., 2016a), we 
decided to quantify both Western blot bands in all subsequent experiments. 
3.5 DCAF1 does not regulate KSR1 expression or localization 
As CRL4-DCAF1’s primary role is to ubiquitinate substrates and the most common 
result of this ubiquitination is protein degradation, we determined whether DCAF1 
regulates KSR1 degradation (Ahn et al., 2011). We previously demonstrated that 
DCAF1 did not regulate KSR1 expression in schwannoma cells (Zhou et al., 2016a). We 
wanted to confirm this result in primary meningioma cells and BenMen-1 cells as 
protein function can be context dependent. We used a shRNA construct targeting 
DCAF1 to knock down DCAF1 expression in primary meningioma cells and observed 
changes in KSR1 expression. Scramble or DCAF1 lentivirus was added for 24 hours 
followed by a 24 hour recovery period. Puromycin was then added for seven days to 
select cell with puromycin resistance which have therefore been successfully 
transduced with the lentivirus. DCAF1 expression was significantly decreased, by an 
average of 53%, in DCAF1 knockdown cells compared with the scramble (Sc) control 
(Student’s Paired T-test, p< 0.01; figure 3.5A and B). Figure 3.5A show that KSR1 
expression is unchanged between scramble and DCAF1 knockdown in primary 
meningioma cells (quantified in figure 3.5B, p> 0.05). We then confirmed this result in 
BenMen-1 cells (figure 3.5C and D). Therefore, DCAF1 does not regulate KSR1 protein 




Figure 3.5 - DCAF1 does not regulate KSR1 degradation in meningioma. A: Western blots of DCAF1 and 
KSR1 expression after DCAF1 knockdown in three meningiomas (MN) representative of seven replicates. 
Scramble (Sc) or DCAF1 (KD) lentivirus was added to cells for 24 hours followed by a 24 hour recovery 
period and then seven days of puromycin selection before cell lysis. B: The graph shows the mean 
DCAF1 and KSR1 expression with SEM in shDCAF1 treated MN cells normalized to the loading control, 
GAPDH and relative to scramble. DCAF1 expression was reduced whilst KSR1 was unchanged in shDCAF1 
treated cells compared with scramble. **- p< 0.01, ns- not significant. C: Western blots of DCAF1 and 
KSR1 expression after DCAF1 knockdown in the WHO I benign meningioma 1 cell line, BenMen-1. 
Scramble (Sc) or DCAF1 (KD) lentivirus was added to cells for 24 hours followed by a 24 hour recovery 
period and then seven days of puromycin selection before cell lysis. D: The graph shows the mean 
DCAF1 and KSR1 expression with SEM in shDCAF1 treated BenMen-1 cells normalized to the loading 
control, GAPDH and relative to scramble. DCAF1 expression was reduced whilst KSR1 was unchanged in 








We used a cytoplasmic and nuclear extraction kit to establish DCAF1 and KSR1 
localization in Schwann and schwannoma cells. In order to assess protein cross-
contamination between the two cellular compartments, we used GAPDH as a 
cytoplasmic control and Histone deacetylase 1 (HDAC1) as a nuclear control. Figure 
3.6A shows that DCAF1 and KSR1 are predominantly nuclear in Schwann cells with 
some cytoplasmic DCAF1 expression in two out of four Schwann cells analysed. Figure 
3.6B shows the localization of DCAF1 and KSR1 in schwannoma. DCAF1 was 
predominantly nuclear in schwannoma with a faint band observed in the cytoplasm of 
three out of three schwannomas analysed. KSR1 is localised in the cytoplasm and the 
nucleus in two out of three schwannoma and exclusively in the nucleus of one 
schwannoma. In one schwannoma, the upper KSR1 band was predominantly 
cytoplasmic whereas the lower KSR1 band was nuclear.  
Mono-ubiquitination has been reported to alter cellular localization of substrates (Wu 
et al., 2011). As KSR1 expression in the cytoplasm was increased in schwannoma 
compared with Schwann cells we determined if DCAF1 regulated KSR1 localization, 
possibly in a mono-ubiquitin dependent manner. We knocked down DCAF1 expression 
using an shRNA construct and performed cytoplasmic and nuclear extraction. The 
Western blots in figure 3.7A-C demonstrate that KSR1 localization was unchanged after 
DCAF1 knockdown in schwannoma. Therefore, DCAF1 does not regulate KSR1 
localization in schwannoma.  
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Figure 3.6 - Cytoplasmic KSR1 is increased in schwannoma compared with Schwann cells. A: Western 
blots of Schwann cell (MOS) total, cytoplasmic (C) and nuclear (N) lysates after cytoplasmic and nuclear 
enrichment. DCAF1 and KSR1 were predominantly nuclear in MOS. B: Western blots of schwannoma 
(NF) total, cytoplasmic and nuclear lysates after cytoplasmic and nuclear enrichment. DCAF1 and KSR1 
were mostly nuclear but also expressed in the cytoplasm of NF. GAPDH-cytoplasmic control and HDAC1-




Figure 3.7 - DCAF1 does not regulate KSR1 localization in schwannoma. A, B, C: Western blots to show 
KSR1 localization after DCAF1 knockdown in schwannoma (NF). Scramble or DCAF1 lentivirus was added 
for 24 hours followed by a 24 hour recovery period and then seven days of puromycin selection before 
cytoplasmic (C) and nuclear (N) enrichment. KSR1 localization did not change after DCAF1 knockdown. 












In contrast to Schwann cells and schwannoma, Figure 3.8 and supplementary figure 1 
illustrate that DCAF1 and KSR1 localization were unchanged in the benign meningioma 
cell line, BenMen-1 compared with HMC. We then performed DCAF1 knockdown in 
primary meningioma cells and performed cytoplasmic and nuclear extraction. Figure 
3.9A-B shows that KSR1 localization was unchanged after DCAF1 knockdown in 
meningioma. Similarly, we knocked down DCAF1 in BenMen-1 and KSR1 localization 
did not change consistent with results in schwannoma demonstrating that DCAF1 does 

























Figure 3.8 - Cytoplasmic KSR1 is not upregulated in BenMen-1 compared with HMC. A: Western blot of 
DCAF1 and KSR1 in total, cytoplasmic (C) and nuclear (N) lysate of human meningeal cells (HMC) and the 
Benign meningioma cell line BenMen-1, representative of three replicates. Nuclear DCAF1 was increased 
in BenMen-1 compared with HMC whilst KSR1 localization was unchanged. GAPDH-cytoplasmic control 













Figure 3.9 - DCAF1 does not regulate KSR1 localization in meningioma or BenMen-1. A, B, C: Western 
blots to show KSR1 localization after DCAF1 knockdown in meningioma (MN). Scramble or DCAF1 
lentivirus was added for 24 hours followed by a 24 hour recovery period and then seven days of 
puromycin selection before cytoplasmic and nuclear enrichment. KSR1 localization did not change after 
DCAF1 knockdown. D: Western blot to show KSR1 localization in the Benign meningioma cell line, 
BenMen-1 after DCAF1 knockdown followed by cytoplasmic (C) and nuclear (N) enrichment 
representative of three replicates. KSR1 localization did not change after DCAF1 knockdown. GAPDH-
cytoplasmic control and HDAC1-nuclear control. 
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3.6 DCAF1 regulates RAF/MEK/ERK activity in schwannoma and reduces proliferation 
of schwannoma and meningioma 
Mono-ubiquitination can also modulate protein activity and we hypothesised that 
DCAF1 regulates KSR1 activity in the form of RAF/MEK/ERK activation (Chen, 2005). 
We knocked down DCAF1 expression in schwannoma and analysed the expression of 
phosphorylated ERK1/2 relative to total ERK1/2 to capture changes in activity. ShRNA-
mediated DCAF1 knockdown efficiency was evaluated by Western blot in schwannoma 
cells (figure 3.10A). Quantification of six independent experiments demonstrated a 
significant 71% reduction of DCAF1 expression between scramble and DCAF1 
knockdown (Student’s paired T test, p< 0.01; figure 3.10B), which led to a significant 
reduction in pERK1/2 expression (35% reduction; p< 0.05) when quantified taking into 
account both ERK1/2 and GAPDH expression (figure 3.10B). Therefore, DCAF1 
regulates RAF/MEK/ERK signalling in schwannoma. CYCLIN D1 is a downstream target 
of pERK1/2 so we monitored its protein levels following DCAF1 knockdown. 
Interestingly, our results demonstrated that CYCLIN D1 expression was unchanged  
suggesting that RAF/MEK/ERK inhibition by DCAF1 knockdown was not sufficient to 







Figure 3.10 - DCAF1 knockdown reduces pERK1/2, but not CYCLIN D1 in schwannoma. A: Western 
blots of DCAF1, pERK1/2, ERK1/2 and CYCLIN D1 expression after DCAF1 knockdown in three 
schwannoma (NF) representative of six replicates. Scramble (Sc) or DCAF1 (KD) lentivirus was added to 
cells for 24 hours followed by a 24 hour recovery period and then seven days of puromycin selection 
before cell lysis. B: Mean DCAF1, pERK1/2 and CYCLIN D1 expression and SEM in shDCAF1 treated NF 
cells normalized to the loading control and relative to scramble. DCAF1 and pERK1/2 expression were 
reduced whilst CYCLIN D1 was unchanged in shDCAF1 treated cells compared with scramble. *- p< 0.05, 












To determine if DCAF1 regulates RAF/MEK/ERK signalling in meningioma, we 
performed the same experiment in primary meningioma and BenMen-1 cells. Whilst in 
some meningioma samples pERK1/2 expression was reduced, in others DCAF1 
knockdown led to an increase in pERK1/2 (figure 3.11A). In addition, in BenMen-1, 
DCAF1 knockdown did not alter pERK1/2 or CYCLIN D1 expression (figure 3.12A-B). 
Therefore, DCAF1 does not regulate RAF/MEK/ERK signalling in meningioma.  
Interestingly, DCAF1 knockdown resulted in a significant reduction in proliferation (as 
measured by proportion of Ki-67 cells) in both primary meningioma cells and BenMen-
1 cells, consistent with schwannoma (p< 0.05) (Zhou et al., 2016). Figure 3.11C and 
3.12C show representative Ki-67 images at 20x magnification of meningioma and 
BenMen-1, respectively. DCAF1 knockdown reduced proliferation to an average of 35% 
of the scramble control in meningioma and to an average of 61% in BenMen-1 (figure 
3.11C and 3.12D) (Student’s Paired T test; p< 0.05). Altogether, these data suggest that 
RAF/MEK/ERK activity is regulated by DCAF1 in schwannoma but not in meningioma 










Figure 3.11 - DCAF1 knockdown does not alter pERK1/2 but significantly reduces proliferation in 
meningioma. A: Western blots of DCAF1, pERK1/2, ERK1/2 and CYCLIN D1 expression after Scramble 
(Sc) or DCAF1 knockdown (KD) in three meningioma (MN) representative of seven replicates. Scramble 
or DCAF1 lentivirus was added to cells for 24 hours followed by a 24 hour recovery period and then 
seven days of puromycin selection before cell lysis. B: Mean pERK1/2 and CYCLIN D1 expression and 
SEM in shDCAF1 treated NF cells normalized to the loading control, GAPDH and relative to scramble. 
pERK1/2 and CYCLIN D1 were unchanged in shDCAF1 treated cells compared with scramble (ns- not 
significant, p>0.05). pERK1/2 was normalized to both ERK1/2 and GAPDH C: Representative 
immunocytochemistry images, at 20x magnification, of scramble and shDCAF1 meningioma cells stained 
with Ki-67 antibody and 4',6-diamidino-2-phenylindole (DAPI), Scale bar- 50 µM. D: Mean proportion of 
Ki-67 positive cells in DCAF1 knockdown meningioma cells relative to scramble control and SEM. At least 
three images each of seven biological replicates were quantified. DCAF1 knockdown significantly 





Figure 3.12 - DCAF1 knockdown does not alter pERK1/2 but significantly reduces proliferation in 
BenMen-1. A: Western blots of DCAF1, pERK1/2, ERK1/2 and CYCLIN D1 after DCAF1 knockdown (KD) in 
the Benign meningioma cell line BenMen-1, representative of four replicates. Scramble (Sc) or DCAF1 
lentivirus was added to cells for 24 hours followed by a 24 hour recovery period and then seven days of 
puromycin selection before cell lysis. B: Mean pERK1/2 and CYCLIN D1 expression with SEM in shDCAF1 
treated BenMen-1 cells normalized to the loading control, GAPDH and relative to scramble (ns- not 
significant, p> 0.05). pERK1/2 and CYCLIN D1 were unchanged in shDCAF1 treated cells compared with 
scramble. pERK1/2 was normalized to both ERK1.2 and GAPDH. C: Representative immunocytochemistry 
images, at 20x magnification, of scramble and shDCAF1 BenMen-1 cells stained with Ki-67 antibody and 
DAPI, Scale bar- 50 µM. D: Mean proportion of Ki-67 positive cells in DCAF1 knockdown BenMen-1 cells 
relative to scramble control with SEM. At least three images each of three replicates were quantified. 







3.7 Targeting DCAF1 and KSR1 together reduces proliferation in BenMen-1 similar to 
schwannoma 
Several reports suggest that DCAF1 and KSR1 have important roles in Merlin-deficient 
tumourigenesis; in fact, DCAF1 and KSR1 knockdown led to a significant reduction of 
schwannoma cell proliferation, determined by Ki-67 index, compared with DCAF1 of 
KSR1 knockdown alone (Li et al., 2010; Zhou et al., 2016a). Therefore, we explored the 
hypothesis that targeting both DCAF1 and KSR1 in Merlin-deficient schwannoma, 
meningioma and BenMen-1 would have an additive benefit when compared with 
DCAF1 or KSR1 knockdown alone. We also wanted to determine if this additive effect 
was due to RAF/MEK/ERK pathway inhibition and therefore we examined pMEK1/2, 
MEK1/2, pERK1/2, ERK1/2 and CYCLIN D1 expression by Western blot in schwannoma 
(figure 3.13A). DCAF1 and KSR1 expression were quantified and normalized to GAPDH 
for three independent experiments in schwannoma (figure 3.13B). DCAF1 and KSR1 
knockdown reduced DCAF1 and KSR1 protein expression levels in individual 
experiments, as reported in figure 3.13A but this was not significant (One-way ANOVA 
with Tukey Multiple Comparison Post Test, p> 0.05). We quantified pMEK1/2 (relative 
to MEK1/2 and GAPDH), pERK1/2 (relative to ERK1/2 and GAPDH) and CYCLIN D1 
(relative to GAPDH) and found that adding the DCAF1 or KSR1 shRNA construct 
individually did not significantly reduce protein expression. pERK1/2 expression was 
not significantly reduced in this experimental setup, in contradiction to earlier results 
in this chapter as well as Zhou et al., 2016a. This could be due to the different sample 
sizes used and different shRNA KSR1 construct used, respectively. However, we found 
a significant decrease in pMEK1/2 expression when DCAF1 and KSR1 shRNA constructs 
were added together compared with the scramble control suggesting a possible 
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additive effect of DCAF1 and KSR1 knockdown on RAF/MEK/ERK activity (figure 3.13B; 











Figure 3.13 - DCAF1 and KSR1 knockdown reduces pMEK1/2 but not pERK1/2 or CYCLIN D1 in 
schwannoma. A: Western blots of DCAF1, KSR1, pMEK1/2, MEK1/2, pERK1/2, ERK1/2 and CYCLIN D1 
expression after DCAF1, KSR1 or DCAF1 and KSR1 knockdown in schwannoma (NF) cells. Scramble, 
DCAF1 and/or KSR1 lentivirus was added to cells for 24 hours followed by a 24 hour recovery period and 
then seven days of puromycin selection before cell lysis. B: Mean DCAF1, KSR1, pMEK1/2, pERK1/2 and 
CYCLIN D1 expression and SEM in shDCAF1 (shD), shKSR1 (shK) or shDCAF1 and shKSR1 treated 
schwannoma cells normalized to the loading control, GAPDH and relative to scramble (Sc). pMEK1/2 was 
reduced in shDCAF1 and shKSR1 treated cells compared with scramble,*- p< 0.05. pMEK1/2 and 
pERK1/2 were unchanged in shDCAF1 or shKSR1 treated cells (ns- not significant, p>0.05). pMEK1/2 was 










We repeated the experiment in primary meningioma cells and the cell line, BenMen-1. 
Unfortunately, DCAF1 and KSR1 knockdown was not successful in primary meningioma 
cells and therefore, only data from BenMen-1 is shown. DCAF1 knockdown was 
significantly reduced in BenMen-1 following the addition of a DCAF1 shRNA construct 
(p< 0.05). However, whilst KSR1 was reduced after adding a KSR1 shRNA construct in 
individual experiments, this was not significant (p> 0.05, figure 3.14A-B). 
Unfortunately, the KSR1 shRNA construct used did not significantly reduce pERK1/2 or 
CYCLIN D1 expression. This is in contrast to KSR1 knockdown in schwannoma which 
significantly reduced both pERK1/2 and CYCLIN D1 (Zhou et al., 2016a). In addition, 
DCAF1 and KSR1 shRNA constructs added together did not significantly affect 
RAF/MEK/ERK activity or CYCLIN D1 expression. Therefore, there was no additive 












Figure 3.14 - DCAF1 and KSR1 knockdown does not reduce pERK1/2 in BenMen-1. A: Western blots of 
DCAF1, KSR1, pERK1/2, ERK1/2 and CYCLIN D1 expression after DCAF1, KSR1 or DCAF1 and KSR1 
knockdown in the Benign meningioma cell line, BenMen-1. Scramble, DCAF1 or KSR1 lentivirus was 
added to cells for 24 hours followed by a 24 hour recovery period and then seven days of puromycin 
selection before cell lysis. B: Mean DCAF1, KSR1, pERK1/2 and CYCLIN D1 expression and SEM in 
shDCAF1 (shD), shKSR1 (shK) or shDCAF1 and shKSR1 treated BenMen-1 cells normalized to the loading 
control, GAPDH and relative to scramble (Sc). pERK1/2 and CYCLIN D1 were unchanged in shDCAF1 and 
shKSR1 treated cells compared with scramble,*- p< 0.05, **- p< 0.01, ns- not significant. pERK1/2 was 



















Interestingly, DCAF1 and KSR1 knockdown in BenMen-1 cells significantly reduced 
proliferation compared with scramble control and compared with either DCAF1 or 
KSR1 knockdown alone (figure 3.15A and B). Figure 3.15A illustrates the reduction in 
the proportion of Ki-67 positive cells following DCAF1 knockdown and is representative 
of images taken across three biological replicates. The proportion of Ki-67 cells was 
calculated and plotted relative to scramble control in figure 3.15B. Both DCAF1 and 
KSR1 knockdown alone significantly reduced proliferation whilst DCAF1 and KSR1 
added together had an additive effect on proliferation (Repeated Measures ANOVA 
with Tukey Multiple Comparison Post Test; p< 0.01). This suggests that DCAF1 or KSR1 
are potential targets for meningioma and that targeting both proteins can have a 



















Figure 3.15 - DCAF1 and KSR1 knockdown reduces proliferation of BenMen-1 cells. A: Representative 
immunocytochemistry images, at 20x magnification, of scramble, shDCAF1, shKSR1 and shDCAF1 and 
shKSR1 in BenMen-1 cells stained with Ki-67 antibody and DAPI, Scale bar- 50 µM. B: Mean proportion 
of Ki-67 positive cells in knockdown BenMen-1 cells relative to scramble control and SEM. At least three 
images each of three replicates were quantified. DCAF1 and KSR1 knockdown significantly decreased 










Whilst DCAF1 protein was clearly over-expressed in tissue samples, the expression was 
much more variable in schwannoma cells derived from schwannoma tumour tissue 
(figure 3.1 and 3.2). There was also a large variation in DCAF1 expression in Schwann 
cells, most probably due to variation in proliferative rates in vitro (figure 3.2). Growth 
factors are added to cell culture medium to stimulate Schwann cell growth and can 
have varying effects at different passages. We excluded the possibility of cell 
contamination by confirming more than 90% S100 protein expression (figure 2.2), 
characteristic of Schwann cells. Analysis of tissue samples is more reflective of in vivo 
protein expression than analysis of cells derived from tissue. However, cells have the 
added benefit of allowing in vitro drug testing and analysis of cell signalling 
mechanisms; therefore, they represent a highly relevant model.  
Both, DCAF1 and KSR1 were highly expressed in meningioma tissue and were 
significantly higher than the expression levels in meninges (figure 3.3). However, there 
was also a large proportion of cells in the meninges that expressed KSR1. Often with 
immunohistochemistry, there is more non-specific staining around the edges of the 
tissue, coincidently, the location of the meninges (True, 2008). Therefore, some DCAF1 
and KSR1 staining may be artefact and may not reflect real meningeal expression. We 
also analysed DCAF1 and KSR1 expression in tissue by Western blot to confirm 
overexpression (figure 3.4). There were a lot of non-specific staining of DCAF1 and 
KSR1 in the meninges but DCAF1 and KSR1 expression in meningioma was significantly 
higher and the Western blot band corresponding to the correct protein size was much 
clearer in meningioma tissue than in meninges demonstrating that DCAF1 and KSR1 
are overexpressed in meningioma tissue.  
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We derived meningioma cells from meningioma tissue and compared DCAF1 and KSR1 
expression with that of human meningeal cells (HMC), which were derived from 
embryonic/fetal meningeal cells and grown in medium enriched with growth factors. 
This can make comparison between HMC and adult meningioma tissue difficult. 
Despite this, DCAF1 and KSR1 protein expression was significantly increased in 
meningioma cells compared with HMC (figure 3.4). As expected, we detected some 
variability in expression between tumours, similar to schwannoma. In addition, one 
particular meningioma sample had very low DCAF1 and KSR1 expression (MN006). We 
analysed the clinical data and discovered that the tumour was removed after radiation 
treatment. Therefore, we did not include this tumour in the subsequent Western blot 
analysis. 
There were a number of samples with loss of Merlin expression and a confirmed 
heterozygous Traf7 mutation including MN078, MN036 and MN056. Nf2 and Traf7 
mutations are mutually exclusive in meningioma and therefore it is unlikely that the 
Traf7 mutant meningioma samples also have an Nf2 mutation (Clark et al., 2013; Zotti 
et al., 2017). Therefore, we removed these samples from Western blot analysis and 
subsequent experiments. The absence of Merlin protein in Traf7 mutant samples 
suggests that TRAF7 could regulate Merlin expression. The expression of Merlin 
protein in non-Merlin mutant meningioma tumours has not yet been reported in the 
literature. Sequencing of the Nf2 gene to identify and confirm the Merlin mutation in 
each tumour would be beneficial, although this would be expensive considering the 
number of samples used. 
We discovered that DCAF1 and KSR1 were not significantly upregulated in BenMen-1 
compared with HMC (figure 3.4). DCAF1 was significantly overexpressed in KT21-MG1-
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Luc5D compared with HMC whereas KSR1 was unchanged. These results were 
disappointing as we had hoped for a Merlin-deficient meningioma model with high 
levels of DCAF1 and KSR1 expression so we could more easily investigate the DCAF1 
and KSR1 interaction.   
DCAF1 knockdown did not lead to an increase in KSR1 protein, confirming that KSR1 
degradation is not regulated by DCAF1 in meningioma (figure 3.5). Whilst it may seem 
logical to overexpress DCAF1 to show that KSR1 protein is not downregulated, DCAF1 
exists in an E3 ubiquitin complex containing several proteins (Cullin 4A/B and DDB1), 
which modulate its ubiquitination function, therefore, overexpressing DCAF1 alone 
would be unlikely to alter ubiquitin functions. 
KSR1 overexpression had been previously reported in schwannoma; therefore, we 
wanted to determine the localization of KSR1 (Zhou et al., 2016a). In Schwann cells, 
KSR1 was predominantly nuclear, which is in contrast to published data suggesting 
KSR1 is cytoplasmic and is redistributed to the cell membrane when signalling is 
activated (Müller et al., 2001). KSR1 cycles through the nucleus similar to MEK1/2 and 
ERK1/2 (Kortum et al., 2005; Razidlo et al., 2004). However, there is no known role of 
nuclear KSR1. In schwannoma, KSR1 was localized to the cytoplasm and nucleus 
suggesting increased cytoplasmic signalling which may be Merlin-dependent. However, 
there was no increase in cytoplasmic KSR1 in BenMen-1 compared with HMC 
demonstrating that the increase in cytoplasmic KSR1 observed in schwannoma may 
not be Merlin-dependent. 
If KSR1 localization was regulated by DCAF1, we would see a decrease in cytoplasmic 
KSR1 upon DCAF1 knockdown. However, we did not see any significant changes in 
KSR1 localization in schwannoma (figure 3.7). We replicated these experiments in 
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meningioma to confirm DCAF1’s role (figure 3.9 and supplementary figure 2). As 
expected, DCAF1 knockdown did not consistently alter KSR1 localization in primary 
meningioma or BenMen-1. Therefore, DCAF1 does not regulate KSR1 expression or 
localization in Merlin-deficient cells. 
Phosphorylated ERK1/2 was significantly reduced upon DCAF1 knockdown in 
schwannoma; however, there was only a 35% reduction suggesting that KSR1 activity is 
only partly dependent on DCAF1 (figure 3.10). Conversely, it could also suggest that 
RAF/MEK/ERK activity is only partially dependent on active KSR1 in schwannoma. 
CYCLIN D1 expression, a downstream target of pERK1/2, did not change demonstrating 
that the inhibition of ERK1/2 phosphorylation was not sufficiently high enough to 
affect CYCLIN D1. Unfortunately, DCAF1-dependent inhibition of pERK1/2 was not 
translatable to meningioma. In some experiments, pERK1/2 was reduced upon DCAF1 
knockdown, whereas in others it was increased (figure 3.11 and figure 3.12). This 
suggests that there is much more variability in the primary meningioma cohort than in 
primary schwannoma. In addition, there was a much smaller reduction in DCAF1 
expression upon DCAF1 knockdown in meningioma compared with schwannoma that 
may not have been sufficient to inhibit RAF/MEK/ERK activity.  
DCAF1 knockdown significantly reduced the proliferation of both primary meningioma 
cells and BenMen-1 (figure 3.11 and 3.12). As there were no significant changes in 
pERK1/2 expression upon DCAF1 knockdown, this suggests that DCAF1 knockdown 
reduces proliferation independent of KSR1 and RAF/MEK/ERK activity in meningioma. 
However, there may be a proportion of cells that have a greater DCAF1 knockdown 
and therefore some cells stop proliferating in a RAF/MEK/ERK dependent manner 
whereas others retain more DCAF1 protein and continue to proliferate. This is more 
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the case in BenMen-1 as a greater proportion of cells are still proliferating upon DCAF1 
knockdown (figure 3.12). Whilst the best method of protein knockdown is to isolate 
individual clones, this was not possible with primary schwannoma or meningioma cells 
(including BenMen-1) as they need close contact with other tumour cells in order to 
proliferate.  
We previously demonstrated that targeting both DCAF1 and KSR1 in schwannoma had 
an additive effect on reducing proliferation in schwannoma (Zhou et al., 2016a). We 
wanted to determine if DCAF1 and KSR1 together had an additive effect on 
RAF/MEK/ERK inhibition to demonstrate potential for a combination therapy targeting 
these two proteins. Unfortunately, there was no significant DCAF1 or KSR1 knockdown 
in schwannoma (figure 3.13). This is possibly because the sample size used (n=3) did 
not have enough power to detect the change in DCAF1 and KSR1 expression. In 
individual experiments, a decrease in DCAF1 and KSR1 can be clearly seen. We used a 
different shRNA construct targeting KSR1 than has previously been published in 
schwannoma because we had difficulty transfecting primary meningioma and 
BenMen-1. This KSR1 construct did not reduce pERK1/2 or CYCLIN D1 in schwannoma, 
in contrast to published data (Zhou et al., 2016a). This is probably because the 
knockdown was less successful and therefore KSR1 was still active in KSR1 knockdown 
lysates. However, DCAF1 and KSR1 knockdown significantly reduced pMEK1/2 in 
schwannoma suggesting more robust and consistent inhibition of MEK1/2 activity in 
comparison to DCAF1 or KSR1 knockdown alone.  
We added DCAF1 and KSR1 shRNA constructs to BenMen-1 cells and probed for the 
RAF/MEK/ERK pathway (figure 3.14). DCAF1 was successfully knocked down whereas 
the reduction in KSR1 expression was not significant. DCAF1 and KSR1 knockdown did 
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not reduce pERK1/2 or CYCLIN D1 expression. KSR1-dependent RAF/MEK/ERK 
activation has not been fully explored in meningioma and therefore future 
experiments should use a more effective shRNA construct to knockdown KSR1. 
Interestingly, KSR1 knockdown significantly reduced BenMen-1 proliferation, 
suggesting that the Western blot experiment did not have enough statistical power to 
detect the knockdown (figure 3.15). In addition, DCAF1 and KSR1 knockdown 
significantly reduced proliferation compared with either construct alone. This 
demonstrates the additive value of targeting both DCAF1 and KSR1 in schwannoma 
and meningioma.  
DCAF1 also leads to Hippo pathway inactivation and therefore activation of gene 
transcription (Li et al., 2014). The inhibitory effect of DCAF1 knockdown on Merlin-
deficient schwannoma and meningioma proliferation could be Hippo pathway-
dependent rather than RAF/MEK/ERK-dependent and this possibility must be further 
investigated. Indeed, it has been shown that the Hippo pathway is inhibited in Merlin-
deficient cells, contributing to tumourigenesis (Li et al., 2014; Serrano et al., 2013; 
Striedinger et al., 2008).  
3.9 Conclusion 
DCAF1 and KSR1 are upregulated in Merlin-deficient cells, including schwannoma and 
meningioma. The expression of these proteins is variable between individual tumours 
and the meningioma cell line, BenMen-1. DCAF1 regulates RAF/MEK/ERK activity in 
schwannoma which may be KSR-1-dependent. DCAF1 does not significantly affect 
RAF/MEK/ERK activity in primary meningioma or BenMen-1; however, DCAF1 
knockdown significantly reduces proliferation of schwannoma, meningioma and 
BenMen-1, suggesting that DCAF1 is a potential therapeutic target for Merlin-deficient 
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tumours. In addition, DCAF1 and KSR1 knockdown further reduced proliferation of 
BenMen-1 cells compared with either knockdown alone, therefore, targeting both 

























 Merlin has been shown to inhibit DCAF1 ubiquitin ligase activity in the nucleus (Li et 
al., 2014; Li et al., 2010). In Merlin-deficient tumours, DCAF1 is therefore activated and 
contributes to tumourigenesis. The mechanisms of DCAF1-mediated tumourigenesis is 
not fully understood. We previously showed that KSR1 was upregulated and important 
in Merlin-deficient tumourigenesis (Zhou et al., 2016a).  
We co-immunoprecipitated overexpressed Merlin and overexpressed KSR1 in a 
HEK293T model (Zhou et al., 2016a). Mass spectrometry revealed CRL4-DCAF1 
components as common interactors between Merlin and KSR1 (Zhou et al., 2016a). 
The DCAF1/KSR1 interaction was confirmed by immunoprecipitating overexpressed 
KSR1 in HEK293T cells and probing for DCAF1 via Western blot (Zhou et al., 2016a). 
Therefore elucidating KSR1’s involvement in DCAF1-mediated tumourigenesis is 
pertinent. The aim of this chapter is to show that endogenous DCAF1 and KSR1 
interact in a Merlin-deficient model, to identify if DCAF1 and KSR1 interact in the 
nucleus and to further characterize the DCAF1/KSR1 interaction using overexpressed 
protein in HEK293T cells.  
4.2 Endogenous DCAF1 and KSR1 interact in Merlin-deficient meningioma 
To show that there is an endogenous DCAF1/KSR1 interaction in Merlin-deficient cells 
we used the benign Merlin-deficient meningioma cell line, BenMen-1. BenMen-1 
protein lysate was concentrated and DCAF1 was immunoprecipitated from 3 mg of 
protein using a DCAF1 antibody. We used IgG as a negative immunoprecipitation 
control to determine any proteins interacting with IgG of the same species of the 
DCAF1 antibody. The immunoprecipitated samples were separated by Western blot 
along with an input sample of BenMen-1 lysate (to show endogenous protein 
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expression) and probed for DCAF1, KSR1 and DDB1 (figure 4.1A and supplementary 
figure 3B-C). DCAF1 and DDB1 (positive control) were detected in the DCAF1 lane and 
was absent in the IgG lane demonstrating successful DCAF1 immunoprecipitation. A 
band corresponding to KSR1 was detected when DCAF1 was immunoprecipitated 
suggesting that endogenous DCAF1 and KSR1 interact in Merlin-deficient cells (figure 





Figure 4.1 - Endogenous DCAF1 and KSR1 interact in BenMen-1. A: Western blot of DCAF1, KSR1 and 
DDB1 in the benign meningioma cell line, BenMen-1 (input), immunoprecipitated IgG and 
immunoprecipitated DCAF1 from 3mg BenMen-1 protein lysate, representative of three replicates. 
DCAF1 was immunoprecipitated from BenMen-1 lysates using a mouse (M) DCAF1 antibody 




Interestingly, an additional band, 130–180 kDa in size, was visible when probing with a 
KSR1 antibody that was specific to immunoprecipitated DCAF1 and was absent in the 
IgG lane (supplementary figure 3A-C). This additional band was also present when 
immunoprecipitating DCAF1 using 3 mg of protein from KT21-MG1-Luc5D cells 
(supplementary figure 3D) (n=1). We were unable to detect KSR1 in the DCAF1 
complex when DCAF1 was immunoprecipitated from an alternative Merlin-deficient 
model (schwannoma lysate and tissue) although much less protein was available (< 1 
mg) (data not shown). To confirm the DCAF1/KSR1 interaction, we 
immunoprecipitated the KSR1 complex in BenMen-1 using 3 mg protein and 
unfortunately we were unable to detect DCAF1 probably due to the low endogenous 
expression of KSR1 in BenMen-1 (data not shown).  
4.3 The C-terminus of DCAF1 interacts with the N-terminus of KSR1 in the cytoplasm 
and nucleus 
We wanted to identify the DCAF1 domains responsible for KSR1 binding to determine a 
possible function of the DCAF1/KSR1 interaction. DCAF1 plasmids corresponding to the 
wild type DCAF1 sequence (D1), the N terminus (1–744 amino acids (aa)) (D2) and the 
C terminus (745–1507 aa) (D3), all with a myc-tag were used and figure 4.2A illustrates 
the domains in each plasmid sequence. D2 contained the armadillo-like and cromo-like 
domains whereas D3 contained the LisH, WD40 and acidic domains of DCAF1. The 
restriction enzymes, SalI and NotI were used to digest the plasmids and we confirmed 
the expected DNA bands for D1, D2 and D3 digestion by agarose gel electrophoresis 
(figure 2.4). We transfected HEK293T cells with the D1, D2 and D3 plasmids and 
confirmed DCAF1 overexpression using a myc-tag antibody. We then used a myc-tag 
antibody to immunoprecipitate the DCAF1-containing complexes, from 1 mg of 
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HEK293T protein, and separated these proteins by Western blot. We probed the 
membrane for myc-tag and confirmed that overexpressed DCAF1 protein was 
successfully immunoprecipitated (figure 4.2B and supplementary figure 4A-B). We also 
immunoprecipitated myc-tag containing complexes in non-transfected HEK293T cells 
which identified non-specific protein binding to the myc-tag antibody. The D1 
immunoprecipitated complex did not contain KSR1, as there was no specific band 
visible (that was also absent in the non-transfected control) around 100 kDa when 
probing with KSR1 antibody. The D2 (N-terminal DCAF1) immunoprecipitated complex 
also did not contain KSR1 whereas the D3 (C-terminal DCAF1) immunoprecipitated 
complex did contain KSR1. The D3 complex had a clear band, around 100 kDa, when 
probing with KSR1 antibody in all three repeats (indicated by an arrow) (figure 4.2B 
and supplementary figure 4A-B). DDB1 was present in the D1 and D3 complexes, as 
expected, suggesting that the DCAF1 immunoprecipitation successfully pulled down 
DCAF1-interacting proteins. Unexpectedly, there was an additional KSR1 reactive band, 
around 180 kDa, detected in the D1 complexes which was absent in the non-
transfected control and D2. A faint 180 kDa band can also be seen in two out of three 
repeats in the D3 complex (figure 4.2B and supplementary figure 4B). We repeated the 
experiment using an alternative myc-tag antibody to determine if the results seen in 
figure 4.2 could be replicated (supplementary figure 4C). We immunoprecipitated the 
DCAF1 containing complexes and identified KSR1 in the D3 complex and a 180 kDa 
KSR1-reactive band in the D1 complex (n=1).  
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Figure 4.2 - DCAF1 interacts with KSR1 via the C terminal of DCAF1. A: DCAF1 domains within 
sequences used. wild type DCAF1 (D1) contained an armadillo-like and cromo-like domain at the N 
terminal followed by a LisH domain, a WD40 domain and an acidic C-terminal domain. The N-terminal 
DCAF1 (D2) sequence (1–744 amino acids (a.a)) contained the armadillo-like and cromo-like domain. The 
C-terminal DCAF1 (D3) sequence (745–1507 a.a) contained the LisH, WD40 and acidic domains. B: The 
DCAF1 sequences D1, D2 and D3, with a Myc-tag, were overexpressed in HEK293T and 
immunoprecipitated from 1 mg HEK293T using a Myc-tag antibody. The Western blot shown is 
representative of three repeats and was probed for KSR1, Myc, DDB1 and GAPDH. KSR1 was present in 
the C-terminal DCAF1 complex (D3) (indicated by the arrow) and a high molecular weight KSR1-reactive 
band was present in the wild-type DCAF1 (D1) complex. Myc-tag antibody reactive proteins were 









To explore the DCAF1/KSR1 interaction further we used KSR1 plasmids corresponding 
to wild-type KSR1 (K1), N-terminal KSR1 (1–539 aa) (KN) and C-terminal KSR1 (540–873 
aa) (KC), all with a FLAG tag, to determine the domains responsible for DCAF1 binding 
(figure 4.3A). We confirmed plasmid identity using restriction enzymes to digest the 
plasmid at specific known sites producing bands of expected sizes (figure 2.5). For 
example, the pCMV5 vector containing the wild-type KSR1 sequence (K1) was digested 
using the EcorI and KpnI restriction enzymes producing DNA bands at 4700 bp and 
2700 bp as expected according to the plasmid map (figure 2.5). We transfected 
HEK293T with the K1, KC and KN plasmids to overexpress the KSR1 proteins and 
immunoprecipitated these complexes using a FLAG tag antibody. We separated the 
protein complexes by Western blot and probed for DCAF1, DDB1, FLAG and MEK1/2 
(figure 4.3B and supplementary figure 5A-B). We confirmed successful FLAG-KSR1 
immunoprecipitation and identified MEK1/2 in the K1 and KC complexes as expected. 
DCAF1 and DDB1 were identified in the K1 and KN complex demonstrating that the 
CRL4-DCAF1 complex interacts with the N-terminal of KSR1 (1–539 aa). In two out of 
three replicates, DCAF1 and DDB1 were also present in the KC immunoprecipitated 
complex, however, the band was much weaker suggesting decreased DCAF1 binding in 




Figure 4.3 - KSR1 interacts with the CRL4-DCAF1 complex via the N-terminal of KSR1. A: KSR1 domains 
within the sequences used. Wild type KSR1 (K1) contained CA1–5 domains. The N-terminal KSR1 (KN) 
sequence (1–539 amino acids (a.a)) contained CA1–4 domains. The C-terminal KSR1 (KC) sequence (540–
873a.a) contained the CA5 domain. B: The KSR1 sequences K1, KC and KN, with a FLAG-tag, were 
overexpressed in HEK293T and immunoprecipitated from 1 mg HEK293T using a FLAG-tag antibody. The 
Western blot shown is representative of three repeats and was probed for DCAF1, DDB1, FLAG, MEK1/2 
and GAPDH. DCAF1 and DDB1 were present in the wild-type and N-terminal KSR1 complexes. FLAG-tag 








As the Merlin/DCAF1 interaction occurs in the nucleus, we wanted to determine if the 
DCAF1/KSR1 interaction is also nuclear and thus highlight the possible nature of the 
interaction. First, we wanted to establish where the KSR1 constructs localized in the 
cell (figure 4.4A). We transfected K1, KC and KN in HEK293T cells and stained the cells 
with a FLAG-tag antibody counterstained with DAPI. K1 predominantly localized to the 
cytoplasm with some nuclear expression observed (figure 4.4A). Similarly, KC was 
predominantly cytoplasmic with stronger peri-nuclear staining and some nuclear 
expression. Conversely, KN was mostly nuclear with weaker cytoplasmic expression. As 
all three complexes were present in both the cytoplasm and the nucleus of HEK293T 










Figure 4.4 - KSR1 construct localization in HEK293T cells. A: HEK293T cells were transfected with wild 
type KSR1 (K1), C-terminal KSR1 (KC) sequence (540–873 amino acids (a.a)) or N-terminal KSR1 (KN) 
sequence (1–539 a.a) and stained with FLAG-tag antibody (Sigma) (green) and DAPI nuclear stain. 
Images were taken at 60x magnification, scale bar- 50 µM. The images show that K1 is predominantly 
localized to the cytoplasm. KC is also predominantly expressed in the cytoplasm. KN is predominantly 












We overexpressed K1 in HEK293T cells and then performed cytoplasmic and nuclear 
extraction. Figure 4.5A shows successful fractionation as HDAC1 was mostly nuclear 
and GAPDH was mostly cytoplasmic as expected. K1 was also confirmed to be present 
in the cytoplasm and the nucleus of transfected cells although there was much more 
cytoplasmic expression. Endogenous DCAF1 and DDB1 were confirmed in the 
cytoplasm and nucleus of HEK293T cells. Interestingly, DCAF1 was mostly cytoplasmic 
in contrast to Schwann and schwannoma cells in which DCAF1 is mostly nuclear.  
We immunoprecipitated the K1 complex using a FLAG-tag antibody in at least 100 µg 
of K1 transfected total, cytoplasmic and nuclear HEK293T lysates (figure 4.5B). We also 
immunoprecipitated FLAG-tag binding proteins from non-transfected total, 
cytoplasmic and nuclear HEK293T lysates as a control to determine non-specific 
binding to the FLAG-tag antibody. Figure 4.5B shows that DCAF1 and DDB1 interact in 
the cytoplasm and the nucleus of HEK293T cells in a complex with MEK1/2. There was 
more DCAF1 in the cytoplasmic KSR1 complex than the nuclear complex, however, the 
predominant cytoplasmic DCAF1 distribution in the immunoprecipitation input 









Figure 4.5 - The DCAF1/KSR1 interaction occurs both in the cytoplasm and nucleus of HEK293T cells. A: 
Wild-type KSR1 (K1) with a FLAG-tag was overexpressed in HEK293T cells and the cytoplasm and nucleus 
was extracted from HEK293T lysate. The Western blot shows that DCAF1, DDB1, FLAG and MEK1/2 are 
present in the cytoplasmic (C) and nuclear (N) fractions. HDAC1 and GAPDH are nuclear and cytoplasmic 
respectively and determine cross-contamination between fractions. B: K1 was immunoprecipitated from 
the total (T), cytoplasmic and nuclear fractions using a FLAG-tag antibody. The Western blot shows 
DCAF1, DDB1, FLAG and MEK1/2 in non-transfected (-) and K1-transfected immunoprecipitates, 
representative of three repeats. DCAF1 and DDB1 were in the cytoplasmic KSR1 complex. DCAF1 was 




4.4 C-terminal KSR1 ubiquitination is not dependent on DCAF1 
We suspected that KSR1 was a CRL4-DCAF1 substrate for ubiquitination and therefore 
we immunoprecipitated overexpressed truncated KSR1 constructs to determine if 
KSR1 was ubiquitinated. We overexpressed K1, KC and KN in HEK293T followed by 
FLAG-KSR1 immunoprecipitation and Western blotting in the same experimental set 
up as figure 4.3. We probed the entire membrane with an ubiquitin antibody and 





Figure 4.6 - Wild type KSR1 and C-terminal KSR1 are ubiquitinated in HEK293T cells. A: The KSR1 
sequences K1, KC and KN, with a FLAG-tag, were overexpressed in HEK293T and immunoprecipitated 
from 1 mg HEK293T protein lysate using a FLAG-tag antibody. The Western blot shown is representative 
of three repeats and was probed for Ubiquitin and FLAG-tag. Ubiquitin was present in the K1 and KC 
complexes and not the KN complex. FLAG-tag interacting proteins were immunoprecipitated from non-
transfected HEK293T (-) as a negative control. HEK293T protein lysate (input) was probed with ubiquitin 




We then wanted to determine if KSR1 poly-ubiquitination was dependent on DCAF1 
expression. In the HEK293T model we used a shRNA construct targeting DCAF1 
expression and then overexpressed human wild type KSR1 (hK1) tagged with FLAG 
using an overexpression lentiviral vector. We confirmed successful DCAF1 knockdown 
and hK1 overexpression by Western blot using DCAF1, FLAG and KSR1 (H70) antibodies 
(figure 4.7A). We used these lysates as well as appropriate scramble control lysates 
and immunoprecipitated hK1 with a FLAG tag antibody. The immunoprecipitated 
proteins were separated by Western blot and probed with an ubiquitin antibody 
(figure 4.7B). There were no clear or consistent differences in the amount of ubiquitin 
present in the hK1 complexes between scramble and DCAF1 knockdown lysates. 
Successful and comparable FLAG-hK1 immunoprecipitation was confirmed in figure 
4.8A and supplementary figure 6A-B. 
4.5 DCAF1 facilitates the association of KSR1 with MEK1/2 and ERK1/2 
To understand the purpose of the DCAF1/KSR1 interaction, we immunoprecipitated 
hK1 complexes and experimental input samples from the previous experiment and 
probed for components of the RAF/MEK/ERK pathway by Western blot (figure 4.7). 
KSR1 is a scaffold protein that facilitates RAF/MEK/ERK pathway activation and 
therefore we also probed for phosphorylated MEK1/2 and ERK1/2. Figure 4.8A and 
supplementary figure 6A-B shows that DCAF1 knockdown reduced the amount of total 
MEK1/2 and ERK1/2 in the KSR1 complex. Total C-RAF (figure 4.8) was decreased in 
one replicate and increased in one replicate (supplementary figure 6A) when DCAF1 
expression is reduced, whilst it was absent in supplementary figure 6B. Phosphorylated 
MEK1/2 and ERK1/2 were reduced in the KSR1 complex upon DCAF1 knockdown. 
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Altogether, this evidence suggests that DCAF1 enhances the binding of MEK1/2 and 










Figure 4.7 - KSR1 poly-ubiquitination is not dependent on DCAF1 in HEK293T cells. A: DCAF1 
expression was knocked down in HEK293T cells and then human KSR1 (hK1) with a FLAG-tag was 
overexpressed. Scramble (Sc) or DCAF1 shRNA (shD) lentivirus was added for 24 hours and then fresh 
medium for 24 hours followed by four days of puromycin selection. Cells were split and Sc or hK1 
lentivirus was added after 24 hours, for 48 hours before cell lysis. The Western blot confirmed DCAF1 
knockdown and hK1 overexpression. B: hK1 complexes were immunoprecipitated using a FLAG antibody 
from 1 mg of HEK293T lysate. Western blot shows immunoprecipitated FLAG complexes (IP) and input 
lysates probed with ubiquitin, representative of three repeats. The amount of Ubiquitin in the hK1 
complexes was not affected by DCAF1 knockdown. FLAG-tag interacting proteins were 
immunoprecipitated from Sc/sc and Sc/shD as negative controls. The input lanes shows endogenous 






Figure 4.8 - KSR1 and RAF/MEK/ERK binding is partly dependent on DCAF1 in HEK293T cells. A: DCAF1 
expression was targeted with a shRNA lentiviral plasmid in HEK293T cells and then human KSR1 (hK1) 
with a FLAG-tag was overexpressed. DCAF1 lentivirus was added for 24 hours and then fresh medium 
was added for 24 hours followed by four days of puromycin selection. Cells were then split and 24 hours 
later hK1 lentivirus was added for 48 hours followed by cell lysis. hK1 complexes were 
immunoprecipitated using a FLAG antibody from 1 mg of HEK293T lysate. Western blot shows 
immunoprecipitated FLAG complexes and input lysates probed with FLAG, C-RAF, pMEK1/2, MEK1/2, 
pERK1/2. ERK1/2 and GAPDH, representative of three repeats. The amount of pMEK1/2, MEK1/2, 
pERK1/2 and ERK1/2 in the hK1 complex was reduced when DCAF1 expression was knocked down. 
FLAG-tag interacting proteins were immunoprecipitated from Scramble (Sc)/Sc and Sc/DCAF1 
knockdown (shD) lysates as a negative control. Input lysates show endogenous expression in lysates 
prior to the immunoprecipitation. 2% of the total protein amount used for the immunoprecipitation was 





We have shown for the first time that endogenous DCAF1 and KSR1 interact in a 
Merlin-deficient model (figure 4.1A). However, the KSR1 band at 100 kDa was faint in 
all experiments which is probably reflective of low endogenous expression. 
Interestingly, there was also a higher molecular weight KSR1 band specific to 
immunoprecipitated DCAF1. This band was between 130 kDa and 180 kDa (much 
higher than the additional KSR1 band present in BenMen-1 input lysate). The higher 
molecular weight band was not specific to BenMen-1 lysate as we also identified the 
same band in immunoprecipitated DCAF1 from KT21-MG1-Luc5D lysate 
(supplementary figure 3D). In addition, a band of the same size was detected when 
immunoprecipitating overexpressed DCAF1 using a myc-tag antibody demonstrating 
that the band was not a non-specific signal caused by the DCAF1 antibody used for 
immunoprecipitation (figure 4.2). Indeed, a multiprotein KSR1 complex has previously 
been reported by Stewart et al. (Stewart et al., 1999). This complex remained even 
under high-salt conditions (up to 1 M sodium chloride) or in the presence of 0.1% SDS 
and contained Heat shock protein 70 (HSP70), Heat shock protein 90 (HSP90), MEK1/2 
and 14-3-3 proteins (Stewart et al., 1999). However, this complex was reported to be 
around 1000 kDa in size, dissimilar to the size of the band we detected. Nonetheless, it 
is interesting that the higher molecular weight band was present exclusively when full 
length DCAF1 is expressed and not when the C-terminal of DCAF1 was expressed. Thus, 
suggesting that wild-type DCAF1 is required for high molecular weight KSR1 complexes 
to be formed. 
 We found that KSR1 binds specifically to the C-terminal of DCAF1 between 745–1507 
amino acids (figure 4.2). This portion of the protein contains a LisH domain regulating 
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DCAF1 dimerization, a WD40 domain responsible for DCAF1 interaction with DDB1 and 
an acidic C-terminus which is required for Merlin binding (Nakagawa, Mondal & 
Swanson, 2013). Further analysis is required to determine the role of KSR1 binding and 
elucidate if KSR1 is a substrate for ubiquitination via the CRL4-DCAF1 complex. We 
then overexpressed truncated KSR1 constructs and identified that DCAF1 binding was 
specific to the N-terminal of KSR1 (figure 4.3). Interestingly, there was also a weak 
band in the C-terminal KSR1 lane suggesting that DCAF1 may bind to multiple locations 
on KSR1. The C-terminal contained the kinase domain responsible for MEK1/2 and C-
RAF binding and facilitating RAF/MEK/ERK activation whereas the N-terminal (1–539 
amino acids) contained domains CA1-CA4 that also bind C-RAF (CA1) as well as ERK1/2 
(CA4) and are responsible for KSR1 regulation by 14-3-3 proteins (Morrison, 2001). 
We performed cytoplasmic and nuclear fractionation of HEK293T overexpressing 
FLAG-KSR1 (K1) and immunoprecipitated the KSR1 complex discovering that the 
DCAF1/KSR1 interaction surprisingly occurred in the cytoplasm of HEK293T cells 
(although some nuclear protein was detected in some replicates) (figure 4.5B). 
However, endogenous DCAF1 protein in HEK293T was mostly cytoplasmic, in contrast 
to Merlin-deficient cells in which it was mostly nuclear (figure 4.5A). Therefore, it is 
important to repeat this experiment in a relevant Merlin-deficient model to confirm 
the location of the interaction in Merlin-deficient cells. Unfortunately, attempts to 
overexpress KSR1 in the Merlin-deficient cell line BenMen-1 failed using both 
lipofectamine and lentiviral methods (data not shown). 
We showed that KSR1 was poly-ubiquitinated at the C-terminal containing CA5 
domains and was not dependent on DCAF1 expression (figure 4.6 and 4.7). This is in 
keeping with the previous data in chapter 3 that excludes the possibility that DCAF1 
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regulates KSR1 degradation, often mediated by poly-ubiquitination. In addition, it has 
recently been shown that KSR1 poly-ubiquitination is dependent on PRAJA2 (Rinaldi et 
al., 2016). Unfortunately, we could not determine if KSR1 was mono-ubiquitinated as 
there are no specific mono-ubiquitin antibodies. We also did not overexpress 
ubiquitin, therefore, the assay used may not have been sensitive enough to detect N-
terminal KSR1 mono-ubiquitination. However, we cannot exclude the possibility that 
DCAF1 mono-ubiquitinates KSR1 and in this manner regulates RAF/MEK/ERK activity.  
We used the previous experimental setup to determine if DCAF1 regulates KSR1 
binding to RAF/MEK/ERK. We identified a reduction in pMEK, MEK1/2, pERK1/2 and 
ERK1/2 bound to KSR1 when DCAF1 expression was knocked down (figure 4.8 and 
supplementary figure 6). Therefore, demonstrating that DCAF1 enhances 
RAF/MEK/ERK activity in a KSR1-dependent manner. Interestingly, C-RAF bound to 
KSR1 is unchanged upon DCAF1 knockdown suggesting that DCAF1 specifically 
enhances MEK1/2 binding to KSR1 and subsequent phosphorylation. MEK1/2 binds to 
the CA5 domain of KSR1 whereas DCAF1 binds to a domain between CA1 and CA4 
(Morrison, 2001). How DCAF1 enhances KSR1 binding to MEK1/2 is a mystery but it 
may involve DCAF1-dependent changes in KSR1 spatial conformation or changes in 
membrane localization that must be further investigated.  
4.7 Conclusion 
We have shown, for the first time that endogenous DCAF1 and KSR1 interact in a 
Merlin deficient model (BenMen-1 cells). In addition, there was a high molecular 
weight KSR1 complex in DCAF1 immunoprecipitated from BenMen-1 lysates. This 
complex was also present when overexpressed DCAF1 is isolated from HE293T lysates 
but not when C-terminal DCAF1 was overexpressed and immunoprecipitated. 
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Therefore, suggesting that DCAF1 facilitates the formation of a high molecular weight 
KSR1 complex which is dependent on full length DCAF1. 
We have also shown evidence that KSR1 interacts with a DCAF1 domain between 745–
1507 amino acids and that DCAF1 interacts with KSR1 domains between 1–539 amino 
acids. There may also be a DCAF1 and KSR1 interaction between 540–873 amino acids 
but this is at least partly dependent on the presence of amino acids 1–539 of KSR1.The 
DCAF1/KSR1 interaction occurred in the cytoplasm of HEK293T cells but they may also 
interact in the nucleus, particularly when nuclear DCAF1 expression is increased. We 
have shown evidence that the DCAF1/KSR1 interaction enhances KSR1 binding to 
MEK1/2 and ERK1/2 and increases MEK1/2 and ERK1/2 phosphorylation. Therefore, 
DCAF1 regulates RAF/MEK/ERK activity in a KSR1-dependent manner and may be a 















There are currently no specific inhibitors of CRL4-DCAF1 activity. As CRL4-DCAF1 is 
activated by neddylation, we identified the neddylation inhibitor, MLN3651, a 
successor of MLN4924. MLN3651 (Takeda, UK) was developed to overcome the 
problems with MLN4924 such as its bioavailability. MLN3651 is an orally available 
inhibitor with pre-clinical activity. We aimed to determine if MLN3651 had significant 
anti-tumour activity in Merlin-deficient schwannoma and meningioma.  
We identified that DCAF1 protein expression was increased in schwannoma and 
meningioma in previous chapters. Thus, we hypothesised that DCAF1 kinase activity 
was also upregulated in Merlin-deficient tumours. Therefore, we also aimed to 
investigate the potency of the DCAF1 kinase inhibitor, B32B3 in Merlin-deficient cells.  
5.2 MLN3651 treatment reduces NEDD8-conjugates and activates the Hippo pathway 
in Merlin-deficient cells 
We confirmed MLN3651 drug activity by observing NEDD8-conjugates, by Western 
blot. In preliminary experiments we found that a 24 hour MLN3651 treatment in 
schwannoma cells was not sufficient to reduce cell viability (data not shown). 
Therefore, we treated primary schwannoma cells for 72 hours whereas primary 
meningioma and BenMen-1 cells were treated for 24 hours with MLN3651 and then 
NEDD8-conjugates were analysed using a neddylation antibody (figure 5.1A-C). 
BenMen-1 cells were treated with a lower concentration of MLN3651 as we 
determined BenMen-1 cells were much more sensitive to MLN3651 (data not shown). 
In all treated cells, NEDD8-conjugates were dramatically reduced demonstrating that 
MLN3651 treatment of cells in culture successfully inhibits neddylation. 
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Figure 5.1 - MLN3651 reduces NEDD8-conjugates in Merlin-deficient tumours. A: Western blot of three 
primary schwannomas treated with DMSO or 1 µM MLN3651 for 72 hours and probed for NEDD8-
conjugates and GAPDH, the loading control. MLN3651 led to a clear reduction in NEDD8-conjugates in 
schwannoma. B: Western blot of three primary meningiomas (MN) treated with DMSO or 1 µM 
MLN3651 for 24 hours and probed for NEDD8-conjugates and GAPDH, representative of nine replicates. 
MLN3651 led to a clear reduction in NEDD8-conjugates in meningioma. C: Western blot of the benign 
meningioma cell line, BenMen-1 treated with DMSO or 0.3 µM MLN3651 for 24 hours and probed for 
NEDD8-conjugates and GAPDH, representative of three replicates. MLN3651 led to a clear reduction in 




CRL4-DCAF1 is more active in Merlin-deficient cells and leads to Hippo pathway 
inhibition by ubiquitinating LATS1/2 (Li et al., 2014). LATS1/2 ubiquitination causes 
changes in LATS1/2 degradation and activity preventing phosphorylation of YAP (Li et 
al., 2014). Therefore, Merlin-deficient cells have an increase in nuclear YAP which 
activates transcription of genes involved in tumourigenesis (Li et al., 2014; Zhang et al., 
2010). Merlin-deficient cells have more active CRL4-DCAF1 and this may make them 
more sensitive to neddylation inhibition. We analysed the expression of LATS2 and 
pYAP after MLN3651 treatment of schwannoma cells to determine if MLN3651 inhibits 
CRL4-DCAF1 activity and to investigate the effects on downstream Hippo pathway 
signalling.  
We treated schwannoma cells for 72 hours with MLN3651 as they were less sensitive 
to the drug than other tumours in preliminary experiments. Figure 5.2A shows 
Western blots from schwannoma lysates treated with MLN3651 for 72 hours and 
probed with LATS2 and pYAP. LATS2 and pYAP expression were significantly increased 
with MLN3651 treatments as low as 0.3 µM indicating activation of the Hippo pathway 
and suggesting that MLN3651 inhibits CRL4-DCAF1 activity (Repeated Measures 
ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.05) (figure 5.2B).  
In primary meningioma, a four hour treatment with MLN3651 was sufficient to lead to 
a significant increase in LATS1 expression (Student’s Paired T test; p< 0.05) (figure 
5.3A-B). However, there was only an average increase in LATS1 expression of 23% 
whereas there was an average increase of 88% LATS2 expression that was not 
statistically significant (p= 0.06). After four hours treatment in meningioma, pYAP 
expression was not increased but there was a clear increase in two out of the three 
meningioma samples treated figure 5.3A-B). Therefore, we analysed LATS2 and pYAP 
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expression after 24 hours MLN3651 treatment to determine whether Hippo pathway 
activation would occur at a later time point (figure 5.3C-D). Indeed, 24 hours treatment 
with 1 µM MLN3651 led to a significant increase in LATS2 expression. In addition, pYAP 
expression was increased in four out of the six replicates but this was not significant. 
Altogether suggesting that MLN3651 inhibits CRL4-DCAF1 activity in primary 
meningioma and leads to Hippo pathway activation.  
MLN3651 treatment of BenMen-1 cells did not lead to any significant changes in Hippo 
pathway activation at four hours or 24 hours (figure 5.4A-D). However, increases in 
LATS1 and LATS2 were observed in some Western blot replicates (data not shown). 
Therefore, there is no strong evidence that MLN3651 inhibits CRL4-DCAF1 activity in 













Figure 5.2 - MLN3651 activates the Hippo pathway in schwannoma. A: Western blot of three primary 
schwannomas treated with DMSO, 0.3 µM, 0.6 µM or 1 µM MLN3651 for 72 hours and probed for LATS2 
and pYAP of the Hippo pathway and GAPDH (loading control). MLN3651 led to an increase in the 
expression of LATS2 and pYAP in schwannoma showing Hippo pathway activation after treatment. B: 
Mean LATS2 and pYAP expression and SEM in MLN3651 treated schwannoma cells normalized to the 
loading control and relative to DMSO. LATS2 and pYAP were significantly increased with MLN3651 




Figure 5.3 - MLN3651 activates the Hippo pathway in meningioma. A: Western blot of three primary 
meningiomas treated with DMSO or 1 µM MLN3651 for four hours and probed for LATS1, LATS2, pYAP 
(Hippo pathway) and GAPDH (loading control). B: Mean LATS1, LATS2 and pYAP expression and SEM in 
MLN3651 treated meningioma cells normalized to the loading control and relative to DMSO. LATS1 was 
significantly increased with MLN3651 treatment compared with the DMSO control, *- p< 0.05. The 
mean expression of LATS2 and pYAP was increased in MLN3651 treated meningioma cells but this was 
not significant, ns- not significant showing some evidence for Hippo pathway activation. C: Western blot 
of three meningiomas treated with DMSO, 0.3 µM, 0.6 µM or 1 µM MLN3651 for 24 hours and probed 
for LATS2, pYAP and GAPDH, representative of six replicates. LATS2 expression increased with MLN3651 
treatment. D: Mean LATS2 and pYAP expression and SEM in MLN3651 treated meningioma cells 
normalized to the loading control and relative to DMSO. LATS2 was significantly increased with 1 µM 
MLN3651 treatment compared with the DMSO control, *- p< 0.05. The mean expression of pYAP was 
increased in MLN3651 treated meningioma cells but it was not significant showing some evidence of 




Figure 5.4 - MLN3651 does not activate the Hippo pathway in BenMen-1. A: Western blot of the 
benign meningioma cell line (BenMen-1) treated with DMSO or 0.3 µM MLN3651 for four hours and 
probed for LATS1, LATS2, pYAP and GAPDH (loading control), representative of three replicates. B: Mean 
LATS1, LATS2 and pYAP expression and SEM in MLN3651 treated meningioma cells normalized to the 
loading control and relative to DMSO. The mean expression of LATS1 and LATS2 were increased in 
MLN3651 treated BenMen-1 cells but this was not significant, ns- not significant, therefore there is no 
evidence for Hippo pathway activation in this cell model. C: Western blot of BenMen-1 cells treated with 
DMSO, 0.3 µM, 0.6 µM or 1 µM MLN3651 for 24 hours and probed for LATS2, pYAP and GAPDH, 
representative of three replicates. LATS2 expression increased with MLN3651 treatment. D: Mean 
LATS2 and pYAP expression and SEM in MLN3651 treated BenMen-1 cells normalized to the loading 
control and relative to DMSO. The mean expression of LATS2 was increased in MLN3651 treated 
BenMen-1 cells but this was not significant, pYAP expression was not increased by MLN3651, ns- not 
significant. There is no evidence for Hippo pathway activation in the BenMen-1 model after 24 hours 
MLN3651 treatment.   
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5.3 MLN3651 treatment leads to enhanced RAF/MEK/ERK activity in Merlin-deficient 
cells 
We hypothesised that CRL4-DCAF1 regulates KSR1 activity and therefore 
RAF/MEK/ERK activity. As MLN3651 targets CRL4-DCAF1 neddylation, we suspected 
that MLN3651 treatment would inhibit the RAF/MEK/ERK pathway. Therefore, we 
analysed pERK1/2 and ERK1/2 expression following MLN3651 treatment of Merlin-
deficient cells. Figure 5.5A-B shows that pERK1/2 was significantly increased in 
schwannoma cells after 72 hours MLN3651 treatment (0.6 µM) (Repeated Measures 
ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.05). Similarly, 24 hours 
MLN3651 treatment of primary meningioma cells significantly increased 
phosphorylation of ERK1/2 (p< 0.05) (figure 5.6A-B). In contrast, 24 hours MLN3651 




Figure 5.5 - MLN3651 increases pERK1/2 in schwannoma. A: Western blot of three primary 
schwannomas (NF) treated with DMSO, 0.3 µM, 0.6 µM or 1 µM MLN3651 for 72 hours and probed for 
pERK1/2 (showing activation), ERK1/2 and GAPDH (loading control). MLN3651 led to an increase in the 
expression of pERK1/2 in schwannoma. B: Mean pERK1/2 expression and SEM in MLN3651 treated 
schwannoma cells normalized to total ERK1/2 and the loading control (GAPDH), relative to DMSO. 
pERK1/2 expression was significantly increased with 0.6 µM MLN3651 treatment compared with the 
DMSO control, *- p< 0.05. ns- not significant showing that MLN3651 activates the RAF/MEK/ERK 




Figure 5.6 - MLN3651 increases pERK1/2 in meningioma but not BenMen-1. A: Western blot of three 
primary meningiomas (MN) treated with DMSO, 0.3 µM, 0.6 µM or 1 µM MLN3651 for 24 hours and 
probed for pERK1/2 (showing activation), ERK1/2 and GAPDH (loading control). MLN3651 led to an 
increase in the expression of pERK1/2 in meningioma demonstrating increased RAF/MEK/ERK activation 
in response to MLN3651. B: Mean pERK1/2 expression and SEM in MLN3651 treated meningioma cells 
normalized to total ERK1/2 and the loading control (GAPDH), relative to DMSO. pERK1/2 expression was 
significantly increased with MLN3651 treatment compared with the DMSO control, *- p< 0.05. C: 
Western blot of the benign meningioma cell line (BenMen-1) treated with DMSO, 0.3 µM, 0.6 µM or 1 
µM MLN3651 for 24 hours and probed for pERK1/2, ERK1/2 and GAPDH, representative of three 
replicates. MLN3651 led to an increase in the expression of pERK1/2 in BenMen-1. D: Mean pERK1/2 
expression and SEM in MLN3651 treated meningioma cells normalized to total ERK1/2 and the loading 
control (GAPDH), relative to DMSO. The mean expression of pERK1/2 was increased in MLN3651 treated 
BenMen-1 cells but this was not significant, ns- not significant. Therefore, there is no evidence that 




5.4 MLN3651 reduces cell viability and proliferation of Merlin-deficient schwannoma 
To assess the efficacy of MLN3651, we analysed the viability of Merlin-deficient cells 
after treatment with concentrations of 0.1-10 µM MLN3651. We treated primary 
schwannoma cells, in triplicate, for 72 hours with different concentrations of MLN3651 
(stable for up to 72 hours). Figure 5.7A shows the average luminescent signal, 
correlating with ATP concentration, relative to DMSO control for each drug 
concentration with the SEM where each line represents a different tumour (biological 
replicate) (n=3). The average IC50, the concentration at which cell viability was halved, 
was 23.76 µM. However, viability was significantly reduced from 1 µM demonstrating 
that MLN3651 has an effect on a proportion of cells (Repeated Measures ANOVA with 
Tukey’s Multiple Comparison Post Test; p< 0.01). A 72 hour treatment was not long 
enough to induce reductions in viability below 50% and therefore we extended the 
treatment time. 
We hypothesised that a longer treatment would have more of an effect on viability 
and therefore, we treated cells for 72 + 72 hours. MLN3651 is stable for 72 hours but 
longer time points have not been investigated and therefore we added fresh drug after 
72 hours (personal communication with Takeda). Two 72 hours treatments (144 hours) 
of primary Merlin-deficient schwannoma significantly reduced viability at 
concentrations of 0.3 µM (p< 0.001) (figure 5.7B). The average IC50 was 3.14 µM with 
a 2.34 µM standard error of the mean. As the standard error was relatively large, we 
removed the ‘non-responder’ and the average IC50 was reduced to 1.01 µM with a 
standard error of 0.18 µM. 
We treated primary schwannoma cells, in triplicate, with 0.3–1 µM of MLN3651 for 72 
hours and analysed cleaved Caspase 3/7 expression using a luminescent assay. Figure 
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5.7C shows the average changes in Caspase 3/7 activity in three biological replicates 
after MLN3651 treatment. MLN3651 significantly increased cleaved Caspase 3/7 at all 
concentrations tested (Repeated Measures Analysis of Variance (ANOVA) with Tukey’s 
Multiple Comparison Post Test; p< 0.05). Therefore, reduced viability after MLN3651 
treatment was caused by changes in apoptosis in schwannoma. 
Changes in proliferation and cell death can affect cell viability and therefore we 
determined the effect of MLN3651 treatment on primary schwannoma cell 
proliferation. Figure 5.8A shows representative images of schwannoma cells stained 
with Ki-67 antibody and counterstained with 4', 6-diamidino-2-phenylindole (DAPI) 
after 72 hours of MLN3651 treatment at 0.3 µM, 0.6 µM and 1 µM. There is a clear 
decrease in the proportion of Ki-67 cells, representing active proliferation, as well as a 
decrease in the total number of cells. We quantified the proportion of Ki-67 positive 
cells in at least three images from each of four biological replicates (figure 5.8B). Figure 
5.8B shows that 0.6 µM MLN3651 significantly reduced proliferation, of schwannoma 
cells, by an average of 68% (Repeated Measures ANOVA with Tukey’s Multiple 








Figure 5.7 - MLN3651 reduces cell viability and increases apoptosis in schwannoma. A: Merlin-deficient 
schwannoma cells were treated with MLN3651, in triplicate, and subjected to CellTiter-Glo® luminescent 
cell viability assay after 72 hours (n=3). Viability of MLN3651-treated cells was normalized to respective 
DMSO-treated controls. The concentration of MLN3651 required to reduce cell viability by 50% (IC50) is 
indicated with the standard error of the mean (SEM). Each colour in the graph represents a different 
primary schwannoma sample. Error bars show the SEM of technical replicates. MLN3651 was ineffective 
at the 72 hour timepoint. B: Merlin-deficient schwannoma cells were treated with increasing doses of 
MLN3651 every 72 hours, in triplicate, and subjected to CellTiter-Glo® luminescent cell viability assay 
after 144 hours (n=6). The IC50 is indicated with the SEM. Each colour in the graph represents a 
different primary schwannoma sample and the error bars show the SEM of the technical replicates. 
MLN3651 reduced schwannoma viability after 144 hours treatment. C: Merlin-deficient schwannoma 
cells were treated with MLN3651, in triplicate, and subjected to Caspase-Glo® 3/7 assay after 72 hours 
(n=3). Caspase 3/7 activity in MLN3651-treated cells was normalized to respective DMSO-treated 
controls. Caspase 3/7 activity was significantly higher in MLN3651-treated cells compared with DMSO-
treated cells showing that MLN3651 activates apoptosis, *-p< 0.05, **- p< 0.01, ns- not significant, error 





Figure 5.8 - MLN3651 reduces proliferation of schwannoma. A: Representative immunocytochemistry 
images, at 20x magnification, of Merlin-deficient schwannoma cells treated with DMSO, 0.3 µM, 0.6 µM 
or 1 µM MLN3651 for 72 hours and stained with Ki-67 antibody and DAPI, Scale bar- 50 µM. B: At least 
three images from each treatment group in A was quantified to calculate the proportion of Ki-67 
positive cells in each group. Four different schwannoma tumours were treated with MLN3651 and 
quantified in this way. The mean proportion of Ki-67 positive cells in MLN3651-treated schwannoma 
cells relative to DMSO control is plotted and SEM in B. 0.6 µM and 1 µM MLN3651 significantly reduced 











5.5 MLN3651 reduces cell viability and proliferation of Merlin-deficient meningioma 
As MLN3651 reduced the viability of primary Merlin-deficient schwannoma cells we 
tested the efficacy of MLN3651 in primary Merlin-deficient meningioma cells. 
Meningioma cells were treated with 0.1-10 µM MLN3651, in triplicate, for 72 hours. An 
ATP luminescent assay was used to determine the viability of meningioma after 
treatment. There were two distinct groups of meningioma after MLN3651 treatment; 
those that had an IC50 of less than 3 µM and those that had an IC50 of more than 7 
µM. These groups were defined as ‘responders’ and ‘non-responders’ and plotted 
separately in figure 5.9A-B. The graphs show the average luminescent signal for each 
tumour (each in a different colour) relative to the luminescent signal in the DMSO 
control. Viability was significantly reduced in cells treated with 0.3 µM (Repeated 
Measures ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.01) in the 
‘responder’ group and 3 µM (p< 0.001) in the ‘non-responder’ group. Interestingly, 
viability was significantly increased after 0.1 µM MLN3651 treatment in the ‘non-
responder’ group (p< 0.05). The average IC50, that reduced cell viability by half, was 
1.31 µM in the ‘responder’ group and 12.81 µM in the ‘non-responder’ group. As there 
was a large amount of variability in viability response to MLN3651 treatment after 72 
hours, we increased the treatment time to 144 hours (two 72 hour treatments). 
After a 144 hour MLN3651 treatment of primary meningioma cells from both the 
‘responder’ and ‘non-responder’ groups, viability was significantly reduced at 0.1 µM 
(p< 0.05) demonstrating increased sensitivity to MLN3651 compared with a 72 hour 
treatment. There was no significant difference between the IC50 of ‘responder’ and 
‘non-responder’ tumours after 144 hours MLN3651 treatment and the average IC50 
was 0.38 µM with a standard error of 0.18 µM, shown in figure 5.9C. The colours of the 
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lines representing individual tumours were consistent between figure 5.9A-B and C for 
comparison. Therefore, prolonged treatment can effectively reduce cell viability of the 
‘non-responder’ group. Furthermore, 0.3 µM MLN3651 treatment for 24 hours 
significantly increased Caspase 3/7 activity in meningioma (figure 5.9D) (n=10) 
(Repeated Measures ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.001). 
Figure 5.10A shows representative images of primary meningioma cells stained with 
Ki-67 and DAPI after a 72 hour treatment of MLN3651 at concentrations of 0.3 µM, 0.6 
µM and 1 µM. At least three images from each of nine biological replicates were 
analysed and the proportion of Ki-67 positive cells relative to DMSO control was 
plotted in figure 5.10B. Treatment of meningioma cells with 0.3 µM significantly 
reduced proliferation, by an average of 51%, relative to DMSO control (Repeated 
Measures ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.001). Similar to 
schwannoma, MLN3651 reduced viability of meningioma cells by inducing apoptosis 





Figure 5.9 - MLN3651 reduces cell viability and increases apoptosis in meningioma. A,B: Merlin-
deficient meningioma cells were treated with increasing doses of MLN3651, in triplicate, and subjected 
to CellTiter-Glo® luminescent cell viability assay after 72 hours (n=11). Viability of MLN3651-treated cells 
was normalized to respective DMSO-treated controls. The concentration of MLN3651 required to 
reduce cell viability by 50% (IC50) is indicated with the standard error of the mean (SEM). meningioma 
cells with an average IC50 < 3 µM were plotted in A (n=6) and considered to be sensitive to MLN3651 
whereas meningioma cells with an average IC50 > 7 µM were plotted in B (n=5). Each colour represents 
a different primary meningioma tumour and the error bars show the SEM of technical replicates for 
each tumour. C: Merlin-deficient meningioma cells were treated with increasing doses of MLN3651 
every 72 hours, in triplicate, and subjected to CellTiter-Glo® luminescent cell viability assay after 144 
hours (n=7). The IC50 is indicated with the SEM. Colours in the graph are consistent with those in A, B 
and represent different primary meningioma tumours. MLN3651 reduced the viability of all meningioma 
tumours after 144 hours treatment. D: Merlin-deficient meningioma cells were treated with increasing 
doses of MLN3651, in triplicate, and subjected to Caspase-Glo® 3/7 assay after 72 hours (n=10). Caspase 
3/7 activity in MLN3651-treated cells was normalized to respective DMSO-treated controls. Caspase 3/7 
activity was significantly higher in MLN3651-treated cells compared with DMSO-treated cells MLN3651 













Figure 5.10 – MLN3651 reduces proliferation of meningioma cells. A: Representative 
immunocytochemistry images, at 20x magnification, of Merlin-deficient meningioma cells treated with 
DMSO, 0.3 µM, 0.6 µM or 1 µM MLN3651 for 72 hours and stained with Ki-67 antibody and DAPI, Scale 
bar- 50 µM. B: Mean proportion of Ki-67 positive cells in MLN3651-treated meningioma cells relative to 
DMSO control and SEM. At least three images each of nine replicates were quantified. MLN3651 










We treated BenMen-1 cells with MLN3651 at concentrations between 0.1–10 µM and 
analysed the amount of ATP, consistent with number of cells, after 72 hours. The graph 
in figure 5.11A shows the ATP concentrations at each concentration, relative to DMSO, 
for seven replicates. Cell viability was significantly reduced when cells were treated 
with as little as 0.1 µM MLN3651 and the average IC50 was 0.28 µM (Repeated 
Measures ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.05). An extended 
treatment was not required in this case as BenMen-1 cells are much more sensitive to 
MLN3651 than primary cells. We showed that Caspase 3/7 activity was significantly 
increased after 0.1 µM MLN3651 treatment for 24 hours (p< 0.01) (figure 5.11B). 
Proliferation was significantly reduced after 72 hours at 0.3 µM to less than 50% of the 




Figure 5.11 - MLN3651 reduces cell viability and increases apoptosis in BenMen-1. A: The benign 
meningioma cell line (BenMen-1) was treated with increasing doses of MLN3651, in triplicate, and 
subjected to CellTiter-Glo® luminescent cell viability assay after 72 hours (n=7). Viability of MLN3651-
treated cells was normalized to respective DMSO-treated controls. The concentration of MLN3651 
required to reduce cell viability by 50% (IC50) is indicated with the standard error of the mean (SEM). 
Each colour represents a technical replicate of the experiment. The error bars show the SEM in each 
individual experiment. MLN3651 reduced the viability of BenMen-1 cells. B: BenMen-1 cells were 
treated with increasing doses of MLN3651, in triplicate, and subjected to Caspase-Glo® 3/7 assay after 
24 hours (n=3). Caspase 3/7 activity in MLN3651-treated cells was normalized to respective DMSO-
treated controls. Caspase 3/7 activity was significantly higher in MLN3651-treated cells compared with 





Figure 5.12 – MLN3651 reduces proliferation of BenMen-1 cells. A: Representative 
immunocytochemistry images, at 20x magnification, of BenMen-1 cells treated with DMSO, 0.3 µM, 0.6 
µM or 1 µM MLN3651 for 72 hours and stained with Ki-67 antibody and DAPI, Scale bar- 50 µM. B: Mean 
proportion of Ki-67 positive cells in MLN3651-treated BenMen-1 cells relative to DMSO control and 
SEM. At least three images each of three replicates were quantified. MLN3651 significantly reduces 
proliferation of meningioma compared with DMSO.   
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We also tested MLN3651’s effect on viability of WHO II Merlin-deficient meningioma 
(figure 5.13A-B). The availability of WHO II meningioma was limited and therefore we 
were only able to test two samples after 72 hours MLN3651 treatment and one sample 
after 144 hours treatment. A 72 hours treatment reduced viability of both tumours 
with an average IC50 of 3.10 µM (figure 5.13A). Furthermore, the IC50 of the WHO II 
sample tested after 144 hours MLN3651 treatment was 0.75 µM, comparable to the 
IC50’s identified in WHO I meningiomas demonstrating equivalent MLN3651 sensitivity 
in higher grade meningiomas (figure 5.13B).  
There were no WHO III primary Merlin-deficient tumours that we could successfully 
culture. Therefore, we utilised the Merlin-deficient WHO III meningioma cell line, 
KT21-MG1-Luc5D and identified an average IC50 of 0.18 µM with a small SEM of 0.02 
µM between technical repeats when cells were treated with MLN3651 for 72 hours 
(figure 5.13C). Thus, demonstrating that KT21-MG1-Luc5D WHO III cells were more 
sensitive to MLN3651 than WHO I BenMen-1 cells and MLN3651 may be a potential 










Figure 5.13 - Viability of WHO II and III meningiomas after MLN3651 treatment. A: Merlin-deficient 
WHO II meningioma cells were treated with increasing doses of MLN3651, in triplicate, and subjected to 
CellTiter-Glo® luminescent cell viability assay after 72 hours (n=2). Viability of MLN3651-treated cells 
was normalized to respective DMSO-treated controls. The concentration of MLN3651 required to 
reduce cell viability by 50% (IC50) is indicated with the standard error of the mean (SEM). Each colour 
represents a different meningioma tumour. B: Merlin-deficient WHO II meningioma cells were treated 
with increasing doses of MLN3651 every 72 hours, in triplicate, and subjected to CellTiter-Glo® 
luminescent cell viability assay after 144 hours (n=1). The IC50 of the one sample tested is indicated. C: 
The Merlin-deficient WHO III cell line KT21-MG1-Luc5D (KT21), was treated with MLN3651, in triplicate, 
and subjected to CellTiter-Glo® luminescent cell viability assay after 144 hours (n=3). The average IC50 is 
indicated. KT21 is sensitive to low doses of MLN3651. The experiments in this figure were carried out by 








5.6 Merlin-positive schwannoma and meningioma cells are less sensitive to MLN3651 
than Merlin-negative cells  
Figure 5.14 illustrates the effect of MLN3651 on the viability of Merlin-positive 
schwannoma and meningioma cells. The viability curve for the only schwannoma 
tested after 72 hours treatment and three schwannomas after 144 hours treatment 
did not converge demonstrating that an IC50 was not detected (figure 5.14A-B). In 
addition, one schwannoma sample after 24 hours had an IC50 of 6.7 µM, less sensitive 
than Merlin-deficient schwannoma at the same time point. We treated three Merlin-
positive meningioma with MLN3651 for 72 hours and assessed viability (figure 5.14C). 
The average IC50 was 10.04 µM with an SEM of 2.52 µM, again, less sensitive than 
Merlin-deficient meningiomas at the same time point. We analysed the viability of one 
Merlin-positive meningioma after 144 hours MLN3651 treatment (two 72 hour 
treatments) and the concentration that reduced the viability by half was 2.75 µM 
(figure 5.14D). Finally, we treated one Merlin-positive grade II meningioma sample for 
72 hours and 144 hours, at 72 hours the viability curve did not converge whereas after 









Figure 5.14 - Viability of Merlin-positive schwannoma and meningioma after MLN3651 treatment. A: 
Merlin-positive schwannoma cells were treated with MLN3651, in triplicate, and subjected to CellTiter-
Glo® luminescent cell viability assay after 72 hours (n=1). Viability of MLN3651-treated cells was 
normalized to respective DMSO-treated controls. The curve did not converge and therefore the 
concentration of MLN3651 required to reduce cell viability by 50% (IC50) could not be calculated. Each 
colour represents a different tumour. B: Merlin-positive schwannoma cells were treated with MLN3651 
every 72 hours, in triplicate, and subjected to CellTiter-Glo® luminescent cell viability assay after 144 
hours (n=4). One sample converged and had an IC50 of 6.70 µM. C: Merlin-positive meningioma cells 
were treated with MLN3651, in triplicate, and subjected to CellTiter-Glo® luminescent cell viability assay 
after 72 hours (n=3). D: Merlin-positive meningioma cells were treated with MLN3651 every 72 hours, in 
triplicate, and subjected to CellTiter-Glo® luminescent cell viability assay after 144 hours (n=1). The IC50 
of the one sample tested is indicated. E: Merlin-positive WHO II meningioma cells were treated with 
MLN3651, in triplicate, and subjected to CellTiter-Glo® luminescent cell viability assay after 72 hours 
(n=1). The sample did not converge and therefore an IC50 cannot be calculated. F: Merlin-positive WHO 
II meningioma cells were treated with MLN3651 every 72 hours, in triplicate, and subjected to CellTiter-
Glo® luminescent cell viability assay after 144 hours (n=1). 
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5.7 Control cells are less sensitive to MLN3651 than Merlin-deficient tumour cells 
Primary Schwann cells were plated in 96 well plates, in triplicate, and treated with 
MLN3651 for 72 hours (figure 5.15A) and 144 hours (two 72 hour treatments) (figure 
5.15B) to assess the effects of MLN3651 on normal cells. Four different primary 
Schwann cells were assessed for viability after a 72 hour MLN3651 treatment and the 
average IC50 for three samples was 8.44 µM whereas one sample did not converge. 
There was also a large standard of error of 8.11 µM representing the variability 
observed in the graph (figure 5.15A). After two 72 hour MLN3651 treatments (144 
hours), three different Schwann cells had an average IC50 of 7.78 µM, with a large 
standard error of 4.46 µM. Overall, primary Schwann cells were less sensitive to 
MLN3651 than Merlin-deficient schwannoma but viability was significantly reduced 
with treatment and some individual Schwann cell samples were particularly sensitive 
(Repeated Measures ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.05). 
We treated HMC with MLN3651 for 72 hours or 144 hours (two 72 hour treatments) 
(figure 5.15C-D). Two out of the three replicates did not converge and therefore an 
IC50 could not be calculated. One replicate had an IC50 of 8.55 µM after a 72 hour 
treatment (figure 5.15C). We also analysed cell viability after 144 hours of MLN3651 
treatment and none of the three replicates converged (figure 5.15D). Interestingly, 0.1 
µM of MLN3651 significantly increased the viability of HMC after 72 hours and 
concentrations up to 1 µM significantly increased HMC viability after a 144 hour 
treatment (Repeated Measures ANOVA with Tukey’s Multiple Comparison Post Test; 
p< 0.001). We also analysed apoptosis of HMC after 72 hours of MLN3651 treatment 
(figure 5.15E). Caspase 3/7 activity was significantly increased in HMC cells after 
treatment with 0.6 µM MLN3651 (p< 0.05). As HMC experiments were cultured and 
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experiments carried out in a medium enriched with growth factors (as provided by the 
manufacturer), we decided to repeat the viability assay with HMC cultured in 
meningioma medium to ensure consistency with primary meningioma experiments 
and allow the experiments to be directly comparable (figure 5.15F). The meningioma 
medium made HMC much more sensitive to MLN3651 after 72 hours with an average 
IC50 of 0.72 µM, lower than the average IC50 of Merlin-deficient meningioma cells 
after 72 hours MLN3651 treatment.  
There is a stark difference in the sensitivity between HMC cultured in HMC medium 
and meningioma medium and therefore, HMC medium may lead to MLN3651 
resistance. We tested the difference in sensitivity between Merlin-deficient 
meningioma cells cultured in meningioma medium and the same samples cultured in 
HMC medium (figure 5.16A-B). HMC medium dramatically reduced the sensitivity of all 
three meningioma samples assessed after a 72 hour MLN3651 treatment, and of two 
samples after 144 hours. Therefore, suggesting that a component of HMC medium 
protects both HMC and meningioma cells from MLN3651 induced changes in viability 
(figure 5.16A-B).  
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Figure 5.15 - Human Schwann cells and HMC are less sensitive to MLN3651 than tumour cells. A: 
Primary Schwann cells were treated with MLN3651 (at concentrations indicated), in triplicate, and 
subjected to CellTiter-Glo® luminescent cell viability assay after 72 hours (n=4). Viability of MLN3651-
treated cells was normalized to respective DMSO-treated controls. The concentration of MLN3651 
required to reduce cell viability by 50% (IC50) is indicated with the standard error of the mean (SEM). 
Each colour represent a different primary Schwann cell sample. MLN3651 reduced the viability of some 
Schwann cell samples. The error bars show the SEM of technical replicates for each experiment. B: 
Primary Schwann cells were treated with MLN3651 every 72 hours, in triplicate, and subjected to 
CellTiter-Glo® luminescent cell viability assay after 144 hours (n=3). Each colour represents a different 
primary Schwann cell sample. MLN3651 reduced the viability of some Schwann cell samples. C: Human 
meningeal cells (HMC) were treated with MLN3651, in triplicate, and subjected to CellTiter-Glo® 
luminescent cell viability assay after 72 hours (n=3). Each colour represents a technical replicate of the 
experiment. D: Human meningeal cells (HMC), a normal meningeal control cell line were treated with 
MLN3651 every 72 hours, in triplicate, and subjected to CellTiter-Glo® luminescent cell viability assay 
after 144 hours (n=3). Each colour represents a technical replicate of the experiment. HMC cells were 
not as sensitive to MLN3651 as meningioma cells. MLN3651 did not reduce the viability of HMC cells. E: 
HMC were treated with MLN3651, in triplicate, and subjected to Caspase-Glo® 3/7 assay after 72 hours 
(n=3). Caspase 3/7 activity in MLN3651-treated cells was normalized to respective DMSO-treated 
controls. Caspase 3/7 activity was significantly higher in 0.6 µM and 1 µM MLN3651-treated cells 
compared with DMSO-treated cells, *-p< 0.05, **-p< 0.01, ns- not significant. F: HMC were grown in 
meningioma medium for at least a week and then treated with MLN3651, in triplicate, and subjected to 
CellTiter-Glo® luminescent cell viability assay after 72 hours (n=2). HMC cells were very sensitive to 
MLN3651 when grown in meningioma medium.  
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Figure 5.16 - Viability of meningioma in HMC or meningioma medium after MLN3651 treatment. A: 
Merlin-deficient meningioma cells were grown in meningioma medium or HMC medium for at least a 
week and then treated with increasing doses of MLN3651, in triplicate, and subjected to CellTiter-Glo® 
luminescent cell viability assay after 72 hours (n=3). Viability of MLN3651-treated cells was normalized 
to respective DMSO-treated controls. Coloured lines represent samples cultured in meningioma medium 
whereas dotted lines represent samples culture in HMC medium. Viability of meningioma cells grown in 
HMC medium was much higher than meningioma grown in meningioma medium after MLN3651 
treatment demonstrating that HMC medium decreases the sensitivity of meningioma cells to MLN3651. 
B: Merlin-deficient meningioma cells were grown in meningioma medium or HMC medium for at least a 
week and then treated with increasing doses of MLN3651 every 72 hours, in triplicate, and subjected to 
CellTiter-Glo® luminescent cell viability assay after 144 hours (n=2). Coloured lines represent samples 
cultured in meningioma medium whereas dotted lines represent samples culture in HMC medium. 
Viability of meningioma cells grown in HMC medium was much higher than meningioma grown in 
meningioma medium after MLN3651 treatment demonstrating that HMC medium decreases the 
sensitivity of meningioma cells to MLN3651. The experiments in this figure were carried out by Dr 






5.8 B32B3 reduces viability and proliferation of Merlin-deficient cells 
We tested the effect of B32B3 treatment on the viability of primary Merlin-deficient 
schwannoma cells by quantifying the proportion of ATP present in each treated well 
compared with DMSO control (figure 5.17A). We treated cells with 0.1–20 µM B32B3 
for 72 hours and assessed viability. A B32B3 treatment of 10 µM significantly reduced 
cell viability (Repeated Measures ANOVA with Tukey’s Multiple Comparison Post Test; 
p<0.001) and the average IC50 was 11.07 µM (figure 5.17A) whereas one sample did 
not converge. We also analysed the proliferation of schwannoma cells after 72 hours 
B32B3 treatment. We identified a significant decrease in the proportion of Ki-67 
positive cells at 5 µM and 10 µM compared with DMSO (Repeated Measures ANOVA 
with Tukey’s Multiple Comparison Post Test; p< 0.05) (figure 5.17B). Figure 5.17C 
shows representative images of a schwannoma treated with B32B3 and stained with a 





Figure 5.17 - B32B3 effect on viability and proliferation of schwannoma. A: Merlin-deficient 
schwannoma cells were treated with increasing doses of B32B3, in triplicate, and subjected to CellTiter-
Glo® luminescent cell viability assay after 72 hours (n=4). Viability of B32B3-treated cells was normalized 
to respective DMSO-treated controls. The concentration of B32B3 required to reduce cell viability by 
50% (IC50) is indicated with the standard error of the mean (SEM). Each colour represents a different 
primary schwannoma tumour. The error bars show the SEM of the technical replicates for each 
schwannoma tumour. B32B3 reduces schwannoma viability at high concentrations. B: Mean proportion 
of Ki-67 positive cells in B32B3-treated schwannoma cells relative to DMSO control and SEM. At least 
three images each of three replicates from C were quantified. 5 µM and 10 µM B32B3 significantly 
reduced proliferation of schwannoma compared with DMSO, *-p< 0.05, ns- not significant, error bars 
are ±SEM. C: Representative immunocytochemistry images, at 20x magnification, of Merlin-deficient 
schwannoma cells treated with DMSO, 1 µM, 5 µM or 10 µM B32B3 for 72 hours and stained with Ki-67 




Primary Merlin-deficient meningioma cells were treated with B32B3 for 72 hours and 
assessed for changes in cell viability (figure 5.18A). Meningioma cells had a similar 
sensitivity to B32B3 as schwannoma cells with an average IC50 of 13.92 µM and a 
standard error of 1.84 µM. Viability was significantly reduced at 10 µM (Repeated 
Measures ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.001). We also 
treated meningioma cells with B32B3 for 72 hours and assessed proliferation via Ki-67 
staining (representative images shown in figure 5.18C). Quantification of proportion of 
Ki-67 positive cells from at least three images of six different meningiomas is shown in 
figure 5.18B. B32B3 significantly reduces meningioma proliferation, by an average of 
50%, at 1 µM (Repeated Measures ANOVA with Tukey’s Multiple Comparison Post 
Test; p< 0.05). BenMen-1 cells treated with B32B3 for 72 hours had a significantly 
increased cell viability up to 2 µM (p< 0.05) and a significantly reduced proliferation at 
1 µM (p< 0.05) (figure 5.19A). The average IC50 across the three repeats was 9.22 µM 
and proliferation was also significantly reduced at 5 µM, as measured by Ki-67 index 





Figure 5.18 - B32B3 effect on viability and proliferation of meningioma. A: Merlin-deficient 
meningioma cells were treated with increasing doses of B32B3, in triplicate, and subjected to CellTiter-
Glo® luminescent cell viability assay after 72 hours (n=3). Viability of B32B3-treated cells was normalized 
to respective DMSO-treated controls. The concentration of B32B3 required to reduce cell viability by 
50% (IC50) is indicated with the standard error of the mean (SEM). Each colour on the graph represents 
a different primary meningioma tumour. The error bars show the SEM of technical replicates for each 
meningioma tumour. B32B3 reduced meningioma viability at higher concentrations. B: Mean proportion 
of Ki-67 positive cells in B32B3-treated meningioma cells relative to DMSO control and SEM. At least 
three images each of six replicates from C were quantified. 1 µM, 5 µM and 10 µM B32B3 significantly 
reduced proliferation of meningioma compared with DMSO, *-p< 0.05, **-p< 0.01, ns- not significant, 
error bars are ±SEM. C: Representative immunocytochemistry images, at 20x magnification, of Merlin-
deficient meningioma cells treated with DMSO, 1 µM, 5 µM or 10 µM B32B3 for 72 hours and stained 
with Ki-67 antibody and DAPI, Scale bar- 50 µM.  
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Figure 5.19 - B32B3 effect on viability and proliferation of BenMen-1. A: The Benign meningioma cell 
line (BenMen-1) was treated with increasing doses of B32B3, in triplicate, and subjected to CellTiter-
Glo® luminescent cell viability assay after 72 hours (n=3). Viability of B32B3-treated cells was normalized 
to respective DMSO-treated controls. The concentration of B32B3 required to reduce cell viability by 
50% (IC50) is indicated with the standard error of the mean (SEM). Each colour on the graph represents 
a technical replicate of the experiment. Error bars show the SEM of the technical replicates for each 
experiment. B32B3 reduced BenMen-1 viability at higher concentrations. B: Mean proportion of Ki-67 
positive cells in B32B3-treated BenMen-1 cells relative to DMSO control and SEM. At least three images 
each of three replicates were quantified from C. 5 µM and 10 µM B32B3 significantly reduced 
proliferation of BenMen-1 compared with DMSO, *-p< 0.05, **-p< 0.01, ns- not significant, error bars 
are ±SEM. C: Representative immunocytochemistry images, at 20x magnification, of BenMen-1 cells 
treated with DMSO, 1 µM, 5 µM or 10 µM B32B3 for 72 hours and stained with Ki-67 antibody and DAPI, 





MLN4924 is a first in class NAE inhibitor that inhibits neddylation and has activity in a 
number of tumours to induce cell cycle arrest and apoptosis (Lin et al., 2010; Luo et al., 
2012; Milhollen et al., 2010; Swords et al., 2015; Wei et al., 2012; Yang et al., 2012; 
Zhang et al., 2016; Zhao et al., 2012). Previous research in schwannoma and Merlin-
deficient mesothelioma has demonstrated increased sensitivity to MLN4924 compared 
with Merlin-positive samples (Cooper et al., 2017). MLN3651 has significant pre-clinical 
activity equal to or exceeding MLN4924 (personal communication with Takeda) and 
therefore we tested the potential of MLN3651 in Merlin-deficient tumours. As the drug 
mechanisms are very similar, we hypothesised that Merlin-deficient cells would be 
more sensitive to MLN3651 compared with Merlin-positive cells.  
We confirmed drug activity by observing NEDD8-conjugates after MLN3651 treatment. 
In all treated cells (schwannoma, meningioma and BenMen-1) neddylation was 
significantly reduced with minimal signal in treated samples (figure 5.1). Many proteins 
are neddylated, most important are Cullins (between 75–100 kDa), which inhibit 
ubiquitin ligase complex formation and activation (Deshaies, Emberley & Saha, 2010). 
We confirmed that neddylation of Cullins was inhibited as the protein bands around 
75–100 kDa were reduced.  
 CRL4-DCAF1 ubiquitinates both LATS1 and LATS2 leading to LATS1 degradation and 
inhibition of LATS2 kinase activity (Li et al., 2014). Therefore, inhibiting CRL4-DCAF1 
inhibition should lead to an increase in LATS1 and not LATS2. However, Cooper et al. 
reported no significant changes in LATS1 following MLN4924 treatment (Cooper et al., 
2017). We identified a significant increase in LATS1 protein following four hours 
MLN3651 treatment in primary meningioma but these differences were small (figure 
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5.3A). There was a much larger change in the average LATS2 expression after MLN3651 
treatment (although not significant) and therefore we decided to analyse LATS2 in all 
other MLN3651 experiments (figure 5.3B). After 24 hours MLN3651 treatment, in 
meningioma, we detected a significant increase in LATS2 protein expression confirming 
Hippo pathway activation (figure 5.3C). However, there were no significant changes in 
pYAP. As phosphorylation of YAP leads to nuclear exclusion and subsequent 
degradation, changes in pYAP may be undetectable at this time point (Sayedyahossein 
et al., 2016; Zhao et al., 2010; Zhao et al., 2007). A longer treatment of 72 hours may 
show significant changes in pYAP similar to schwannoma.  
MLN3651 treatment in BenMen-1 for four hours or 24 hours did not induce any 
significant changes in LATS2 or pYAP expression suggesting that MLN3651 does not 
activate the Hippo pathway in this cell line (figure 5.4). Therefore, MLN3651’s effects 
on proliferation and apoptosis in BenMen-1 is independent of CRL4-DCAF1 activity. 
MLN4924 induced accumulation of CDT1, p21 and p27 to induce cell cycle arrest in 
gastric cancer and this may be the MLN3651 mechanism of action in BenMen-1 cells 
rather than Hippo pathway activation (Lan et al., 2016).   
Surprisingly, MLN3651 treatment increased pERK1/2 and therefore ERK1/2 activity 
(Figure 5.5 and 5.6). This is possibly in a CRL4-DCAF1 independent manner as in 
previous chapters DCAF1 depletion led to a decrease in RAF/MEK/ERK activity (figure 
3.10). Although we expected a decrease in RAF/MEK/ERK activity, the increase seen 
provides an additional rationale for combination therapy of MLN3651 with a 
RAF/MEK/ERK activity or KSR1 inhibitor.  
Both cell proliferation and cell death contributed to the changes in cell viability 
observed after MLN3651 treatment (figure 5.7-5.12). A 72 hour MLN3651 treatment 
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significantly reduced proliferation and significantly increased apoptosis suggesting that 
MLN3651 inhibits cell cycle progression and activates apoptosis in schwannoma 
consistent with MLN4924 treatment in other cancers (Lin et al., 2010; Lin et al., 2018; 
Luo et al., 2012), including schwannoma (Cooper et al., 2017).  
Elucidating the reason for differences in drug sensitivity of Merlin-deficient 
meningioma is particularly important to determine which patients may benefit from 
MLN3651. One potential reason for the ‘responder’ and ‘non-responder’ sub-groups 
could be the Nf2 mutation type (figure 5.9). Yang et al. reported that missense Nf2 
mutations are transcribed at the same rate as wild-type Nf2 genes in meningioma and 
that the decreased Merlin protein levels observed in Nf2 mutant meningiomas are due 
to increased protein degradation (Yang et al., 2011). Indeed, treatment of missense 
Nf2 meningioma cells with Celastrol, a proteasome inhibitor, led to increased Merlin 
protein expression and decreased proliferation (Yang et al., 2011). Therefore 
meningiomas with missense Nf2 mutations may be more sensitive to MLN3651 
compared with other Nf2 mutation types. We could not confirm this as we did not 
determine the type of Nf2 mutation in ‘responder’ or ‘non-responder’ meningiomas 
sub-groups. 
Interestingly, low concentrations significantly increased the cell viability of tumours in 
the non-responder group suggesting that drug concentrations at the site of the tumour 
should be closely monitored in future patients dosed with MLN3651 (figure 5.9B) (p< 
0.05). Consistent with this, Zhou et al. identified that low doses of MLN4924 
(nanomolar) significantly increased the proliferation of lung cancer (H1299), breast 
cancer (MCF7 and SUM159) and colorectal cancer (HCT116) cell lines when cultured in 




We confirmed that increased MLN3651 sensitivity was Merlin-dependent by treating 
Merlin-positive schwannoma and meningioma for 72 hours and 144 hours (figure 
5.14). The average IC50 of all Merlin-deficient schwannoma (including the outlier) was 
3.14 µM whereas only one of four Merlin-positive schwannoma converged at 6.70 µM 
demonstrating reduced drug sensitivity (figure 5.7B and figure 5.14). Cooper et al. 
predicted a 10 fold increased sensitivity of Merlin-deficient schwannoma cell to 
MLN4924 compared with Merlin-positive Schwann cells (Cooper et al., 2017). 
However, this was using a mouse model and normal Merlin-positive cells whereas we 
compared the response between primary human Merlin-deficient and Merlin-positive 
meningioma to MLN3651. Unfortunately, as most of the Merlin-positive samples did 
not converge, we cannot calculate a fold change of sensitivity (figure 5.14). Future 
experiments should determine if Merlin-deficient cells are more sensitive because of 
increased CRL4-DCAF1 activity or hyper-activation of other pathways.  
In the meningioma model, we tested three Merlin-positive meningioma at 72 hours 
and found an average IC50 of 10.04 µM (figure 5.14). As the average IC50 of Merlin-
deficient meningiomas in the ‘responder’ sub-group at the same time point was 1.31 
µM, we estimate a 7.5 fold increased sensitivity of Merlin-deficient meningioma cells 
compared with Merlin-positive cells (figure 5.9A). However, this does not take into 
account the ‘non-responder’ sub-group and this group had an IC50 of 12.81 µM which 
is higher than the average IC50 of Merlin-positive meningioma tumours (figure 5.9B). 
Although we only tested one Merlin-positive meningioma after 144 hours MLN3651 
treatment, the IC50 was 2.75 µM and again, Merlin negative meningiomas had an 
approximate 7.5 fold increased sensitivity at the same time point (figure 5.9C and 
208 
 
figure 5.14D). This is particularly interesting because the 144 hour Merlin-deficient 
meningioma tumours included both ‘responders’ and ‘non-responders’. This suggests 
that prolonged treatment sensitizes ‘non-responders’ meningioma cells but prolonged 
treatment in Merlin-positive meningioma cells does not have the same effect. 
Human Merlin-positive Schwann cells were treated with MLN3651 for 72 hours or 144 
hours (figure 5.15A-B). Two Schwann cell samples were particularly sensitive to a 72 
hour treatment of MLN3651 whereas two were not. The average IC50 was 8.44 µM 
but, as expected, had a large standard error. Indeed, there was a similar pattern 
observed after a 144 hour MLN3651 treatment. Two out of the three Schwann cells 
tested were resistant whereas one sample showed sensitivity. Only one sample was 
tested at both a 72 hour and a 144 hour timepoint, and interestingly, this sample was 
less sensitive after 144 hours than after 72 hours (black line) (figure 5.15A-B). This 
could be due to the proliferative rate or passage at the time of the experiment as the 
time points were performed independently and at different times due to primary 
Schwann cell availability. Therefore, it is difficult to ascertain if Schwann cells are 
sensitive to MLN3651 or not. It could be that the sensitive Schwann cells were 
proliferating at a much faster rate than the other two samples. Importantly, 
differentiated Schwann cells do not divide in vivo in the absence of nerve injury; 
therefore non-proliferating Schwann cells may respond differently to MLN3651 (Kim et 
al., 2000; Webster, Martin & O'Connell, 1973). The suitability of using in vitro primary 
human Schwann cells as a drug control is in question. Further information is needed 




HMC are much less sensitive to MLN3651 compared with the ‘responder’ meningiomas 
after 72 hours (figure 5.15C). However, HMC were more sensitive to MLN3651 than 
the ‘non-responder’ group and lower doses of MLN3651 significantly increased 
viability in both HMC and ‘non-responders’ (figure 5.9B). We also confirmed that 
MLN3651 activated apoptosis in HMC similar to meningioma tumours (figure 5.15E). 
Therefore, suggesting that MLN3651 may be toxic to normal cells. However, after two 
72 hours MLN3651 treatments (144 hours), HMC viability did not converge suggesting 
that HMC cells can recover with prolonged treatment and are resistant to MLN3651 
(figure 5.15D). Conversely, ‘non-responder’ meningiomas did not recover after 
prolonged MLN3651 treatment and all meningiomas have a lower IC50 than HMC after 
144 hours MLN3651 (figure 5.9B).  
Unfortunately, HMC cultured in meningioma medium were very sensitive to MLN3651 
which induced a significant reduction in viability at low concentrations (figure 5.15F). 
Furthermore, the average IC50 was 0.72 µM after a 72 hour MLN3651 treatment, 
much lower than ‘responder’ and ‘non-responder’ meningiomas (figure 5.9B). Whether 
MLN3651 is truly toxic to HMC, or if meningioma medium prevents the optimal culture 
of HMC (therefore rendering them sensitive to many chemicals) remains to be 
determined. In addition, HMC in culture proliferate and are derived from 
fetal/embryonic meningeal cells whereas adult meningeal cells do not proliferate. 
Furthermore, only a small proportion of meningeal cells, named meningeal stem cells, 
retain the ability to self-renew and proliferate following injury (Decimo et al., 2012). 
Therefore, the use of in vitro HMC cells as a toxicity control for drugs is dubious and in 
vivo toxicity studies are essential. 
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Interestingly, cells cultured in HMC medium were more resistant to MLN3651 than 
cells, derived from the same tumours, cultured in meningioma medium (figure 5.16). 
This difference in sensitivity was more obvious after two 72 hour treatments, providing 
further evidence that a component of HMC medium promotes resistance to MLN3651 
(figure 5.16B). This is an interesting and important future area of investigation. Growth 
factors and nutrients are often added to enhance conditions for in vitro cell culture. 
Overproduction of growth factors could also be the potential mechanism of MLN3651 
resistance observed in the ‘non-responder’ meningioma sub-group after 72 hours 
MLN3651 treatment (figure 5.9B). Alternatively, MLN3651 could be inhibited or 
degraded by a component of the HMC medium. As HMC medium causes MLN3651 
resistance and HMC cells in meningioma medium are sensitive to MLN3651, further 
experiments are needed to assess MLN3651’s effect on normal cells; in vivo 
experiments are planned which will provide reliable data on toxicity. 
DCAF1 has ubiquitin ligase activity and kinase activity independent or the CRL4-DCAF1 
complex. As we found that DCAF1 expression was commonly upregulated, we 
hypothesised that targeting DCAF1 kinase activity may have a therapeutic effect. The 
DCAF1 kinase inhibitior B32B3, significantly reduced the viability of schwannoma cells 
with an average IC50 of 11.07 µM (figure 5.17A). In addition, 5 µM B32B3 treatment 
significantly decreased proliferation (figure 5.17B). In DU145 cells, 0.5 µM B32B3 
treatment for 24 hours was sufficient to inhibit H2A phosphorylation downstream of 
kinase activity (Kim et al., 2013). Therefore, the effect of B32B3 on schwannoma 
viability is unlikely to be dependent on DCAF1 kinase activity and may be due to 
inhibition of off-target proteins.  
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The effect of B32B3 on meningioma viability is similar to that in schwannoma, again 
suggesting that DCAF1 activity is not significant in Merlin-deficient tumours (figure 
5.18). However, B32B3 reduced meningioma cell proliferation at 1 µM, demonstrating 
some anti-tumourigenic activity that should be further explored (figure 5.18B). We did 
not analyse H2A phosphorylation in Merlin-deficient tumours and without significant 
evidence of B32B3 activity, we cannot determine if DCAF1 kinase activity is increased 
or significant in these tumours.  
5.10 Conclusion 
We have shown that MLN3651 inhibits neddylation in Merlin-deficient tumours and 
that this inhibition is sufficient to activate the Hippo pathway in schwannoma and 
meningioma but not in BenMen-1. The Hippo pathway is downstream of CRL4-DCAF1 
in Merlin-deficient cells and therefore MLN3651 possibly inhibits CRL4-DCAF1 activity 
in schwannoma and meningioma. In addition, MLN3651 also activates RAF/MEK/ERK 
signalling in Merlin-deficient tumours. RAF/MEK/ERK drives growth in Merlin-deficient 
tumours and therefore may limit the efficacy of MLN3651 as a monotherapy. 
MLN3651 treatment significantly reduces cell viability, proliferation and increases 
apoptosis in Merlin-deficient cells, at therapeutically relevant concentrations. 
MLN3651 sensitivity is dependent on Merlin loss as Merlin-positive tumours were 
much more resistant to treatment. However, we could not accurately assess MLN3651 
toxicity due to variability of response observed in Merlin-positive Schwann cells and 
cell culture medium-dependent MLN3652 resistance in HMC. MLN3651 toxicity must 
therefore be assessed in vivo before translation to the clinic. In addition, the evidence 
suggests that MLN3651 sensitivity is not completely dependent on CRL4-DCAF1 
212 
 
inhibition as BenMen-1 cells (in which the Hippo pathway was not activated by 
MLN3651) were equally or more sensitive to MLN3651 than primary cells.  
Finally, we tested the efficacy of the DCAF1 kinase inhibitor, B32B3. Whilst B32B3 was 
effective at reducing cell viability of schwannoma and meningioma, the concentrations 
required were much higher than those that inhibit DCAF1 kinase activity. Therefore, 
DCAF1 kinase activity is unlikely to be significant in Merlin-deficient tumourigenesis, 
despite increased DCAF1 protein expression in many primary tumours. However, we 























This chapter investigates the potential of targeting both DCAF1 and KSR1 activity 
together. We previously showed that targeting DCAF1 and KSR1 expression together 
had an additive effect on proliferation and therefore we expected that utilizing drugs 
targeting both these pathways would be beneficial (Zhou et al., 2016a and chapter 3). 
APS_2_79 was identified as an inhibitor of KSR1 activity by inhibiting the activation of 
KSR-bound MEK1/2 and therefore preventing MEK1/2 and ERK1/2 phosphorylation 
(Dhawan, Scopton & Dar, 2016). As KSR1 was overexpressed in Merlin-deficient 
schwannomas and meningiomas, we tested APS_2_79 as a potential therapeutic.  
In addition, we tested the neddylation inhibitor, MLN3651 in combination with the 
MEK1/2 inhibitor, AZD6244. AZD6244 has potential as a therapeutic to treat 
schwannoma and successfully reduced PDGF-induced proliferation (Ammoun et al., 
2010b). We tested if the combination of MLN3651 with a MEK1/2 inhibitor would 
inhibit the increase in RAF/MEK/ERK activity observed with MLN3651 alone and 
therefore target multiple pathways simultaneously. 
6.2 APS_2_79 has no effect on RAF/MEK/ERK activity or proliferation of Merlin-
deficient schwannoma and meningioma  
To test the effect of inhibiting KSR1-dependent RAF/MEK/ERK activity in Merlin-
deficient tumours we treated primary schwannoma cells with 5 µM APS_2_79 for 24 
hours. There was no clear change in pMEK1/2 or pERK1/2 protein expression (data not 
shown). There was also no significant changes in pERK1/2 protein expression when 
Merlin-deficient primary meningioma cells were treated with 10µM APS_2_79 for 24 
hours (data not shown).  
215 
 
In addition, a 72 hour treatment of schwannoma cells with 1, 5 or 10 µM APS_2_79 did 
not affect cell proliferation (data not shown). A treatment of 10 µM APS_2_79 for 72 
hours significantly reduced meningioma cell proliferation (data not shown). However, 
BenMen-1 proliferation was not reduced by any concentration of APS_2_79 treatment 
for 72 hours (data not shown). Therefore, APS_2_79 is not effective as a monotherapy 
in Merlin-deficient tumours.  
6.3 MLN3651 and AZD6244 treatment inhibits RAF/MEK/ERK activity and activates 
the Hippo pathway 
As APS_2_79 was ineffective at reducing RAF/MEK/ERK activity in Merlin-deficient 
tumours, we did not investigate the combinational potential of APS_2_79 with 
MLN3651. Instead, we used the MEK1/2 inhibitor AZD6244 in combination with 
MLN3651. We treated Merlin-deficient cells with MLN3651 and AZD6244 to determine 
if the drug combination would inhibit the RAF/MEK/ERK activation observed when 
Merlin-deficient cells were treated with MLN3651 alone.  
Primary schwannoma cells were treated with 0.1 µM AZD6244, 1 µM AZD6244, 1 µM 
MLN3651, or a combination of the two drugs for 72 hours and probed for LATS2 (to 
indicate Hippo pathway activation), pERK1/2, ERK1/2 and CYCLIN D1 (for 
RAF/MEK/ERK activity) and GAPDH (the loading control) (figure 6.1A). Figure 6.1B 
shows that LATS2 expression was significantly increased when MLN3651 is added 
alone, and in combination with 0.1 µM and 1 µM AZD6244 indicating that combination 
of MLN3651 and AZD6244 maintained MLN3651-mediated Hippo pathway activation 
(Repeated Measures ANOVA with Tukey’s Multiple Comparison Post Test; p< 0.01). 
Ammoun et al. demonstrated that 1 µM AZD6244 was sufficient to reduce 
schwannoma ERK1/2 activity (Ammoun et al., 2010b). Figure 6.1B demonstrates that 
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both 0.1 µM and 1 µM AZD6244 significantly reduced pERK1/2 expression in 
schwannoma, as expected (p< 0.05). Combining MLN3651 and AZD6244 reduced the 
average pERK1/2 expression to baseline levels although this reduction was not 
significant compared with MLN3651 treatment alone. Therefore, AZD6244 treatment 
cannot inhibit RAF/MEK/ERK activation observed after MLN3651 treatment alone in 
schwannoma.  
To further investigate the combinatorial benefits of MLN3651 and AZD6244, We 
analysed the effect of the combination on schwannoma cell proliferation (figure 6.2A 
and B). We chose the MLN3651 concentration that was closest to the IC50 for 
schwannoma viability (excluding the outlier). We found that AZD6244 or MLN3651 
treatment alone did not significantly reduce proliferation in contrast to Ammoun et 
al.,2010b and chapter 5 (figure 6.2). This results shows that AZD6244 alone has no 
potential as a therapeutic in schwannoma. The combination of 1 µM MLN3651 and 1 
µM AZD6244 significantly reduced proliferation compared with 1 µM AZD6244 alone 
but not compared with 1 µM MLN3651 alone (Repeated Measures ANOVA with 
Tukey’s Multiple Comparison Post Test; p< 0.05).   
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Figure 6.1 - MLN3651 and AZD6244 treatment activates the Hippo pathway in schwannoma. A: 
Western blot of three primary schwannomas treated with MLN3651 and/or AZD6244 (MEK1/2 inhibitor) 
for 72 hours and probed for LATS2 (Hippo pathway), pERK1/2 (activated ERK), ERK1/2, CYCLIN D1 and 
GAPDH (loading control), representative of six replicates. B: Mean LATS2 and pERK1/2 expression ±SEM 
in drug treated schwannoma cells normalized to the loading control (ERK1/2 and/or GAPDH), relative to 
DMSO. LATS2 expression was significantly increased by MLN3651 and, MLN3651 and AZD6244 
compared with DMSO control showing that MLN3651 activates the Hippo pathway even when treated 
in combination with AZD6244. pERK1/2 expression was significantly decreased with AZD6244 alone 
showing that AZD6244 inhibits RAF/MEK/ERK activity. However, combination of MLN3651 and AZD6244 
did not inhibit RAF/MEK/ERK activity compared to MLN3651 treatment alone., *- p< 0.05, **- p< 0.01, 




Figure 6.2 - MLN3651 and AZD6244 effect on proliferation in schwannoma. A: Representative 
immunocytochemistry images, at 20x magnification, of schwannoma cells treated with DMSO, 1 µM 
AZD6244 (MEK1/2 inhibitor), 1 µM MLN3651 or 1 µM AZD6244 and 1 µM MLN3651 for 72 hours and 
stained with Ki-67 antibody and DAPI, Scale bar- 50 µM. B: Mean proportion of Ki-67 positive cells in 
drug treated schwannoma cells relative to DMSO control ±SEM. At least three images each of three 
replicates were quantified. AZD6244 did not inhibit schwannoma proliferation. Combination of AZD6244 
and MLN3651 significantly reduced proliferation compared with AZD6244 alone but not compared with 







We replicated the MLN3651 and AZD6244 combination experiment in meningioma 
cells and probed Western blots for LATS2, pERK1/2, ERK1/2, CYCLIN D1 and GAPDH 
(figure 6.3A). MLN3651 treatment (1 µM) alone did not significantly increase Hippo 
pathway activation, via LATS2 expression (figure 6.3B). However, combination of 1 µM 
MLN3651 with 1 µM AZD6244 significantly increased LATS2 expression compared with 
DMSO control demonstrating robust Hippo pathway activation (p< 0.05). We also 
analysed ERK1/2 activation and identified a significant increase in pERK1/2 expression 
after a 72 hour treatment of cells with 1 µM MLN3651 (p< 0.01). We also discovered 
that combining 0.1 µM AZD6244 or 1 µM AZD6244 with 1 µM MLN3651 significantly 
decreased pERK1/2 expression compared with MLN3651 alone (p< 0.01) (figure 6.3B). 
Unfortunately, none of the treatments, shown in figure 5.4A and B, significantly 
reduced proliferation of meningioma cells. However, the average rate of proliferation 
was much lower in cells treated with 1 µM MLN3651 and 1 µM AZD6244 compared 




Figure 6.3 - MLN3651 and AZD6244 treatment activates the Hippo pathway and prevents ERK1/2 
activation in meningioma. A: Western blot of three primary meningiomas treated with MLN3651 
and/or AZD6244 (MEK1/2 inhibitor) for 72 hours and probed for LATS2 (Hippo pathway), pERK1/2 
(activated ERK), ERK1/2, CYCLIN D1 and GAPDH (loading control), representative of five replicates. B: 
Mean LATS2 and pERK1/2 expression ±SEM in drug treated schwannoma cells normalized to the loading 
control (ERK1/2 and/or GAPDH), relative to DMSO. LATS2 expression was significantly increased by the 
combination of AZD6244 and MLN3651 compared with DMSO control showing sustained Hippo pathway 
activation when the drugs are combined. pERK1/2 expression was significantly decreased when 
AZD6244 and MLN3651 are combined compared with MLN3651 alone showing that RAF/MEK/ERK 




Figure 6.4 - MLN3651 and AZD6244 effect on proliferation in meningioma. A: Representative 
immunocytochemistry images, at 20x magnification, of meningioma cells treated with DMSO, 1 µM 
AZD6244 (MEK1/2 inhibitor), 1 µM MLN3651 or 1 µM AZD6244 and 1 µM MLN3651 for 72 hours and 
stained with Ki-67 antibody and DAPI, Scale bar- 50 µM. B: Mean proportion of Ki-67 positive cells in 
drug treated meningioma cells relative to DMSO control ±SEM. At least three images each of four 
replicates were quantified. Combination of AZD6244 and MLN3651 significantly reduced the mean 







We also assessed the effect of combining MLN3651 and AZD6244 treatment in 
BenMen-1 cells. We postulated that BenMen-1 results would be more consistent than 
primary cells and therefore, the Ki-67 proliferation assay would be more sensitive. In 
addition, we used a lower MLN3651 concentration of 0.3 µM compared with 1 µM 
used in primary cells. This was because the average IC50 for BenMen-1 viability after 
MLN3651 treatment was 0.3 µM after 72 hours, much lower than primary tumours. 
Treatment with 0.3 µM MLN3651 and 1 µM AZD6244, for 72 hours, significantly 
increased LATS2 expression compared with DMSO whereas MLN3651 alone did not (p< 
0.05) (figure 6.5A-B). This indicates that combination of MLN3651 and AZD6244 
produces a more robust and prolonged activation of the Hippo pathway compared 
with MLN3651 alone. Similar to meningioma, MLN3651 treatment significantly 
increased pERK1/2 expression after 72 hours (p< 0.01) (figure 6.5B). Addition of 1 µM 
AZD6244 significantly decreased ERK1/2 activation of BenMen-1 cells compared with 
MLN3651 whilst 0.1 µM was not able to reduce pERK1/2 expression (p< 0.05) (figure 
6.5B). We treated cells for 72 hours with 1 µM AZD6244, 0.3 µM MLN3651 or both 
drugs and analysed proliferation by Ki-67 index (figure 6.6A and B). AZD6244 and 
MLN3651 significantly reduced proliferation compared with DMSO and either drug 




Figure 6.5 - MLN3651 and AZD6244 activates the Hippo pathway and prevents ERK1/2 activation in 
BenMen-1. A: Western blot of the benign meningioma cell line, BenMen-1, treated with MLN3651 
and/or AZD6244 (MEK1/2 inhibitor) for 72 hours and probed for LATS2 (Hippo pathway), pERK1/2 
(activated ERK), ERK1/2, CYCLIN D1 and GAPDH (loading control), representative of three replicates. B: 
Mean LATS2 and pERK1/2 expression ±SEM in drug treated schwannoma cells normalized to the loading 
control (ERK1/2 and/or GAPDH), relative to DMSO. LATS2 expression was significantly increased by the 
combination of AZD6244 and MLN3651 compared with DMSO control showing sustained Hippo pathway 
activation when combining both drugs. pERK1/2 expression was significantly decreased when AZD6244 
and MLN3651 are combined compared with MLN3651 alone demonstrating RAF/MEK/ERK inhibition, *- 












Figure 6.6 - MLN3651 and AZD6244 reduces proliferation in BenMen-1. A: Representative 
immunocytochemistry images, at 20x magnification, of a benign meningioma cell line (BenMen-1) 
treated with DMSO, 1 µM AZD6244 (MEK1/2 inhibitor), 0.3 µM MLN3651 or 1 µM AZD6244 and 0.3 µM 
MLN3651 for 72 hours and stained with Ki-67 antibody and DAPI, Scale bar- 50 µM. B: Mean proportion 
of Ki-67 positive cells in drug treated BenMen-1 cells relative to DMSO control ±SEM. At least three 
images each of three replicates were quantified. Combination of AZD6244 and MLN3651 significantly 
reduced the proliferation rate compared with either treatment alone demonstrating the additive benefit 







We could not confirm an additive effect of MLN3651 and AZD6244 on proliferation in 
primary schwannoma or meningioma so we wanted to determine if there was a 
synergistic effect of the drugs on cell viability. We tested the effect of AZD6244 on cell 
viability of schwannoma and meningioma (data not shown). There was no significant 
changes to viability at any concentration (0.1–20 µM) and therefore we concluded it 
was inappropriate to combine MLN3651 and AZD6244 in this assay.  
6.4 Discussion 
Dhawan, Scopton & Dar, 2016 found that the KSR1 inhibitor APS_2_79, was ineffective 
as a monotherapy. However, we postulated that as KSR1 and RAF/MEK/ERK are hyper-
active in Merlin-deficient tumours, APS_2_79 alone would be sufficient to inhibit KSR1-
dependent RAF/MEK/ERK activation and proliferation. Unfortunately, we found that 
neither RAF/MEK/ERK activity or proliferation were reduced by APS_2_79 in Merlin-
deficient tumours (data not shown). It can be hypothesised that APS_2_79 did not 
reach a high enough intracellular concentration to inhibit all KSR1-MEK1/2 binding at 
the concentrations tested. Alternatively, the compound purchased may have differed 
to the one used in Dhawan et al. such as purity, manufacturing method or 
concentration. Future experiments should determine if the APS_2_79 we purchased 
matches the efficacy of the compound used in Dhawan et al. (Dhawan, Scopton & Dar, 
2016). 
We found that a 72 hour treatment of 1 µM AZD6244 in primary schwannoma did not 
significantly reduce proliferation in contrast to Ammoun et al (Ammoun et al., 
2010b)(figure 6.2). However, Ammoun et al. stimulated cells with PDGF before 
AZD6244 treatment whereas we did not which could explain the discrepancy 
(Ammoun et al., 2010b). In addition, 1 µM MLN3651 did not significantly reduce 
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proliferation compared with DMSO, in contrast to the previous chapter. This 
discrepancy is probably due to the small number of samples used in this experiment 
therefore limiting the statistical power. Further experiments should assess the efficacy 
of combining a wider range of MLN3651 and AZD6244 concentrations in schwannoma.  
In meningioma, a 72 hour treatment of 1 µM MLN3651 did not significantly increase 
LATS2 expression (figure 6.3). In the previous chapter, a 24 hour 1 µM MLN3651 
treatment was sufficient to increase LATS2 expression and therefore Hippo pathway 
activation. At 72 hours, there may be a signalling feedback mechanism that prevents 
LATS2 activation. Interestingly, combination of 1 µM MLN3651 with 1 µM AZD6244 
significantly increased LATS2 expression compared with DMSO, suggesting that the 
RAF/MEK/ERK pathway is upstream of the Hippo pathway in Merlin-deficient cells 
(figure 6.3). We also analysed the RAF/MEK/ERK pathway after treatment. A 72 hour 
treatment of 1 µM AZD6244 significantly reduced pERK1/2 expression whilst a 1 µM 
MLN3651 treatment significantly increased pERK1/2 in meningioma (figure 6.4). 
Combination of 0.1 µM or 1 µM AZD6244 significantly decreased pERK1/2 expression 
compared with 1 µM MLN3651 treatment suggesting there is a therapeutic benefit of 
combining both drugs. Whilst there was a trend in reduced proliferation of 
combination-treated meningioma cells compared to either drug treatment alone; this 
was not statistically significantly (figure 6.4). However, the sample size was much lower 
than that reported in previous chapters limiting the statistical power of this 
experiment. The sample size must be increased in order to assess the efficacy of 
combining MLN3651 and AZD6244 in meningioma. In addition, variability in baseline 
proliferation rates of meningioma is a confounding factor. Indeed, we removed 
samples that were proliferating at a rate lower than 8% in the DMSO control as it was 
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difficult to assess drug efficacy with such low baseline proliferation. We concluded that 
measuring proportions of Ki-67 cells was not the most sensitive method to assess drug 
combinations.  
Consistent with chapter 5, LATS2 expression was not significantly increased in 
BenMen-1 after MLN3651 treatment alone, even after 72 hours (figure 6.5). However, 
combination of MLN3651 with 1 µM AZD6244 significantly increased LATS2 expression 
compared with DMSO control. Therefore suggesting that AZD6244 enhances Hippo 
pathway activation in MLN3651 treated cells. Additionally, the combination of 
MLN3651 with 1 µM AZD6244 significantly decreased pERK1/2 expression compared 
with MLN3651 treatment alone, in agreement with primary meningioma data (figure 
6.3 and 6.5).  
Interestingly, proliferation was significantly decreased with the combination of 0.3 µM 
MLN3651 and 1 µM AZD6244 compared with DMSO and either drug alone (figure 6.6). 
The lower MLN3651 concentration used may enhance the sensitivity of the Ki-67 
proliferation assay. In addition, BenMen-1 baseline proliferation was much higher than 
primary meningioma cells which may make them more sensitive to drug treatment. 
6.5 Conclusion 
The KSR1 inhibitor, APS_2_79 has little therapeutic potential in Merlin-deficient cells 
as it was unable to reduce RAF/MEK/ERK activity or proliferation at relevant 
concentrations. Previous research shows that APS_2_79 must be combined with a 
MEK1/2 inhibitor in order to be efficacious. We did not test this combination in Merlin-
deficient cells but it may be necessary in order to successfully reduce RAF/MEK/ERK 
activity and proliferation. 
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As direct and specific CRL4-DCAF1 and KSR1 inhibition was not possible, we combined 
MLN3651 and AZD6244 to demonstrate therapeutic potential of combination therapy 
targeting the two main downstream pathways (Hippo and RAF/MEK/ERK activity). We 
have shown that combination of MLN3651 and AZD6244 has three additional benefits 
compared with either treatment alone. Firstly, LATS2 expression and therefore the 
Hippo pathway is consistently elevated in combination treated cells (schwannoma, 
meningioma and BenMen-1). Secondly, the increase in RAF/MEK/ERK activity observed 
after MLN3651 treatment is inhibited with the addition of AZD6244 (meningioma and 
BenMen-1). Finally, combination of 0.3 µM MLN3651 and 1 µM AZD6244 reduced 
BenMen-1 cell proliferation compared with either treatment alone. Therefore, 
combination of MLN3651 and AZD6244 is a potential therapeutic option for 














The aims of this project were to assess the potential of targeting CRL4-DCAF1 and KSR1 
in Merlin-deficient schwannoma and meningioma. As CRL4-DCAF1 is a master 
regulator and KSR1 has many roles in Merlin-deficient tumours, we hypothesised that 
CRL4-DCAF1 and KSR1 could be targeted together to improve efficacy compared with 
targeting only one protein or pathway (Li et al., 2010). In order to assess this we first 
needed to determine DCAF1 and KSR1 expression and the meaning of the CRL4-DCAF1 
and KSR1 interaction in Merlin-deficient tumours. We hypothesised that targeting 
CRL4-DCAF1 and KSR1 activity individually, with MLN3651 and APS_2_79 respectively, 
would be efficacious in schwannoma and meningioma. Finally, we hypothesised that 
targeting both CRL4-DCAF1 and KSR1 activity together would have additional benefits. 
KSR1 has been shown to be upregulated in Merlin-deficient schwannoma and 
contributes to tumourigenesis (Zhou et al., 2016a). In addition, targeting DCAF1 and 
KSR1 expression in schwannoma led to an enhanced effect on proliferation compared 
with targeting DCAF1 or KSR1 alone (Zhou et al., 2016a). KSR1 expression has not been 
previously explored in Merlin-deficient meningioma, and DCAF1 expression has not 
been explored in Merlin-deficient schwannoma or meningioma. We found that DCAF1 
and KSR1 were upregulated in Merlin-deficient schwannoma and meningioma. In 
addition, targeting DCAF1 and KSR1 together enhanced the effect on proliferation in 
meningioma.  
CRL4-DCAF1 is inhibited by Merlin in the nucleus; therefore, loss of Merlin leads to 
CRL4-DCAF1 hyper-activity (Li et al., 2010). CRL4-DCAF1 has been described as a 
master regulator in Merlin-deficient tumours and targets the Hippo pathway, among 
others (Li et al., 2014; Zhou & Hanemann, 2012). We showed that CRL4-DCAF1 and 
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KSR1 interact in Merlin-deficient tumours (Zhou et al., 2016a). As KSR1 has an 
important role in Merlin-deficient schwannoma, it is important to understand how 
CRL4-DCAF1 may regulate KSR1 to enhance KSR1 signalling. We showed that CRL4-
DCAF1 enhances KSR1 association with MEK1/2 and ERK1/2 and their subsequent 
phosphorylation. Accordingly, we showed that DCAF1 knockdown in schwannoma 
reduced RAF/MEK/ERK activity, presumably in a KSR1-dependent manner. This 
observation provided the mechanistic basis for combination therapy of a DCAF1 and 
KSR1 inhibitor. 
The treatment options for schwannoma, meningioma and ependymoma are limited to 
surgery and radiotherapy and therefore, a therapeutic strategy is urgently required, 
particularly for NF2 patients who have numerous tumours (Evans, 2009). CRL4-DCAF1 
is a potential therapeutic target for Merlin-deficient tumours and can be targeted by 
the neddylation inhibitor, MLN4924 (Cooper et al., 2017). MLN3651 is a second-
generation NAE inhibitor which can be taken orally and has not yet been tested in any 
indication. We showed that MLN3651 has potential as a treatment for Merlin-deficient 
tumours. KSR1 is also a therapeutic target as it regulates; proliferation, apoptosis, 
adhesion and cell morphology in schwannoma (Zhou et al., 2016a). APS_2_79 is an 
inhibitor of KSR1-dependent RAF/MEK/ERK activity, which has activity when combined 
with a MEK1/2 inhibitor in K-RAS driven tumours (Dhawan, Scopton & Dar, 2016). 
APS_2_79 has not yet been tested in Merlin-deficient tumours. We showed that 
APS_2_79 alone has no or little potential as a treatment for Merlin-deficient tumours. 
Finally, we showed that combination treatment of MLN3651 and AZD6244 had 
additive effects on proliferation in meningioma. We also showed that RAF/MEK/ERK 
activation by MLN3651 could be prevented with the addition of AZD6244. 
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Combination of MLN3651 and AZD6244 had the unexpected effect of activating the 
Hippo pathway more robustly than MLN3651 treatment alone.  
7.2 DCAF1 and KSR1 expression is increased in schwannoma and meningioma 
We have shown for the first time that DCAF1 expression is increased in Merlin-
deficient schwannoma and meningioma compared with normal cells (figure 3.1–4). 
Merlin inhibits CRL4-DCAF1 activity and therefore Merlin-deficient cells have increased 
CRL4-DCAF1 activity (Li et al., 2010). We identified increased DCAF1 expression as 
another mechanism that contributes to increased CRL4-DCAF1 activity and possibly 
increased DCAF1 kinase activity in Merlin-deficient cells.  
We found that KSR1 protein expression was significantly increased in primary 
meningiomas compared with normal meningeal cells supporting the notion that KSR1 
expression is regulated by Merlin (figure 3.3 and 3.4). However, KSR1 expression was 
not increased in the benign meningioma cell line, BenMen-1 (figure 3.4E and F). The 
BenMen-1 cell line was derived from a WHO I meningioma and immortalized by 
manipulating telomerase activity (Püttmann et al., 2005). High telomerase activity 
correlates with higher grade meningiomas allowing unlimited growth (Boldrini et al., 
2003). Therefore BenMen-1 cells may represent a higher grade now they have been 
immortalized and could explain the inconsistencies between BenMen-1 and primary 
cells used in this study. In addition, Mei et al. identified chromosome 5 amplification in 
BenMen-1 cells which may not be present in all primary tumours (Mei et al., 2017). 





7.3 CRL4-DCAF1 does not regulate KSR1 expression or localization 
We previously reported that CRL4-DCAF1 does not regulate KSR1 expression in Merlin-
deficient schwannoma (Zhou et al., 2016a). We confirmed this result in meningioma 
and BenMen-1 by knocking down DCAF1 and observing changes in KSR1 expression 
(figure 3.5). KSR1 was unchanged suggesting that CRL4-DCAF1 does not target KSR1 for 
degradation in meningioma. Poly-ubiquitination of substrates by E3 ubiquitin ligase 
complexes, such as CRL4-DCAF1, often leads to proteasome-dependent degradation. 
We found that DCAF1 knockdown did not affect the poly-ubiquitination of KSR1 
confirming that KSR1 poly-ubiquitination is not CRL4-DCAF1-dependent (figure 4.7). 
Indeed, Rinaldi et al. identified PRAJA2 as the E3 ubiquitin ligase responsible for KSR1 
poly-ubiquitination and subsequent degradation (Rinaldi et al., 2016). The mechanism 
of KSR1 upregulation in Merlin-deficient cells has not yet been determined; therefore, 
PRAJA2 protein expression and activity should be further investigated. 
Although KSR1 was predominantly nuclear in Schwann cells and schwannoma, we 
identified an increase in cytoplasmic KSR1 in schwannoma compared with Schwann 
cells (figure 3.6). Therefore, we hypothesised that nuclear export of KSR1 was 
mediated by CRL4-DCAF1. However, there was no difference in KSR1 localization 
between HMC and BenMen-1 (figure 3.8). Furthermore, DCAF1 knockdown did not 
lead to KSR1 redistribution in schwannoma or meningioma (figure 3.7 and 3.9). 
Accordingly, the evidence suggests that CRL4-DCAF1 does not regulate KSR1 nuclear 
export. We did not explore whether CRL4-DCAF1 regulates KSR1 membrane 





7.4 CRL4-DCAF1 regulates KSR1-dependent RAF/MEK/ERK activity 
DCAF1 knockdown in Merlin-deficient schwannoma led to a significant reduction in 
pERK1/2 expression suggesting that CRL4-DCAF1 regulates RAF/MEK/ERK activity 
(figure 3.10). Unfortunately, we were unable to show this in Merlin-deficient 
meningioma or BenMen-1 (figure 3.11 and 3.12). However, DCAF1 knockdown was 
around 20% less efficient in meningioma than in schwannoma. Therefore, remaining 
DCAF1 expression in meningioma may be sufficient to maintain RAF/MEK/ERK activity. 
To test this theory, an alternative DCAF1 lentivirus with increased efficiency should be 
utilized. Another important consideration is that there may be alternative mechanisms 
regulating RAF/MEK/ERK activity in meningioma that are absent in schwannoma. 
Indeed, Bassiri et al. reported that there were 15 commonly upregulated or 
downregulated phospho-proteins between schwannoma and BenMen-1 cells 
compared with hundreds of phospho-proteins identified in the separate datasets, 
highlighting the substantial differences between schwannoma and meningioma 
signalling (Bassiri et al., 2017). In addition, Nf2 mutant meningiomas tend to be more 
heterogenous than other mutant meningiomas with increased chromosomal instability 
(Clark et al., 2013; Clark et al., 2016). 
Unfortunately, DCAF1 knockdown was not sufficient to downregulate CYCLIN D1 
expression in schwannoma or meningioma, downstream of the RAF/MEK/ERK pathway 
(figure 3.10–12). Therefore, RAF/MEK/ERK signalling is only partly-dependent on 
DCAF1. We hypothesised that targeting DCAF1 and KSR1 together would inhibit 
RAF/MEK/ERK signalling more effectively in schwannoma and lead to downregulation 
of CYCLIN D1. In figure 3.13, DCAF1 or KSR1 knockdown alone did not significantly 
reduce pMEK1/2 or pERK1/2 expression in contrast to our previous experiment and 
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published data by Zhou et al. (Zhou et al., 2016a). This is probably because our sample 
size was small compared with the previous experiment and the KSR1 shRNA construct 
was less effective than the construct used by Zhou et al. However, we observed a 
significant decrease in pMEK1/2 activity in schwannoma after DCAF1 and KSR1 
knockdown compared with the scramble control suggesting that DCAF1 and KSR1 
function together to regulate RAF/MEK/ERK activity in schwannoma (figure 3.13). 
CYCLIN D1 expression was not reduced in schwannoma after DCAF1 and KSR1 
knockdown suggesting that more complete inhibition of DCAF1 and KSR1 expression is 
necessary or that CYCLIN D1 expression is not completely dependent on DCAF1 or 
KSR1 signalling. Similarly, pERK1/2 and CYCLIN D1 expression were not reduced in 
BenMen-1 following DCAF1 and KSR1 knockdown (figure 3.14). 
We showed that DCAF1 and KSR1 interact in a Merlin-deficient model; therefore, we 
wanted to determine if DCAF1 regulation of RAF/MEK/ERK activity was dependent on 
KSR1. We knocked down DCAF1 expression, overexpressed human KSR1 and 
immunoprecipitated the KSR1 complex in a HEK293T model (figure 4.8). DCAF1 
knockdown led to a significant reduction of pMEK1/2, MEK1/2, pERK1/2 and ERK1/2 in 
the KSR1 complex providing evidence that DCAF1 facilitates KSR1’s interaction with the 
RAF/MEK/ERK pathway. Therefore, DCAF1 enhances RAF/MEK/ERK activity in a KSR1-
dependent manner. We also showed, for the first time, that endogenous DCAF1 and 
KSR1 interact in a Merlin-deficient model suggesting that DCAF1-mediated regulation 
of KSR1 activity is important in Merlin-deficient cells (figure 4.1).  
We identified a mechanism by which DCAF1 facilitates RAF/MEK/ERK activity by 
enhancing KSR1 association with MEK1/2 and ERK1/2. To understand more about the 
nature of this regulation we used truncated DCAF1 and KSR1 constructs to identify 
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potential binding sites between DCAF1 and KSR1 (figure 4.2 and 4.3). DCAF1 binds to 
the N-terminal KSR1 complex that contain domains responsible for Raf 
phosphorylation and, ERK1/2 and 14-3-3 protein binding (Morrison, 2001; Müller et al., 
2001; Ritt et al., 2007). DCAF1 knockdown reduced both MEK1/2 and ERK1/2 
association with KSR1 but C-RAF was unchanged (figure 4.8). Therefore, DCAF1 is 
unlikely to specifically modulate C-RAF or ERK1/2 binding to KSR1 and possibly inhibits 
KSR1 binding to 14-3-3 proteins to activate KSR1 activity. In support of this theory, the 
DCAF1/KSR1 interaction occurred predominantly in the cytoplasm of HEK293T cells 
rather than the nucleus (figure 4.5). Further investigation is required to determine the 
specific mechanism of CRL4-DCAF1 regulation of KSR1 activity.  
We identified DDB1 as well as DCAF1 in the wild-type KSR1 and N-terminal KSR1 
complexes suggesting that CRL4-DCAF1 ubiquitin activity enhances KSR1’s 
kinase/scaffolding function rather than DCAF1 kinase activity (figure 4.3). Interestingly 
overexpression of the S518A Merlin mutant, which inhibits CRL4-DCAF1, also reduced 
pMEK1/2 in the KSR1 complex further suggesting that CRL4-DCAF1 ubiquitin activity is 
responsible (Zhou et al., 2016a). Indeed, KSR1 binds to the C-terminal DCAF1 complex 
containing the CRL4-DCAF1 substrate recruitment domain for ubiquitination (Angers et 
al., 2006) (figure 4.2).  
The experimental setup we used to investigate KSR1 ubiquitination was not sensitive 
enough to identify mono-ubiquitination in the presence of poly-ubiquitination and 
therefore it is possible that KSR1 is a CRL4-DCAF1 substrate for mono-ubiquitination 
(figure 4.6). Sagar et al. reported that ubiquitination of Thyroid hormone-activating 
type 2 deiodinase can modify its conformation and therefore inhibit its enzymatic 
activity (Sagar et al., 2007). Similarly, CRL4-DCAF1-mediated monoubiquitylation of 
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LATS2 inhibited its kinase activity (Li et al., 2014). Furthermore, mono-ubiquitination of 
K476 on Zeta-chain-associated protein kinase 70 (ZAP-70) can stabilize its active 
conformation (Ball et al., 2016). Indeed, DCAF1 could ubiquitinate KSR1, changing its 
conformation and interfering with KSR1 binding to 14-3-3 proteins leading to 
enhanced KSR1 activity and plasma membrane accumulation (Jagemann et al., 2008). 
CRL4-DCAF1 mediated KSR1 mono-ubiquitination could be explored utilizing an in vitro 
ubiquitylation assay as reported by Li et al. to test CRL4-DCAF1 ubiquitination of LATS1 
(Li et al., 2014). In addition, mass spectrometry of purified KSR1 could be performed to 
identify the ubiquitination sites and further evaluate the role of ubiquitination. 
7.5 DCAF1 and KSR1 as therapeutic targets 
DCAF1 knockdown significantly reduced proliferation in schwannoma cells and we 
have shown that this is consistent in both meningioma and BenMen-1 cells (figure 3.11 
and 3.12) (Li et al., 2010; Zhou et al., 2016a). We showed that DCAF1 regulates 
RAF/MEK/ERK activity in schwannoma and therefore targeting DCAF1 and KSR1 may 
lead to a greater inhibition of the RAF/MEK/ERK pathway than targeting either protein 
alone (figure 3.10). Although RAF/MEK/ERK inhibition was not achieved by DCAF1 
knockdown in meningioma, we stipulated that DCAF1 and KSR1 knockdown would still 
be beneficial as it would target multiple pathways that are required for Merlin-
deficient tumourigenesis (figure 3.11). For example, Li et al. demonstrated that 
changes in gene transcription following DCAF1 knockdown or Merlin overexpression 
significantly overlap, suggesting DCAF1 is a master regulator in Merlin-deficient cells (Li 
et al., 2010). Furthermore, loss of DCAF1 inhibited integrin and Hippo pathway target 
genes suggesting that the reduction in proliferation observed after DCAF1 knockdown 
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in meningioma and BenMen-1 cells may also involve inhibition of these pathways (Li et 
al., 2010).  
We identified a KSR1 inhibitor (APS_2_79) that disrupts the phosphorylation of 
MEK1/2 bound to KSR1 whereby preventing KSR1-mediated RAF/MEK/ERK activation 
(Dhawan, Scopton & Dar, 2016). We tested the therapeutic potential of APS_2_79 as a 
monotherapy in Merlin-deficient cells because KSR1 and the RAF/MEK/ERK pathway 
were overexpressed. Dhawan et al. showed that APS_2_79 bound to the KSR2 active 
site with an IC50 of 120 nM and activity against KSR1-MEK binding in HEK293T cells. 
Dhawan et al. reported that 3 µM was required to reduce the viability of the K-RAS 
mutant cell line A549: K-RAS G12S, by half (Dhawan, Scopton & Dar, 2016). However, 
APS_2_79 treatment did not reduce RAF/MEK/ERK activity or proliferation of Merlin-
deficient schwannoma or meningioma at concentrations up to 10 µM (data not 
shown). Therefore, we tested the potential of targeting RAF/MEK/ERK activity with 
AZD6244 in combination with MLN3651.  
7.6 MLN3651 inhibits CRL4-DCAF1 activity in Merlin-deficient cells and has potential 
as a therapeutic 
In the absence of a specific CRL4-DCAF1 inhibitor we utilized the NAE inhibitor 
MLN3651, an oral successor of MLN4924. MLN4924 inhibited neddylation-mediated 
activation of E3 ubiquitin ligases including CRL4-DCAF1 (Cooper et al., 2017; Wei et al., 
2014; Yu et al., 2015). We showed that MLN3651 treatment in schwannoma, 
meningioma and BenMen-1 successfully inhibited neddylation (figure 5.1). We also 
showed that MLN3651 activated the Hippo pathway and therefore inhibited Hippo-
mediated gene transcription in Merlin-deficient schwannoma and meningioma (figure 
5.2–4). The Hippo pathway components LATS1/2 are direct targets of CRL4-DCAF1 and 
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these proteins are increased in MLN3651-treated cells suggesting that MLN3651 
inhibits neddylation and activation of CRL4-DCAF1. However, Zou et al. also implicated 
Cullin 7-containing E3 ubiquitin ligase complexes in Hippo pathway regulation and 
showed that MLN4924 Hippo pathway activation is dependent on inhibition of Cullin 7 
neddylation (Zou et al., 2018). Therefore, further evidence is needed to determine if 
CRL4-DCAF1 is effectively inhibited with MLN3651 treatment and if MLN3651’s anti-
tumourigenic effects are CRL4-DCAF1-dependent. 
MLN3651 treatment of Merlin-deficient schwannoma cells for 144 hours significantly 
decreased cell viability (figure 5.7). In addition, proliferation was significantly reduced 
and apoptosis activation was significantly increased after 72 hours of MLN3651 
treatment, demonstrating that MLN3651 is a potent, anti-tumourigenic therapeutic for 
Merlin-deficient schwannoma (figure 5.7 and 5.8). In contrast, Merlin-positive 
schwannoma cells were much less sensitive to MLN3651; therefore, MLN3651 
sensitivity could be CRL4-DCAF1-dependent (figure 5.14). Furthermore, primary human 
Schwann cells were also less sensitive to MLN3651 than Merlin-deficient schwannoma 
suggesting that MLN3651 is less toxic to normal cells (figure 5.15). However, there was 
considerable variation in human Schwann cell response to MLN3651. 
We treated Merlin-deficient meningioma cells with MLN3651 for 72 hours and 
observed considerable variation in sensitivity between individual tumours (figure 5.9A 
and 5.9B). We were able to separate these tumours based on their IC50 to produce 
two different sub-groups; those that responded and those that did not. The responder 
sub-group had an average IC50 of 1.31 µM whilst the non-responder sub-group had an 
average IC50 of 12.81 µM. We did not explore the reason for the differences in 
MLN3651 sensitivity. However, Milhollen et al. reported that NAE mutations can 
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confer resistance to MLN4924 (Milhollen et al., 2012). In addition, Cooper et al. 
demonstrate that MLN4924 does not inhibit the mTOR pathway (Cooper et al., 2017). 
Indeed, it has been shown that mTOR signalling is dysregulated in Merlin-deficient 
meningioma; therefore, this could be a potential resistance mechanism (James et al., 
2009). Interestingly, when we treated meningioma cells for 144 hours with MLN3651, 
there was no difference in response between those that had previously been grouped 
as responders and non-responders suggesting that non-responders can overcome 
resistance mechanisms (figure 5.9C). We also confirmed that after 72 hours of 
MLN3651 treatment, proliferation was significantly reduced and apoptosis was 
significantly increased (figure 5.9D and 5.10. There were no differences in proliferation 
and apoptosis following MLN3651 treatment between responder and non-responder 
sub-groups suggesting another mechanism confers resistance at this time point. We 
did not monitor alternative cell death mechanisms such as autophagy which have been 
shown to be important in the cellular response to MLN4924 (Lan et al., 2016; Luo et 
al., 2012; Zhao et al., 2012).  
Merlin-positive meningioma cells were also much less sensitive to MLN3651 than 
Merlin-deficient meningioma responders after 72 hours of MLN3651 treatment (figure 
5.14). Although Merlin-positive meningioma responded to MLN3651 after 144 hours, 
the IC50 was much higher than Merlin-deficient meningiomas at the same time point, 
suggesting that Merlin-deficient tumours are more sensitive to MLN3651. This 
sensitivity could be mediated by increased CRL4-DCAF1 activity in primary Merlin-
deficient meningioma.  
HMC were less sensitive to MLN3651 at 72 hours and 144 hours compared with 
Merlin-deficient ‘responders’ at 72 hours and all Merlin-deficient meningiomas at 144 
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hours (figure 5.15). However, this resistance was mediated by a component of the 
HMC medium as when we repeated this experiment in meningioma medium (without 
added growth factors), HMC were more sensitive to MLN3651 than Merlin-deficient 
meningioma after 72 hours (figure 5.15). Indeed, when we cultured Merlin-deficient 
meningiomas in HMC medium, they were much more resistant than those culture in 
meningioma medium (figure 5.16). The constituents of the commercially available 
HMC medium are not disclosed; however Kuhn et al. reported that increased 
exogenous Insulin-like growth factor 1 (IGF-1) reduced multiple myeloma cell 
sensitivity to proteasome inhibition providing a possible rationale for HMC medium-
mediated resistance to MLN3651 (Kuhn et al., 2012). Unfortunately, specialized HMC 
medium is required for the optimal growth of HMC; therefore, we cannot accurately 
assess MLN3651 sensitivity in this model and in vivo toxicity studies are required. 
In BenMen-1 cells, the Hippo pathway was not significantly activated after MLN3651 
treatment (figure 5.4). However, 72 hours of MLN3651 treatment significantly reduced 
viability (IC50 - 0.29 µM) and proliferation (figure 5.11A and 5.12). In addition, 24 
hours of MLN3651 treatment significantly increased apoptosis; therefore, MLN3651 
activity in BenMen-1 is independent of Hippo pathway activation and presumably 
CRL4-DCAF1 inhibition (figure 5.11B). The viability of WHO II and WHO III tumours was 
also significantly reduced by MLN3651, suggesting it has potential in higher grade 
Merlin-deficient tumours (figure 5.13). 
7.7 MLN3651 increases RAF/MEK/ERK activity in Merlin-deficient cells 
We reported that CRL4-DCAF1 increased KSR1-mediated RAF/MEK/ERK activity in 
Merlin-deficient cells (figure 3.10 and 4.7). As MLN3651 successfully inhibited CRL4-
DCAF1 in Merlin-deficient cells leading to Hippo pathway activation, we monitored 
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pERK1/2 expression after MLN3651 treatment in schwannoma, meningioma and 
BenMen-1 (figure 5.5 and 5.6). We were surprised that RAF/MEK/ERK activity was 
significantly increased after MLN3651 treatment presumably in a CRL4-DCAF1-
independent manner. Indeed, Zheng et al. reported that MLN4924 activated 
RAF/MEK/ERK activity in acute lymphoblastic leukaemia (ALL) which was induced by 
protein kinase C β2 in MLN4924-treated cells (Zheng et al., 2018). Interestingly, 
RAF/MEK/ERK activity was protective in acute lymphoblastic leukaemia cells by 
preventing apoptotic cell death and indeed, RAF/MEK/ERK inhibition (with AZD6244) 
sensitized cells to MLN4924 (Zheng et al., 2018). Therefore, we postulated that 
combination therapy of MLN3651 and RAF/MEK/ERK inhibition would further sensitize 
Merlin-deficient schwannoma and meningioma.  
In addition, Zhou et al. discovered that low doses of MLN4924 increased cancer cell 
proliferation mediated by enhanced EGFR activation and enhanced PI3K/AKT/MTOR 
and RAF/MEK/ERK signalling (Zhou et al., 2016b). We also observed increases in cell 
viability at low doses of MLN3651 (100 nM), particularly in meningioma (figure 5.9). 
Indeed, EGFR is overexpressed and activated in meningiomas; therefore, increased 
viability may be due to increased EGFR signalling mediated by MLN3651 (Arnli et al., 
2017). Possible EGFR activation with low doses of MLN3651 provides an additional 
rationale for combination therapy of MLN3651 and RAF/MEK/ERK inhibition in 
meningioma. 
7.8 Combination of MLN3651 and AZD6244  
We chose AZD6244 to target RAF/MEK/ERK activity for two reasons. Firstly, APS_2_79 
targeting KSR1-mediated RAF/MEK/ERK activity was ineffective as a monotherapy and 
secondly Ammoun et al. reported anti-proliferative effects of AZD6244 at 
243 
 
therapeutically relevant concentrations in schwannoma (Ammoun et al., 2010b). 
Indeed, 0.1 µM and 1 µM AZD6244 significantly decreased pERK1/2 expression in 
schwannoma after 72 hours, in agreement with Ammoun et al. (figure 6.1). However, 
we did not identify any benefit of combining MLN3651 and AZD6244 in schwannoma 
(figure 6.1 and 6.2). There was a trend of reduced pERK1/2 activity with the 
combination of AZD6244 and MLN3651 compared with MLN3651 alone; however, this 
was not statistically significant. AZD6244 alone did not supress schwannoma 
proliferation, in contrast to Ammoun et al., and combination of MLN3651 and 
AZD6244 did not change proliferation compared with MLN3651 alone (Ammoun et al., 
2010b). Therefore, AZD6244 has little potential as a therapeutic for the treatment of 
schwannoma and more potent RAF/MEK/ERK inhibitors should be assessed in 
combination with MLN3651 to determine synergistic or additive effects. 
In primary Merlin-deficient meningioma, combination of MLN3651 and AZD6244 
unexpectedly activated the Hippo pathway by increasing LATS2 expression after 72 
hours whereas MLN3651 alone did not lead to a significant increase in LATS2 (figure 
6.3). This suggests that RAF/MEK/ERK has a role in regulating LATS2 expression and 
therefore the Hippo pathway in meningioma. Indeed, You et al. reported that ERK1/2 
inhibition led to a decrease in YAP protein in NSCLC cells which could be mediated by 
LATS1/2 (You et al., 2015). In meningioma, a 72 hour 0.1 µM AZD6244 treatment 
period was not sufficient to reduce pERK1/2 expression and 1 µM was required to 
significantly reduce RAF/MEK/ERK activity (figure 6.3). Interestingly, the combination 
of MLN3651 and 0.1 µM or 1 µM AZD6244 led to a significant reduction in pERK1/2 
activity compared with MLN3651 alone in contrast to combination therapy in 
schwannoma. We were able to show that these effects were consistent in BenMen-1 
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demonstrating that robust Hippo pathway activation can be achieved in these cells 
(figure 6.5). Whilst MLN3651 and AZD6244 had no significant effect on the 
proliferation of primary meningioma cells, the combination of MLN3651 and AZD6244 
in BenMen-1 significantly reduced proliferation compared with either treatment alone 
(figure 6.4 and 6.6). Therefore, the combination of MLN3651 and AZD6244 is a 
potential therapy for meningioma.  
7.9 Experimental limitations 
This study is limited to data derived from experiments in primary schwannoma and 
meningioma cell cultures and relevant cell lines. Whilst this data reflects human 
tumours, there is no in vivo data to support the results. Both HMC and Schwann cells 
were less sensitive to MLN3651; however, this sensitivity was mediated by the cell 
culture medium in the case of HMC. In addition in vitro Schwann cells and HMC cells 
proliferate at a much higher rate than those in vivo, in the absence of injury (Decimo et 
al., 2012; Kim et al., 2000; Webster, Martin & O'Connell, 1973). Therefore, further in 
vivo efficacy and toxicity studies are needed to fully assess the potential of MLN3651 
as a therapeutic for NF2-associated tumours. Previously, our human cell model has 
been used to support the translation of Sorafenib into the treatment of NF2-related 
tumours (Ammoun et al., 2008) (EudraCT: 2011-001789-16). However, MLN3651, 
APS_2_79 and B32B3 have not yet been approved for the treatment of any cancers 
making a fast-track translation into clinic more difficult.  
As we primarily used primary samples, the amount of material available for 
experiments was often limited. Primary tumours proliferate for a small number of 
passages before they undergo senescence and eventually die. This was a particular 
problem for primary schwannoma tumours as these samples were often much smaller 
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and tended to proliferate for a smaller number of passages compared with 
meningioma tumours. Therefore, we were unable to complete the required number of 
repeats to detect statistical significance for some experiments. In addition, we were 
unable to acquire enough schwannoma tissue for successful DCAF1 
immunoprecipitation. 
Protein expression and MLN3651 drug response in primary tumours were variable in 
this study confounding our results. This variability could be attributable to variation of 
mutations, epigenetic differences, histopathological subtype and culture passage of 
primary tumours. Unfortunately, we did not stratify the primary tumours into 
mutation type, epigenetic group or histopathological subtype in this study. We 
confirmed loss of Merlin protein expression which correlates well with an Nf2 gene 
mutation but we did not definitively confirm the presence of a Nf2 gene mutation by 
sequencing. Indeed, we recognised some instances where a Traf7 mutation correlated 
with a loss of Merlin protein expression and these tumours were removed from 
analysis. 
An additional limitation is the lack of a specific CRL4-DCAF1 inhibitor. MLN3651 targets 
NAE to prevent neddylation of Cullins as well as p53 and MDM2 (Brownell et al., 2010; 
Dohmesen, Koeppel & Dobbelstein, 2008; Xirodimas et al., 2004). We were able to 
confirm that Merlin-deficient tumour cells have additional sensitivity to MLN3651 
compared with Merlin-positive cells which may be mediated by enhanced CRL4-DCAF1 
activity. However, we have no conclusive evidence that inhibition of CRL4-DCAF1 
mediates the effects of MLN3651 on Merlin-deficient cells. Indeed, it is probably a 




7.10 Translational potential 
We investigated DCAF1 and KSR1 expression in Merlin-deficient tumours and 
demonstrated that CRL4-DCAF1 enhanced KSR1-mediated RAF/MEK/ERK activation in 
HEK293T and schwannoma. CRL4-DCAF1 is also hyper-active in hepatocellular 
carcinoma and DCAF1 in NSCLC is associated with poor prognosis (Ni et al., 2017; Wang 
et al., 2013). Therefore, investigation of CRL4-DCAF1 regulation of KSR1 activity may be 
important in these cancers as well as Merlin-deficient tumours. We also demonstrated 
that targeting DCAF1 and KSR1 expression had additive effects on the proliferation of 
meningioma. KSR1 is upregulated in colorectal cancer, endometrial carcinoma and 
breast cancer whereas DCAF1 expression has not been investigated in these tumours 
(Fisher et al., 2015; Llobet et al., 2011; Stebbing et al., 2015). Whether DCAF1 and 
KSR1 knockdown in these tumours has additive effects on proliferation remains to be 
determined.   
Merlin-deficient schwannoma and meningioma are more sensitive to MLN3651 than 
Merlin-positive tumours. In addition, MLN4924 has potential as a therapeutic for 
mesothelioma which are often Merlin-deficient (Cooper et al., 2017). Therefore, 
MLN3651 should be tested in other tumours in which the nf2 gene is mutated and/or 
Merlin protein expression is reduced such as glioma and hepatocellular carcinoma. In 
addition, we have shown the additive potential of MLN3651 and AZD6244 in 
meningioma which may also have potential in other tumours in which the Hippo 
pathway and RAF/MEK/ERK pathway are dysregulated. 
7.11 Conclusions 
We explored several lines of evidence to demonstrate the potential of targeting CRL4-
DCAF1 and KSR1 in Merlin-deficient tumours both alone and in combination. We 
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discovered that DCAF1 protein is overexpressed in schwannoma and meningioma 
which probably enhances CRL4-DCAF1 and DCAF1 kinase activity. We showed that 
DCAF1 expression is important in Merlin-deficient meningioma and regulates 
proliferation. We also report that KSR1 protein is overexpressed in Merlin-deficient 
meningioma. However, KSR1 expression was not increased in the benign meningioma 
cell line, BenMen-1. In spite of this, KSR1 knockdown significantly decreased 
proliferation in BenMen-1 demonstrating the potential of KSR1 as a target in 
meningioma. Interestingly, combination of DCAF1 and KSR1 knockdown significantly 
reduced proliferation in BenMen-1 compared with DCAF1 or KSR1 knockdown alone. 
Therefore suggesting these proteins have potential to be targeted together. Future 
studies should investigate the mechanisms by which DCAF1 and KSR1 reduce 
proliferation and determine if it is dependent on CRL4-DCAF1 and RAF/MEK/ERK 
activity or independent protein functions. 
We also showed that CRL4-DCAF1 enhanced KSR1-mediated RAF/MEK/ERK signalling in 
schwannoma. Unfortunately, we were not able to show that CRL4-DCAF1 regulation of 
KSR1 was relevant in meningioma cells as DCAF1 knockdown did not result in any 
changes to RAF/MEK/ERK signalling. Future work should elucidate if DCAF1 pro-
tumourigenic functions are partly dependent on RAF/MEK/ERK regulation via KSR1 as 
well as regulation of the Hippo pathway. Furthermore, the mechanism of CRL4-DCAF1 
regulation of KSR1 should also be investigated to determine if it is dependent on CRL4-
DCAF1 ubiquitin ligase activity. 
We showed that MLN3651 was able to inhibit neddylation and activate the Hippo 
pathway. MLN3651 displayed anti-tumourigenic activity in schwannoma and 
meningioma; therefore, has potential as a therapeutic target in Merlin-deficient 
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tumours. MLN3651 also showed significant activity in higher grade meningiomas 
suggesting its use is not limited to low-grade tumours. We were unable to determine if 
MLN3651 activity was dependent on CRL4-DCAF1 inhibition as MLN3651 targets many 
E3 ubiquitin ligases and neddylated substrates. However, we were able to show that 
Merlin-positive schwannoma and meningioma cells were more resistant to MLN3651 
suggesting that Merlin-deficiency sensitizes cells to MLN3651, which could be due to 
activated CRL4-DCAF1. A specific CRL4-DCAF1 inhibitor is required to fully assess the 
potential of targeting CRL4-DCAF1 in Merlin-deficient cells. 
The KSR1 inhibitor APS_2_79 was not able to inhibit RAF/MEK/ERK signalling in 
schwannoma and meningioma and did not affect proliferation. Dhawan et al. show 
that APS_2_79 can sensitize cells to MEK1/2 inhibition; therefore, this combination 
should also be tested in Merlin-deficient cells. Furthermore, whilst APS_2_79 can 
interact with KSR2 at nanomolar concentrations, the APS_2_79 interaction with KSR1 
was not specifically investigated. Therefore, a much higher concentration of APS_2_79 
may be required to inhibit KSR1-mediated RAF/MEK/ERK signalling and a more potent 
and specific therapeutic is necessary to fully evaluate KSR1 as a therapeutic target. 
We combined MLN3651 and AZD6244 because they target Hippo pathway activation 
and RAF/MEK/ERK activity, downstream of CRL4-DCAF1 and KSR1, respectively. DCAF1 
and KSR1 knockdown had an additive effect on proliferation and we hypothesised that 
it was dependent on inhibition of Hippo and RAF/MEK/ERK pathways. We chose 
AZD6244 as APS_2_79 had no therapeutic effect in Merlin-deficient tumours. 
Furthermore, we noticed that MLN3651 led to an increase in RAF/MEK/ERK activity 
providing an additional rationale for combination therapy. Combination therapy of 
MLN3651 and AZD6244 had no additive effect in schwannoma at the concentrations 
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tested. Conversely, combination therapy in meningioma and BenMen-1 led to 
sustained Hippo pathway activation, reduced RAF/MEK/ERK activity and significantly 
reduced proliferation compared with either treatment alone demonstrating that 
MLN3651 and AZD6244 have additive therapeutic potential. Whether MLN3651 and 
AZD6244’s therapeutic potential is dependent on the inhibition of CRL4-DCAF1 and 















Supplementary figure 1 - Additional HMC and BenMen-1 repeats for DCAF1 and KSR1 localization. A, 
B: Additional Western blots of DCAF1 and KSR1 in total, cytoplasmic (C) and nuclear (N) lysate of human 
meningeal cells (HMC) and Benign meningioma 1 (BenMen-1) cells. Nuclear DCAF1 was increased in 






Supplementary figure 2 - Additional BenMen-1 DCAF1 knockdown repeats for KSR1 localization. A: 
Additional Western blots to show KSR1 localization after DCAF1 knockdown in Benign meningioma 1 
(BenMen-1) cells. Scramble or DCAF1 lentivirus (shDCAF1) was added for 24 hours followed by a 24 hour 
recovery period and then 7 days of puromycin selection before cytoplasmic (C) and nuclear (N) 





Supplementary figure 3 - Additional repeats for endogenous DCAF1 and KSR1 interaction in BenMen-1 
and KT21-MG1-Luc5D. A, B, C: Additional Western blots of DCAF1, KSR1 and DDB1 in Benign 
meningioma 1 (BenMen-1) lysate (input), immunoprecipitated IgG (control) and immunoprecipitated 
DCAF1. DCAF1 was immunoprecipitated from 3 mg BenMen-1 lysates using a mouse (M) DCAF1 
antibody (Proteintech). KSR1 and DDB1 were present in the DCAF1 complex. Input samples represent 
protein lysate prior to the immunoprecipitation and 4% of the total protein used for the 
immunoprecipitation was ran in the Western blot. D: Western blot of DCAF1 and KSR1 in WHO III 
meningioma cell line (KT21-MG1-Luc5D) (KT21) (input), immunoprecipitated IgG (control) and 
immunoprecipitated DCAF1. DCAF1 was immunoprecipitated from 2 mg KT21 lysates using a mouse (M) 
DCAF1 antibody (Proteintech). KSR1 was present in the DCAF1 complex. Input samples represent protein 
lysate prior to the immunoprecipitation and 4% of the total protein used for the immunoprecipitation 




Supplementary figure 4 – Additional overexpressed DCAF1 immunoprecipitation experiments. A, B: 
Additional Western blots of DCAF1 sequences D1, D2 and D3, with a Myc-tag, overexpressed in HEK293T 
and immunoprecipitated from 1 mg HEK293T using a Myc-tag antibody. The Western blot shows KSR1, 
Myc, DDB1 and GAPDH. KSR1 was present in the C-terminal DCAF1 complex (indicated by the arrow) 
and a high molecular weight KSR1-reactive band is present in the wild-type DCAF1 complex. DDB1 is the 
positive control and is present in the D1 and D3 immunoprecipitated complexes. Immunoprecipitated 
Myc-tag in non-transfected HEK293T (-) was used as a negative control. Input lysates show protein levels 
prior to immunoprecipitation. 4% of protein amount used in immunoprecipitation was ran as input 
samples. C: An alternative protocol (protocol 2- *) for Myc immunoprecipitation was used to isolate the 
D1, D2 and D3 complexes. KSR1 was present in the C-terminal DCAF1 complex and a high molecular 
weight KSR1-reactive band was present in the wild-type DCAF1 complex. 
255 
 
Supplementary figure 5 - Additional overexpressed KSR1 immunoprecipitation experiments. A, B: 
Additional Western blots of KSR1 sequences K1, KC and KN, with a FLAG-tag, overexpressed in HEK293T 
and immunoprecipitated from 1 mg HEK293T using a FLAG-tag antibody. The Western blot shows 
DCAF1, DDB1, FLAG, MEK1/2 and GAPDH. DCAF1 and DDB1 were present in the K1 and KN complexes 
and a smaller amount in the KC complex. MEK1/2 was used as a positive control and is present in the K1 
and KC complexes. FLAG-tagged proteins were immunoprecipitated from non-transfected HEK293T (-) 
and used as a negative control. Input lysates show protein levels prior to immunoprecipitation. 4% of 





Supplementary figure 6 - Additional human KSR1 immunoprecipitation experiments showing 
RAF/MEK/ERK proteins after DCAF1 knockdown. A, B: DCAF1 expression was targeted with a shRNA 
lentiviral plasmid in HEK293T cells and then human KSR1 (hK1) with a FLAG-tag was overexpressed. 
DCAF1 lentivirus was added for 24 hours and then fresh medium was added for 24 hours followed by 
four days of puromycin selection. Cells were then split and 24 hours later hK1 lentivirus was added for 
48 hours followed by cell lysis. hK1 complexes were immunoprecipitated using FLAG-tag antibody from 
1 mg of HEK293T lysate. Western blots show immunoprecipitated FLAG complexes and input lysates 
probed with FLAG, C-RAF, pMEK1/2, MEK1/2, pERK1/2. ERK1/2 and GAPDH. The amount of pMEK1/2, 
and pERK1/2 in the hK1 complex was reduced when DCAF1 was knocked down. Sc- scramble, shD- 
DCAF1 knockdown. FLAG immunoprecipitated Sc/Sc and Sc/shD lysates represent negative controls and 
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